Substituted thiadiazolyl derivatives as inhibitors of DNA polymerase theta
Patent Information
- Application Number
- JP2023533774
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-08-13
- Filing Date
- 2021-12-01
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2041-12-01
AI Technical Summary
Cancer cells often become dependent on backup DNA repair pathways, particularly the microhomology-mediated end joining (MMEJ) pathway, which is stimulated by DNA polymerase theta (Polθ), making them resistant to current therapies. Existing treatments like PARP inhibitors are ineffective against HR-deficient cancers that rely on Polθ for survival.
Development of thiadiazolyl derivatives that specifically inhibit the ATP-dependent helicase domain of Polθ, disrupting its function in the MMEJ pathway, thereby targeting HR-deficient cancers.
The thiadiazolyl derivatives effectively inhibit Polθ activity, providing a therapeutic strategy to treat HR-deficient cancers that are resistant to PARP inhibitors, including breast, ovarian, and other cancers, by selectively targeting the backup DNA repair mechanism.
Smart Images

Figure 2022118210000001 
Figure 2022118210000002 
Figure 2022118210000003
Abstract
Description
Technical field
[0001] Cross-reference of related applications This application is based on 35 U.S.C. 119(e) of U.S. Provisional Application No. 63 / 120,410, filed on December 2, 2020, and U.S. Provisional Application No. 63 / 232,749, filed on August 13, 2021. each of which is hereby incorporated by reference in its entirety for any purpose. [Background technology]
[0002] Targeting DNA repair defects has become a proven and effective strategy in cancer treatment. However, DNA repair-deficient cancers often become dependent on back-up DNA repair pathways, presenting an "Achilles' heel" that can be targeted to eliminate cancer cells and providing the basis for synthetic lethality. Synthetic lethality is illustrated by the success of poly(ADP-ribose) polymerase (PARP) inhibitors in treating BRCA-deficient breast and ovarian cancers (Audeh M. W., et al., Lancet (2010); 376 (9737) : 245-51).
[0003] DNA damage repair processes are important for genome maintenance and stability, and in particular, double-strand breaks (DSBs) are mainly processed by the non-homologous end joining (NHEJ) pathway during the G1 phase of the cell cycle and by the non-homologous end joining (NHEJ) pathway during the S-G2 phase of the cell cycle. Repaired by homologous recombination (HR). Alternative end joining (alt-EJ), which has received little treatment, is also known as the microhomology-mediated end joining (MMEJ) pathway and is generally considered a "backup" DSB repair pathway when NHEJ or HR are impaired. There is. Many genetic studies have highlighted the role of DNA polymerase theta (Polθ encoded by POLQ) in stimulating MMEJ in higher organisms (Chan S. H., et al., PLoS Genet. (2010); 6: e1001005; Roerink S. F., et. al., Genome research. (2014); 24: 954-962; Ceccaldi R., et. al., Nature (2015); 518: 258-62; and Mateos-Gomez P. A., et al ., Nature (2015); 518: 254-57).
[0004] Polθ is unique among human DNA polymerases, containing not only a C-terminal DNA polymerase domain but also an N-terminal helicase domain separated by a long, less conserved central domain whose function other than Rad51 binding is unknown. (Seki et al. Al, 2003, Shima et al. 2003; Yousefzadeh and Wood 2013). The N-terminal ATPase / helicase domain belongs to the HELQ class of the SF2 helicase superfamily. In homologous recombination-deficient (HRD) cells, Polθ can perform error-prone DNA synthesis at sites of DNA damage via the alt-EJ pathway. The helicase domain of Polθ has been shown to cause repression of the HR pathway by inhibiting Rad51 nucleoprotein complex formation, which is involved in the initiation of HR-dependent DNA repair reactions after ionizing radiation exposure. This anti-recombinase activity of Polθ promotes the alt-EJ pathway. Furthermore, the helicase domain of Polθ contributes to strand annealing via microhomology (Chan SH et al., PLoS Genet. (2010); 6: e1001005; and Kawamura K et al., Int. J. Cancer (2004); 109: 9-16). Polθ utilizes this annealing activity to efficiently promote end joining in the alt-EJ pathway when ssDNA overhangs contain >2 bp of microhomology (Kent T., et al., Elife (2016 ); 5: e13740), and Kent T., et al., Nat. Struct. Mol. Biol. (2015); 22: 230-237). This reannealing activity is achieved through a coupled interaction with Rad51 and subsequent ATPase-mediated exclusion of Rad51 from the DSB damage site. Once annealed, the primer strand of DNA can be extended by the polymerase domain of Polθ.
[0005] Polθ expression is almost absent in normal cells, but is upregulated in breast, lung, and ovarian cancers (Ceccaldi R., et al., Nature (2015); 518, 258-62). Furthermore, increased Polθ expression correlates with poor prognosis of breast cancer (Lemee F et al., Proc Natl Acad Sci USA. (2010);107: 13390-5). Cancer cells deficient in HR, NHEJ or ATM have been shown to be highly dependent on Polθ expression (Ceccaldi R., et al., Nature (2015); 518: 258-62, Mateos-Gomez PA et al., Nature (2015); 518: 254-57, and Wyatt D.W., et al., Mol. Cell (2016); 63: 662-73). Polθ is therefore an attractive target for novel synthetic lethal therapies in cancers containing DNA repair deficiencies. [Summary of the invention]
[0006] Disclosed herein are certain thiadiazolyl derivatives that inhibit the activity of Polθ, particularly by inhibiting the activity of the ATP-dependent helicase domain of Polθ. Further disclosed are pharmaceutical compositions comprising such compounds, and methods of treating and / or preventing diseases that can be treated by inhibition of Polθ, such as cancers, including homologous recombination (HR)-deficient cancers.
[0007] In one embodiment, formula (I): [ka] (In the formula, ring A, Ar 1 ,R 1 ,R 2 ,X 1 , Z and subscripts n and m have the meanings provided in this disclosure) A compound represented by: or a pharmaceutically acceptable salt thereof is provided.
[0008] In another embodiment, formula (II): [ka] (In the formula, ring A, Ar 1 , Ar 2 ,R 1 ,R 2 ,X 1 and subscripts n and m have the meanings provided in this disclosure) A compound represented by: or a pharmaceutically acceptable salt thereof is provided.
[0009] In another embodiment, formula (III): [ka] (In the formula, ring A, Ar 1 , Ar 2 ,R 1 ,R 2 ,X 0 and subscripts n and m have the meanings provided in this disclosure) A compound represented by: or a pharmaceutically acceptable salt thereof is provided.
[0010] In one embodiment, formula (IV): [ka] (In the formula, ring A, Ar 1 ,R 1 ,R 2 ,X 1 , Z 1 and subscripts n and m have the meanings provided in this disclosure) A compound represented by: or a pharmaceutically acceptable salt thereof is provided.
[0011] In a related embodiment, a compound of formula (I), (II), (III), (IV) or a compound of Table 1 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable A pharmaceutical composition comprising an excipient is provided.
[0012] In another embodiment, a method of treating and / or preventing a disease characterized by overexpression of Polθ in a patient, comprising: a therapeutically effective amount of formula (I), (II), (III), (IV); or a compound of Table 1 or a pharmaceutically acceptable salt thereof (or an embodiment thereof disclosed herein) to the patient. In one embodiment, the patient is identified as being in need of such treatment. In another embodiment, a compound of formula (I), (II), (III), (IV) or a compound of Table 1 (or an embodiment thereof disclosed herein) or the pharmaceutical The acceptable salts are administered in the form of pharmaceutical compositions. In yet another embodiment, the disease is cancer.
[0013] In yet another embodiment, a method of treating and / or preventing homologous recombination (HR)-deficient cancer in a patient, comprising: administering a therapeutically effective amount of formula (I), (II), (III), (IV ) or a compound of Table 1 or a pharmaceutically acceptable salt thereof (or an embodiment thereof as disclosed herein) to the patient. In one embodiment, the patient is identified as being in need of such treatment. In another embodiment, a compound of formula (I), (II), (III), (IV) or a compound of Table 1 (or an embodiment thereof disclosed herein) or the pharmaceutical The acceptable salts are administered in the form of pharmaceutical compositions.
[0014] In another embodiment, a method of inhibiting Polθ-mediated DNA repair in cancer cells comprising a therapeutically effective amount of a compound of formula (I), (II), (III), (IV) or A method is provided comprising contacting the cell with a compound (or an embodiment thereof disclosed herein) or a pharmaceutically acceptable salt thereof. In one embodiment, the cancer is an HR-deficient cancer.
[0015] In yet another embodiment, a method of treating and / or preventing cancer characterized by reduced or absent BRCA gene expression, absent or mutated BRAC gene, or reduced function of BRCA proteins in a patient, the method comprising: In the form of a pharmaceutical composition, a therapeutically effective amount of a compound of formula (I), (II), (III), (IV) or a compound of Table 1 (or as disclosed herein) Embodiment) or a pharmaceutically acceptable salt thereof to said patient.
[0016] In yet another embodiment, a compound of formula (I), (II), (III), (IV) or a compound of Table 1 (or herein Disclosed embodiments thereof) or a pharmaceutically acceptable salt thereof are provided. In one embodiment, the cell is an HR-deficient cell.
[0017] In another embodiment, a compound or compound of formula (I), (II), (III), (IV) for use in the treatment and / or prevention of a disease characterized by overexpression of Polθ in a patient. 1 (or embodiments thereof disclosed herein) or a pharmaceutically acceptable salt thereof.
[0018] In yet another embodiment, the formula ( I), (II), (III), (IV) or a compound of Table 1 (or an embodiment thereof disclosed herein) or a pharmaceutically acceptable salt thereof. Ru.
[0019] In yet another embodiment, a compound of formula (I), (II), (III), (IV) or a compound of Table 1 ( or embodiments thereof disclosed herein) or a pharmaceutically acceptable salt thereof.
[0020] In another embodiment, formula (I), (II), (III) for use in the treatment and / or prevention of cancer refractory to poly(ADP-ribose) polymerase (PARP) inhibitor therapy in a patient, A compound of (IV) or a compound of Table 1 (or an embodiment thereof disclosed herein) or a pharmaceutically acceptable salt thereof is provided. Examples of cancers that are resistant to PARP inhibitors include, but are not limited to, breast cancer, ovarian cancer, lung cancer, bladder cancer, liver cancer, head and neck cancer, pancreatic cancer, gastrointestinal cancer, prostate cancer, and Examples include colorectal cancer. In one embodiment, cancers that are resistant to PARP inhibitors include breast cancer, ovarian cancer, prostate cancer, and colorectal cancer.
[0021] In embodiments related to the above methods, uses and compositions, the cancer is lymphoma, rhabdomyomas, multiple myeloma, endometrial cancer, gastric cancer, peripheral nervous system cancer, rhabdomyosarcoma, bone cancer, colorectal cancer. , mesothelioma, breast cancer, ovarian cancer, lung cancer, fibroblast cancer, central nervous system cancer, urinary tract cancer, upper gastrointestinal tract cancer, leukemia, kidney cancer, skin cancer, esophageal cancer, prostate cancer, and pancreatic cancer (cancer Data from a large-scale dropout screen in cell lines showed that some of the cancer cell lines mentioned above are dependent on polymerase theta for proliferation (https: / / depmap.org / portal / ). .
[0022] In some embodiments, the HR-deficient cancer is breast cancer. Breast cancers include, but are not limited to, lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), inflammatory breast cancer, Paget's disease of the nipple, and phyllodes tumors. , angiosarcoma, adenoid cystic carcinoma, low-grade adenosquamous carcinoma, medullary carcinoma, mucinous carcinoma, papillary carcinoma, tubular carcinoma, metaplastic carcinoma, micropapillary carcinoma, mixed carcinoma, or another breast cancer (limited to but not triple negative, HER positive, estrogen receptor positive, progesterone receptor positive, HER and estrogen receptor positive, HER and progesterone receptor positive, estrogen and progesterone receptor positive, and HER and estrogen and progesterone receptor positive (including positive results). In other embodiments, the HR-deficient cancer is ovarian cancer. Ovarian cancers include, but are not limited to, epithelial ovarian cancer (EOC), mature teratomas, dysblastomas, endodermal sinus tumors, granulosa tumors, Sertoli-Leydig cell tumors, and primary peritoneal cancers. . Specific description of the invention
[0023] Before the present invention is further described, it is to be understood that the present invention is not limited to the particular embodiments set forth herein, and that the terms used herein refer to the particular embodiments set forth herein. It is also to be understood that it is for illustrative purposes only and is not intended to be limiting.
[0024] As used in this specification and the appended claims, the singular forms "a," "an," and "the" are used in this specification and the appended claims unless the context clearly dictates otherwise. Contains multiple references unless otherwise specified. Furthermore, it is noted that the claims may be drafted to exclude optional elements. Accordingly, when this specification uses exclusive terms such as "solely," "only," or "negative" limitations in connection with the description of claim elements, It is intended to serve as a precedential basis for the
[0025] When a range of values is stated, unless the context clearly dictates otherwise, each intervening value up to one tenth of a unit between the upper and lower limits of that range, and within that stated range. It is understood that other stated or intervening values are encompassed by the invention. The upper and lower limits of these smaller ranges may be independently included in the smaller ranges and are also encompassed by the invention, subject to specifically excluded upper limits within the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0026] Any definition herein may be used in combination with any other definition to describe a composite structural group, as appropriate. By convention, the last element of such a definition is the one that joins the parent part. For example, the composite group alkoxyalkyl means that the alkoxy group is attached to the parent molecule through an alkyl group.
[0027] Publications discussed herein are indicated solely for their disclosure prior to the filing date of the present application. Furthermore, the publication dates indicated may differ from the actual publication dates, which may need to be separately confirmed.
[0028] Definition: Unless otherwise stated, the following terms, as used in this specification and claims, are defined for the purposes of this application and have the following meanings:
[0029] The term "alkyl" by itself or as part of another substituent, unless otherwise specified, means a saturated straight or branched hydrocarbon group having the specified number of carbon atoms (i.e. C 1-8 means 1 to 8 carbons). Alkyl is C 1-2 ,C 1-3 ,C 1-4 ,C 1-5 ,C 1-6 ,C 1-7 ,C 1-8 ,C 1-9 ,C 1-10 ,C 2-3 ,C 2-4 ,C 2-5 ,C 2-6 ,C 3-4 ,C 3-5 ,C 3-6 ,C 4-5 ,C 4-6 and C 5-6 It can contain any number of carbons, such as. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, etc. .
[0030] The term "alkylene" refers to a straight or branched saturated aliphatic radical, ie, a divalent hydrocarbon group, having the indicated number of carbon atoms and linking at least two other groups. These two moieties linked to alkylene can be linked to the same atom of the alkylene group, or they can be linked to different atoms. For example, a straight chain alkylene is -(CH 2 ) n - may be a divalent group, where n is 1, 2, 3, 4, 5 or 6. Representative alkylene groups include, but are not limited to, methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, pentylene, hexylene, and the like.
[0031] The term "alkoxy" refers to an alkyl group having an oxygen atom connecting the alkyl group to the point of attachment: alkyl-O-. In the case of an alkyl group, the alkoxy group is C 1-6 It can have any suitable number of carbon atoms, such as, and can be straight or branched. Examples of the alkoxy group include methoxy, ethoxy, propoxy, isopropoxy, butoxy, 2-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy, and hexoxy.
[0032] As used herein, the term "cyano" by itself or as part of another substituent refers to a moiety having the formula -CN, ie, a carbon atom triple-bonded to a nitrogen atom.
[0033] The term "cycloalkyl" refers to a saturated or partially unsaturated hydrocarbon ring having the indicated number of ring atoms (e.g., C 3-6 cycloalkyl). Cycloalkyl is C 3-6 ,C 4-6 ,C 5-6 ,C 3-8 ,C 4-8 ,C 5-8 ,C 6-8 ,C 3-9 and C 3-10 It can contain any number of carbons, such as. A partially unsaturated cycloalkyl group has one or more double or triple bonds in the ring, but the cycloalkyl group is not aromatic. Saturated monocyclic cycloalkyl rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclooctyl.
[0034] The term "cycloalkyloxy" refers to a cycloalkyl group having an oxygen atom connecting the cycloalkyl group to the point of attachment: cycloalkyl-O-. Cycloalkyl group is as defined herein.
[0035] The term “bridged cyclyl” or “bridged cycloalkyl” means that two non-adjacent ring atoms are (CRR’) n a cycloalkyl group (sometimes referred to herein as a "bridging" group) in which n is 1 to 3 and each R is independently H or methyl; Refers to a ring (having 4 to 8 ring vertices). Bridged cycloalkyl groups do not have heteroatoms as ring vertices. Furthermore, C 5-8 refers to a bridged cycloalkyl group having 5 to 8 ring members. Examples include, but are not limited to, bicyclo[1.1.1]pentane, bicyclo[2.2.2]octane, bicyclo[2.2.1]heptane, and the like.
[0036] The term "spirocyclyl" or "spirocycloalkyl" refers to a saturated or partially unsaturated bicyclic ring having 6 to 12 ring atoms and in which the two rings are joined by a single carbon atom (also called a spiro atom). Refers to the formula ring. A partially unsaturated spirocycloalkyl group has one or more double or triple bonds within the ring, but the spirocycloalkyl group is not aromatic. Representative examples include, but are not limited to, spiro[3.3]heptane, spiro[4.4]nonane, spiro[3.4]octane, and the like.
[0037] The term "heterocycloalkyl" refers to a group having the indicated number of ring vertices (e.g., 3 to 7 membered ring) and 1 to 5 heteroatoms selected from N, O, and S as ring vertices. refers to a saturated or partially unsaturated monocyclic ring. A partially unsaturated heterocycloalkyl group has one or more double or triple bonds in the ring, but the heterocycloalkyl group is not aromatic. A heterocycloalkyl group can contain any number of ring atoms, such as 3-6, 4-6, 5-6, 3-7, 4-7 or 5-7 ring members. Heterocycloalkyl groups include any suitable number of heterocycloalkyl groups, such as 1, 2, 3, or 4, or 1-2, 1-3, 1-4, 2-3, 2-4, or 3-4. May contain atoms. Non-limiting examples of heterocycloalkyl groups include pyrrolidine, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, dioxolane, phthalimide, piperidine, 1,4-dioxane, morpholine, thiomorpholine, thiomorpholine-S -oxide, thiomorpholine-S,S-oxide, piperazine, pyran, pyridone, 3-pyrroline, thiopyran, pyrone, tetrahydrofuran, tetrahydrothiophene, quinuclidine, and the like. A heterocycloalkyl group can be attached to the remainder of the molecule through a ring carbon or heteroatom.
[0038] The term "bicyclic heterocycloalkyl" or "bicyclic heterocyclyl" has the indicated number of ring vertices (e.g., 6-12 membered ring), and the ring vertices are selected from N, O, and S. refers to a saturated or partially unsaturated fused bicyclic ring having 1 to 5 heteroatoms. A partially unsaturated bicyclic heterocycloalkyl group has one or more double or triple bonds in the ring, but the bicyclic heterocycloalkyl group is not aromatic. Bicyclic heterocycloalkyl groups can contain any number of ring atoms, such as from 6 to 8, 6 to 9, 6 to 10, 6 to 11, or 6 to 12 ring members. Heterocycloalkyl groups include any suitable number, such as 1, 2, 3, or 4, or 1-2, 1-3, 1-4, 2-3, 2-4, or 3-4. heteroatoms may be included. Non-limiting examples of bicyclic heterocycloalkyl groups include 3-oxabicyclo[3.1.0]hexane, decahydro-1,5-naphthyridine, octahydropyrrolo[1,2-a]pyrazine, and the like.
[0039] The term “bridged heterocyclyl” or “bridged heterocycloalkyl” means that two non-adjacent ring atoms are (CRR’) n (where n is 1-3 and each R is independently H or methyl) (sometimes referred to herein as a "bridging" group) Refers to a heterocycloalkyl ring (having 7 ring vertices). A bridged heterocyclyl group has 1 to 5 heteroatoms selected from N, O and S as ring vertices. Heteroatom ring vertices can be on both heterocycloalkyl ring moieties as well as bridging groups. When present in a bridging group, the heteroatom replaces the CRR' group. Examples include, but are not limited to, 2-oxabicyclo[2.1.1]hexane, 2-azabicyclo[2.2.2]octane, quinuclidine, 7-oxabicyclo[2.2.1]heptane, and the like.
[0040] The term "spiroheterocyclyl" or "spiroheterocycloalkyl" refers to a saturated or partially unsaturated group having 6 to 12 ring atoms, in which the two rings are linked through a single carbon atom (also called a spiro atom). Refers to a saturated bicyclic ring. The spiroheterocyclyl group has 1 to 5 heteroatoms selected from N, O and S as ring vertices, and the nitrogen atom is optionally quaternized. A partially unsaturated spiroheterocycloalkyl group has one or more double or triple bonds in the ring, but the spiroheterocycloalkyl group is not aromatic. Representative examples include, but are not limited to, 2,6-diazaspiro[3.3]heptane, 2,6-diazaspiro[3.4]octane, 2-azaspiro[3.4]octane, 5-oxaspiro[3.4]octane, Examples include 2,5-dioxaspiro[3.4]octane, 2-azaspiro[3.5]-nonane, and 2,7-diazaspiro[4.4]nonane.
[0041] The term "5-6 membered saturated or partially unsaturated ring comprising 0-2 additional heteroatoms independently selected from the group consisting of N, O and S" is defined herein. Refers to monocyclic 5- or 6-membered cycloalkyl or heterocycloalkyl, such as
[0042] The term "halo" or "halogen" by itself or as part of another substituent means, unless otherwise specified, a fluorine, chlorine, bromine or iodine atom.
[0043] The term "haloalkyl" refers to alkyl as defined above in which some or all of the hydrogen atoms have been replaced with halogen atoms. In the case of alkyl groups, haloalkyl groups are C 1-6 It can have any suitable number of carbon atoms, such as. For example, the term “C 1-4 "Haloalkyl" is meant to include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
[0044] The term "haloalkoxy" refers to an alkoxy group in which some or all of the hydrogen atoms have been replaced with halogen atoms. In the case of alkyl groups, haloalkoxy groups are C 1-6and the like, may have any suitable number of carbon atoms, may be straight chained or branched, and may be substituted with 1, 2, 3, or more halogens. A compound is oversubstituted (eg, perfluorinated) when all hydrogens are replaced with halogens (eg, fluorine). Haloalkoxy includes, but is not limited to, trifluoromethoxy, 2,2,2,-trifluoroethoxy, perfluoroethoxy, and the like.
[0045] The term "hydroxyalkyl" refers to an alkyl group in which one of the hydrogen atoms is replaced with a hydroxy (-OH) group. For alkyl groups, hydroxyalkyl groups are C 1-6 etc., and may have any suitable number of carbon atoms and may be straight or branched. Examples of the hydroxyalkyl group include hydroxymethyl, 1-hydroxylethyl, 2-hydroxyethyl, 2-hydroxylpropan-2-yl, and the like.
[0046] The term "aryl", unless otherwise specified, means a polyunsaturated (typically aromatic) hydrocarbon group which may be monocyclic or fused or covalently bonded polycyclic (up to three rings). . Non-limiting examples of aryl groups include phenyl, naphthyl and biphenyl.
[0047] The term "heteroaryl" refers to a 5- to 10-membered aromatic ring (or fused ring system) containing 1 to 5 heteroatoms selected from N, O, and S. A heteroaryl group can contain any number of ring atoms, such as 5-6, 3-8, 4-8, 5-8, 6-8, 3-9 or 3-10 ring members. Heteroaryl groups include 1, 2, 3, 4 or 5, or 1-2, 1-3, 1-4, 1-5, 2-3, 2-4, 2-5, 3-4 or Any suitable number of heteroatoms can be included, such as from 3 to 5. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom. Non-limiting examples of heteroaryl groups include pyridyl, pyridazinyl, pyrazinyl, pyrimindinyl, triazinyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, benzotriazinyl, purinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl , benzisoxazolyl, isobenzofuryl, isoindolyl, indolizinyl, benzotriazinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridine, benzothiaxolyl, benzofuranyl, benzothienyl, indolyl, quinolyl, isoquinolyl, isothiazolyl, Examples include pyrazolyl, indazolyl, pteridinyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiadiazolyl, pyrrolyl, thiazolyl, furyl, thienyl, and the like.
[0048] As used herein, the term "heteroatom" is meant to include oxygen (O), nitrogen (N), and sulfur (S).
[0049] The term "pharmaceutically acceptable salts" refers to salts of the active compounds prepared with relatively non-toxic acids or bases, depending on the particular substituents found on the compound described herein. It means to include. When compounds of the invention contain relatively acidic functional groups, base addition salts are formed by combining the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. can be obtained by contacting with Examples of salts derived from pharmaceutically acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, Examples include sodium and zinc. Salts derived from pharmaceutically acceptable organic bases include primary, secondary and tertiary amines, including substituted amines, cyclic amines, natural amines, etc. (e.g., arginine, betaine, caffeine, choline). , N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine , methylglucamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, etc.). When compounds of the invention contain relatively basic functional groups, acid addition salts are formed by combining the neutral form of such compounds with a sufficient amount of the desired acid, neat or in a suitable inert solvent. can be obtained by contacting the Examples of pharmaceutically acceptable acid addition salts include inorganic acids (hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrogen carbonic acid, phosphoric acid, monohydrogen phosphoric acid, dihydrogen phosphoric acid, sulfuric acid, monohydrogen sulfuric acid) , hydriodic acid, or phosphorous acid), and relatively non-toxic organic acids (such as acetic acid, propionic acid, isobutyric acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, salts derived from mandelic acid, phthalic acid, benzenesulfonic acid, p-tolylsulfonic acid, citric acid, tartaric acid, methanesulfonic acid, etc.). Also included are salts of amino acids (such as alginate) and salts of organic acids (such as glucuronic acid or galacturonic acid). (See, eg, Berge, S.M., et al, “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain particular compounds of the invention contain both basic and acidic functional groups, allowing the compounds to be converted into either base or acid addition salts.
[0050] The neutral form of the compound may be regenerated by contacting the salt with a base or acid and isolating the parent compound in conventional manner. Although the parent form of a compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, these salts are otherwise equivalent to the parent form of the compound for the purposes of this invention. be.
[0051] In addition to salt forms, the invention also provides prodrug forms of the compounds. Prodrugs of the compounds described herein are compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the invention. Additionally, prodrugs can be converted to compounds of the invention by chemical or biochemical methods in an ex vivo environment. For example, a prodrug can be slowly converted to a compound of the invention when placed in a transdermal patch reservoir using a suitable enzyme or chemical reagent.
[0052] Certain compounds of the invention can exist in unsolvated and solvated forms, including hydrated forms. In general, the solvated forms are equivalent to the unsolvated forms and are intended to be encompassed within the scope of this invention. Certain compounds of the invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by this invention and are intended to be within the scope of this invention.
[0053] Certain compounds of the invention have asymmetric carbon atoms (optical centers) or double bonds; racemates, diastereomers, geometric isomers, positional isomers and individual isomers (e.g., distinct enantiomers) are all intended to be included within the scope of this invention. When a stereochemical depiction is given, it is meant to refer to a compound in which one of the isomers is present and substantially free of the other isomer. "Substantially free of other isomers" refers to a ratio of the two isomers at least 80 / 20, more preferably 90 / 10, or 95 / 5 or more. In some embodiments, one of the isomers is present in an amount of at least 99%.
[0054] The compounds of the invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. A non-natural proportion of an isotope may be defined as a range from the amount found in nature to an amount consisting of 100% of the atoms in question. For example, the compound may contain radioactive isotopes (e.g., tritium ( 3 H), iodine 125( 125 I) or carbon-14( 14 C)), or non-radioactive isotopes (deuterium ( 2 H) or carbon-13( 13 C) etc.) may be incorporated. Such isotopic variations can provide additional utility to those described elsewhere in this application. For example, isotopic variants of the compounds of the invention may find additional utility, including, but not limited to, utility as diagnostic and / or imaging reagents, or as cytotoxic / radiotoxic therapeutic agents. There is. Additionally, isotopic variants of the compounds of the invention may have altered pharmacokinetic and pharmacodynamic properties that may contribute to improved safety, tolerability, or efficacy during treatment. All isotopic variations of the compounds of the invention, whether radioactive or not, are intended to be encompassed within the scope of the invention.
[0055] The terms "patient" or "subject" are used interchangeably to refer to a human or non-human animal (eg, mammal). In one embodiment, the patient is a human.
[0056] The terms "administration", "administering", etc., when applied to a subject, cell, tissue, organ, or biological fluid, e.g., a Polθ modulator, a pharmaceutical composition comprising the same, or a diagnostic agent. refers to contact with an object, cell, tissue, organ, or biological fluid. With respect to cells, administration includes contacting the reagent with the cell (eg, in vitro or ex vivo) as well as contacting the reagent with a fluid (if the fluid is in contact with the cell).
[0057] The terms "treat", "treating", "treatment" and the like refer to at least one of the root causes of the disease, disorder or condition afflicting the subject, or to the disease, disorder or condition afflicting the subject. A sequence of events initiated after a disease, disorder, or condition, or its symptoms, has been diagnosed, observed, etc., so as to temporarily or permanently eliminate, reduce, suppress, alleviate, or ameliorate at least one of the associated symptoms. (such as the administration of a Polθ modulator or a pharmaceutical composition comprising it). Accordingly, treatment includes inhibiting active disease (eg, preventing the onset or further progression of a disease, disorder or condition, or clinical symptoms associated therewith).
[0058] The term "in need of treatment" as used herein refers to a determination made by a physician or other caregiver that a subject is in need of or would benefit from treatment. Point. This determination is based on a variety of factors within the physician's or caregiver's area of expertise. For example, a patient has been diagnosed with a disease associated with overexpression of Polθ or a cancer deficient in homologous recombination (HR).
[0059] The terms "prevent," "preventing," "prophylaxis," etc. mean to temporarily or permanently reduce a subject's risk (e.g., determined by the absence of clinical symptoms) of developing a disease, disorder, condition, etc. prevent, suppress, inhibit or alleviate, or generally, for subjects predisposed to having a particular disease, disorder or condition, in such a manner as to delay its onset (e.g. the onset of a disease, disorder, condition or its symptoms) refers to a course of action (such as administration of a Polθ modulator or a pharmaceutical composition comprising it) that is initiated (before). In certain cases, the term also refers to slowing the progression of a disease, disorder or condition, or inhibiting its progression to a harmful or other undesirable condition.
[0060] The term "in need of prophylaxis" as used herein refers to a determination made by a physician or other caregiver that a subject requires or would benefit from preventive care. refers to This determination is based on a variety of factors within the physician's or caregiver's area of expertise.
[0061] The phrase "therapeutically effective amount" refers to the treatment of any disease, disorder or condition when administered to a subject, either alone or as part of a pharmaceutical composition, and in a single dose or as part of a series of doses. refers to administering to a subject an amount of an agent that can have any detectable positive effect on a symptom, aspect, or characteristic of. A therapeutically effective amount can be ascertained by measuring relevant physiological effects, and can be adjusted in conjunction with the dosing regimen and diagnostic analysis of the subject's condition. As an example, measurement of serum levels of a Polθ modulator (or a metabolite thereof, etc.) at a particular time after administration may be an indication of whether a therapeutically effective amount was used.
[0062] The phrase "an amount sufficient to effect a change" means that there is a detectable difference between the level of the indicator measured before (eg, baseline level) and after administration of a particular therapy. Indicators include any objective parameter (eg, serum concentration) or subjective parameter (eg, subject's sense of well-being).
[0063] The terms "inhibitor" and "antagonist" or "activator" and "agonist" refer to, for example, the activation of a ligand, receptor, cofactor, gene, cell, tissue, or organ, etc. Refers to inhibitory or activating molecules, respectively. An inhibitor is, for example, a molecule that reduces, blocks, suppresses, delays activation, inactivates, desensitizes, or downregulates a gene, protein, ligand, receptor, or cell. be. An activator is, for example, a molecule that increases, activates, promotes, enhances activation, sensitizes, or upregulates a gene, protein, ligand, receptor, or cell. Inhibitors may also be defined as molecules that reduce, block, or inactivate constitutive activity. An "agonist" is a molecule that interacts with a target to cause activation or promote augmentation of that target. An "antagonist" is a molecule that opposes the action of an agonist. An antagonist suppresses, reduces, inhibits, or neutralizes the activity of an agonist, and an antagonist also suppresses the constitutive activity of a target (e.g., a target receptor) even in the absence of an identified agonist. can be suppressed, inhibited, or reduced.
[0064] The terms "modulate," "modulation," and the like refer to the ability of a molecule (eg, an activator or inhibitor) to directly or indirectly increase or decrease the function or activity of Polθ. Modulators may act alone or with cofactors such as proteins, metal ions, or small molecules. Examples of modulators include small molecule compounds and other bioorganic molecules.
[0065] "Activity" of a molecule describes its binding to a ligand or receptor; catalytic activity; ability to stimulate gene expression or cell signaling, differentiation, or maturation; antigenic activity; modulation of the activity of other molecules, etc. , or may point to. The term "proliferative activity" includes, for example, activities that promote, are necessary for, or are specifically associated with normal cell division, as well as cancer, tumors, dysplasia, cell transformation, metastasis, and angiogenesis. do.
[0066] Certain compounds of the present disclosure may exist as tautomers and / or geometric isomers. All possible tautomers, cis and trans isomers, as individual forms and mixtures thereof, are within the scope of this disclosure. For example, certain hydroxy-substituted compounds include: [ka] It may exist as a tautomer as shown in .
[0067] "Pharmaceutically acceptable carrier or excipient" means a carrier useful in preparing pharmaceutical compositions that are generally safe, non-toxic, and not biologically or otherwise undesirable. or excipients, including carriers or excipients that are acceptable for veterinary and human pharmaceutical uses. "Pharmaceutically acceptable carrier / excipient" as used herein and in the claims includes both one and more than one such excipient. include.
[0068] As used herein, a wavy line that intersects a single, double, or triple bond in any chemical structure depicted herein [ka] represents the point of single, double or triple bond attachment to the rest of the molecule. Additionally, a bond extending down the center of a ring (eg, a phenyl ring) is meant to indicate a bond at any of the available ring vertices. Those skilled in the art will appreciate that multiple substituents shown attached to a ring provide stable compounds and occupy otherwise sterically compatible ring vertices.
[0069] "About" as used herein is intended to qualify the numerical value it modifies, and indicates such values as may vary within error. If no specific error is indicated, such as a standard deviation relative to the mean value given in a graph or table of data, the term "about" encompasses ±10%, preferably ±5% of the indicated value. It should be understood to mean and include a range.
[0070] "Disease" as used herein is generally synonymous with the terms "disorder," "syndrome," and "condition" (in medical conditions) and is intended to be used interchangeably; That is, all terms refer to any abnormality of the human or animal body or parts thereof that impairs its normal functioning, is typically manifested by characteristic signs and symptoms, and reduces the human or animal's longevity or quality of life. reflect the current state.
[0071] "Patient" is generally synonymous with the term "subject" and as used herein includes all mammals, including humans. Examples of patients include humans, livestock (such as cows, goats, sheep, pigs and rabbits) and companion animals (such as dogs, cats, rabbits and horses). Preferably the patient is human.
[0072] "Inhibiting", "reducing" or variations of these terms with respect to Polθ include any measurable reduction or complete inhibition to achieve the desired result. For example, about, at most about, or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% of Polθ activity compared to normal activity; Even if there is a reduction of 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or any range derivable therefrom. good.
[0073] The term "homologous recombination" refers to the intracellular process of genetic recombination in which nucleotide sequences are exchanged between two similar or identical DNAs.
[0074] The term "homologous recombination (HR)-deficient cancer" refers to a cancer characterized by a reduction or absence of a functional HR repair pathway. HR deficiency may result from the absence of one or more HR-related genes or the presence of one or more mutations in one or more HR-related genes. Examples of HR-related genes include BRCA1, BRCA2, RAD54, RAD51B, Ct1P (Choline Transporter-Like Protein), PALB2 (Partner and Localizer of BRCA2), XRCC2 (X-ray repair complementing defective repair in Chinese hamster cells 2), RECQL4 (RecQ Protein-Like 4), BLM (Bloom syndrome, RecQ helicase-like), WRN (Werner syndrome, one or more HR-associated genes) Nbs1 (Nibrin), and Fanconi anemia (FA) protein or FA-like gene Genes encoding ), RAD51C and XPF).
[0075] The term "Polθ overexpression" refers to an increase in Polθ expression or activity in a diseased cell (eg, a cancer cell) as compared to Polθ expression or activity in a normal cell (eg, an unaffected cell of the same type). The amount of Polθ can be at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, or more than the Polθ expression of normal cells. Examples of Polθ cancers include, but are not limited to, breast cancer, ovarian cancer, cervical cancer, lung cancer, colon cancer, stomach cancer, bladder cancer, and prostate cancer.
[0076] Compound: In some embodiments, Formula (I): [ka] (In the formula, X 1 is CH 2 and C substituted with 0~1 -OH 2-4 selected from the group consisting of alkylene; Ring A is selected from the group consisting of phenyl and 5-10 membered heteroaryls having 1-4 heteroatoms independently selected from N, O and S as ring vertices; subscripts m and n are each independently 0 or 1; R 1 and R 2 are each independently, C 1-4 Alkyl, C 1-4 alkoxy, halo, C 1-4 haloalkyl, C 1-4 Haloalkoxy, C 1-4 hydroxyalkyl, -X a -O-C 1-4 selected from the group consisting of alkyl, -C(O)OH and cyano, where X a are independently combined and C 1-4 selected from alkylene; Ar 1 is phenyl, 5-6 membered heteroaryl having 1-4 heteroatoms as ring vertices independently selected from N, O and S, 1-3 independently selected from N, O and S 5- to 6-membered heterocycloalkyl having 1 to 4 heteroatoms as ring vertices; 6- to 10-membered bicyclic heterocyclyl having 1 to 4 heteroatoms independently selected from N, O, and S as ring vertices; 6-10 membered bridged heterocyclyl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, and 1-3 heteroatoms independently selected from N, O and S selected from the group consisting of 6- to 12-membered spiroheterocyclyl having an atom as a ring apex, where Ar 1 is 0 to 3 R 3 is replaced with; Each R 3 is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Haloalkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, -X 2 -OH, -X 2 -O-C 1-4 Alkyl, -C(O)-C 1-4 alkyl and -X 2 - selected from the group consisting of cyano; or two R on adjacent ring vertices 3 is combined with C 3-6 Form a cycloalkyl or two R on the same ring apex 3 combine to form oxo, where each 2 are independently combined and C 1-4 selected from alkylene; Z is: (i) A 4- to 6-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices, wherein the ring apex bearing S is optionally S(O ) or S(O) 2 4- to 6-membered heterocycloalkyl, which is oxidized to; (ii)C 5-8 Bridged cycloalkyl; (iii)C 6-12 spirocyclyl; (iv) Adjacent ring vertices are substituted by moieties that combine to form a 5- to 6-membered heteroaryl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices. , thereby forming a fused ring system, C 5-7 cycloalkyl; (v) A 5- to 7-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices, with adjacent ring vertices bonded to N , O and S, substituted by a moiety forming a 5- to 6-membered heteroaryl having 0 to 2 additional heteroatoms independently selected from O and S as ring vertices, thereby forming a fused ring system, 5-7 membered heterocycloalkyl; (vi) A 5- to 6-membered heteroaryl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices, with adjacent ring vertices bonded to N, substituted by two moieties forming a 5- to 6-membered saturated or partially unsaturated ring containing as ring vertices 0 to 2 additional heteroatoms independently selected from the group consisting of O and S; 5- to 6-membered heteroaryl, thereby forming a fused ring system; (vii) C having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices 5-7 Bridged heterocyclyl; (viii) a 6- to 12-membered spiroheterocyclyl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices; and (ix) 4- to 10-membered bicyclic heterocyclyl having 1 to 4 heteroatoms independently selected from N, O, and S as ring vertices; selected from the group consisting of Each Z is 0 to 3 R 4 substituted with substituents, each of which is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Alkoxy, C 1-4 haloalkoxy, -X 3 -OH,C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, -X 3 -cyano, -X 3 -O-C 1-4 Alkyl, -X 3 -C(O)OH, -S(O)(NH)-C 1-4 Alkyl, -S(O) 2 -C 1-4 Alkyl, -C(O)-C 1-4 -X containing alkyl and 4 to 6 ring members and 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices 4 - selected from heterocycloalkyl; or two R 4 the substituents combine to form an oxo moiety; where each cycloalkyl is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Alkoxy, -X 3 -O-C 1-4 Alkyl, -X 3 -C(O)OH and -X 3 substituted with 0 to 3 substituents independently selected from the group consisting of -OH; each X 3 are independently combined and C 1-4 selected from alkylene; each X 4 are, independently, the bond, -O- and C 1-4 selected from alkylene) Provided in this disclosure is a compound represented by: or a pharmaceutically acceptable salt thereof.
[0077] In some embodiments, Formula (I): [ka] (In the formula, X 1 is CH 2 and C substituted with 0~1 -OH 2-4 selected from the group consisting of alkylene; Ring A is selected from the group consisting of phenyl and 5-10 membered heteroaryls having 1-4 heteroatoms independently selected from N, O and S as ring vertices; subscripts m and n are each independently 0 or 1; R 1 and R 2 are each independently, C 1-4 Alkyl, C 1-4 alkoxy, halo, C 1-4 haloalkyl, C 1-4 Haloalkoxy, C 1-4 selected from the group consisting of hydroxyalkyl, -C(O)OH and cyano; Ar 1 is phenyl, 5-6 membered heteroaryl having as ring vertices 1-4 heteroatoms independently selected from N, O and S, 1-3 independently selected from N, O and S 6- to 10-membered bicyclic heterocyclyl having 1 to 4 heteroatoms independently selected from N, O, and S as ring vertices; 6-10 membered bridged heterocyclyl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, and 1-3 heteroatoms independently selected from N, O and S selected from the group consisting of 6- to 12-membered spiroheterocyclyl having an atom as a ring apex, where Ar 1 is 0 to 3 R 3 is replaced with; Each R 3 is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Haloalkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, -X 2 -OH, -X 2 -O-C 1-4 Alkyl, -C(O)-C 1-4 alkyl and -X 2 - selected from the group consisting of cyano; or two R on adjacent ring vertices 3 is combined with C 3-6 Form a cycloalkyl or two R on the same ring apex 3 combine to form oxo, where each 2 are independently combined and C 1-4 selected from alkylene; Z is: (i) A 4- to 6-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices, wherein the ring apex bearing S is optionally S(O ) or S(O) 2 4- to 6-membered heterocycloalkyl, which is oxidized to; (ii)C 5-8 Bridged cycloalkyl; (iii)C 6-12 spirocyclyl; (iv) Adjacent ring vertices are substituted by moieties that combine to form a 5- to 6-membered heteroaryl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices. , thereby forming a fused ring system, C 5-7 cycloalkyl; (v) A 5- to 7-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices, with adjacent ring vertices bonded to N , O and S, substituted by a moiety forming a 5- to 6-membered heteroaryl having 0 to 2 additional heteroatoms independently selected from O and S as ring vertices, thereby forming a fused ring system, 5-7 membered heterocycloalkyl; (vi) A 5- to 6-membered heteroaryl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices, with adjacent ring vertices bonded to N, substituted by two moieties forming a 5- to 6-membered saturated or partially unsaturated ring containing as ring vertices 0 to 2 additional heteroatoms independently selected from the group consisting of O and S; 5- to 6-membered heteroaryl, thereby forming a fused ring system; (vii) C having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices 5-7 bridged heterocyclyl; and (viii) a 6- to 12-membered spiroheterocyclyl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices; selected from the group consisting of Each Z is 0 to 3 R 4 substituted with substituents, each of which is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Alkoxy, C 1-4 haloalkoxy, -X 3 -OH,C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, -X 3 -cyano, -X 3 -O-C 1-4 Alkyl, -X 3 -C(O)OH, -S(O)(NH)-C 1-4 Alkyl, -S(O) 2 -C 1-4 Alkyl, -C(O)-C 1-4 -X containing alkyl and 4 to 6 ring members and 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices 4 - selected from heterocycloalkyl, where each cycloalkyl is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Alkoxy, -X 3 -O-C 1-4 Alkyl, -X 3 -C(O)OH and -X 3 substituted with 0 to 3 substituents independently selected from the group consisting of -OH; each X 3 are independently combined and C 1-4 selected from alkylene; each X 4 are, independently, the bond, -O- and C 1-4 selected from alkylene) Provided in this disclosure is a compound represented by: or a pharmaceutically acceptable salt thereof.
[0078] In some embodiments, Formula (I): [ka] (In the formula, X 1 is CH 2 and C substituted with 0~1 -OH 2-4 selected from the group consisting of alkylene; Ring A is selected from the group consisting of phenyl and 5-10 membered heteroaryls having 1-4 heteroatoms independently selected from N, O and S as ring vertices; subscripts m and n are each independently 0 or 1; R 1 and R 2 are each independently, C 1-4 Alkyl, C 1-4 alkoxy, halo, C 1-4 haloalkyl, C 1-4 Haloalkoxy, C 1-4 selected from the group consisting of hydroxyalkyl, -C(O)OH and cyano; Ar 1 is phenyl, 5-6 membered heteroaryl having as ring vertices 1-4 heteroatoms independently selected from N, O and S, 1-3 independently selected from N, O and S 6- to 10-membered bicyclic heterocyclyl having 1 to 4 heteroatoms independently selected from N, O, and S as ring vertices; 6-10 membered bridged heterocyclyl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, and 1-3 heteroatoms independently selected from N, O and S selected from the group consisting of 6- to 12-membered spiroheterocyclyl having an atom as a ring apex, where Ar 1 is 0 to 3 R 3 is replaced with; Each R 3 is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Haloalkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, -X 2 -OH, -X 2 -O-C 1-4 Alkyl, -C(O)-C 1-4 alkyl and -X 2 - selected from the group consisting of cyano; or two R on adjacent ring vertices 3 is combined with C 3-6 Form a cycloalkyl or two R on the same ring apex 3 combine to form oxo, where each 2 are independently combined and C 1-4 selected from alkylene; Z is: (i) 5- to 6-membered heterocycloalkyl; (ii)C 5-8 Bridged cycloalkyl; (iii)C 6-12 spirocyclyl; (iv) Adjacent ring vertices are substituted by moieties that combine to form a 5- to 6-membered heteroaryl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices. , thereby forming a fused ring system, C 5-7 cycloalkyl; (v) A 5- to 7-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices, with adjacent ring vertices bonded to N , O and S, substituted by a moiety forming a 5- to 6-membered heteroaryl having 0 to 2 additional heteroatoms independently selected from O and S as ring vertices, thereby forming a fused ring system, 5-7 membered heterocycloalkyl; (vi) A 5- to 6-membered heteroaryl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices, with adjacent ring vertices bonded to N, substituted by two moieties forming a 5- to 6-membered saturated or partially unsaturated ring containing as ring vertices 0 to 2 additional heteroatoms independently selected from the group consisting of O and S; a 5- to 6-membered heteroaryl thereby forming a fused ring system; and (vii) C having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices 5-7 bridged heterocyclyl selected from the group consisting of Each Z is 0 to 3 R 4 substituted with substituents, each of which is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Alkoxy, C 1-4 haloalkoxy, -X 3 -OH,C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, -X 3 -cyano, -X 3 -O-C 1-4 Alkyl, -X 3 -C(O)OH, -S(O)(NH)-C 1-4 Alkyl, -S(O) 2 -C 1-4 Alkyl, -C(O)-C 1-4 -X containing alkyl and 4 to 6 ring members and 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices 4 - selected from heterocycloalkyl, where each cycloalkyl is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Alkoxy, -X 3 -O-C 1-4 Alkyl, -X 3 -C(O)OH and -X 3 substituted with 0 to 3 substituents independently selected from the group consisting of -OH; each X 3 are independently combined and C 1-4 selected from alkylene; each X 4 are, independently, the bond, -O- and C 1-4 selected from alkylene) Provided in this disclosure is a compound represented by: or a pharmaceutically acceptable salt thereof.
[0079] In some embodiments, the compound of formula (I) has formula (Ia): [ka] or a pharmaceutically acceptable salt thereof.
[0080] In some embodiments, Z in formula (I) is [ka] It is.
[0081] In some embodiments, Z in formula (I) is [ka] It is.
[0082] In some embodiments, Z in formula (I) is [ka] It is.
[0083] In some embodiments, Z in formula (I) represents 0-3 R 4 is a 4-membered heterocycloalkyl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 azetidinyl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 azetidin-3-yl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 The apex of the thio ring is oxidized with two oxo groups. In some embodiments, Z in formula (I) represents 0-3 R 4 thio ring apex is oxidized with two oxo groups. In some embodiments, Z in formula (I) represents 0-3 R 4 oxetanyl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 oxetan-3-yl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 oxetan-2-yl substituted with In some embodiments, Z in formula (I) is the 4-membered heterocycloalkyl group 4 has been replaced with In some embodiments, the 4-membered heterocycloalkyl group has two R 4 has been replaced with In some embodiments, R 4 is -OH. In some embodiments, R 4 is C 1-4 alkyl, halo, C 1-4 haloalkyl, -X 3 -OH, cyano or -C(O)-C 1-4 It is an alkyl. In some embodiments, R 4 is C 1-4 It is an alkyl. In some embodiments, R 4 is a halo. In some embodiments, R 4 is chloro or fluoro. In some embodiments, R 4 is -OH. In some embodiments, R 4 is cyano. In some embodiments, -C(O)-C 1-4 It is an alkyl.
[0084] In some embodiments, Z in formula (I) represents 0-3 R 4 is a 5-membered heterocycloalkyl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 is tetrahydrofuranyl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 is tetrahydrofuran-3-yl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 pyrrolidinyl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 pyrrolidin-3-yl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 imidazolyl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 imidazol-1-yl substituted with In some embodiments, the 5-membered heterocycloalkyl group has one R 4 has been replaced with In some embodiments, the 5-membered heterocycloalkyl group has two R 4 has been replaced with In some embodiments, the 5-membered heterocycloalkyl group has two R 4 has been replaced with In some embodiments, R 4 is -OH. In some embodiments, R 4 is C 1-4 alkyl, halo, C 1-4 haloalkyl, -X 3 -OH, cyano or -C(O)-C 1-4 It is an alkyl. In some embodiments, R 4 is C 1-4 It is an alkyl. In some embodiments, R 4 is a halo. In some embodiments, R 4 is chloro or fluoro. In some embodiments, R 4 is -OH. In some embodiments, R 4 is cyano. In some embodiments, -C(O)-C 1-4 It is an alkyl.
[0085] In some embodiments, Z in formula (I) represents 0-3 R 4 is a 6-membered heterocycloalkyl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 is tetrahydropyranyl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 is tetrahydropyran-4-yl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 is tetrahydropyran-2-yl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4is a tetrahydrothiopyranyl substituted with , and the apex of the thio ring is oxidized with two oxo groups. In some embodiments, Z in formula (I) represents 0-3 R 4 is tetrahydrothiopyran-4-yl substituted with , and the apex of the thio ring is oxidized with two oxo groups. In some embodiments, Z in formula (I) represents 0-3 R 4 piperidinyl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 piperidin-4-yl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 dioxanyl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 is dioxan-2-yl substituted with In some embodiments, the 6-membered heterocycloalkyl group has one R 4 has been replaced with In some embodiments, the 6-membered heterocycloalkyl group has two R 4 has been replaced with In some embodiments, R 4 is -OH. In some embodiments, R 4 is C 1-4 alkyl, halo, C 1-4 haloalkyl, -X 3 -OH, cyano or -C(O)-C 1-4 It is an alkyl. In some embodiments, R 4 is C 1-4 It is an alkyl. In some embodiments, R 4 is a halo. In some embodiments, R 4 is chloro or fluoro. In some embodiments, R 4 is -OH. In some embodiments, R 4 is cyano. In some embodiments, -C(O)-C 1-4 It is an alkyl.
[0086] In some embodiments, Z in formula (I) represents 0-3 R 4 C replaced with 5-8 It is a bridged cycloalkyl. In some embodiments, Z in formula (I) represents 0-3 R 4 Bicyclo[1.1.1]pentanyl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 Bicyclo[2.2.1]heptanyl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 Bicyclo[2.2.2]octanyl substituted with In some embodiments, the above C 5-8 A bridged cycloalkyl group has one R 4 has been replaced with In some embodiments, the above C 5-8 A bridged cycloalkyl group consists of two R 4 has been replaced with In some embodiments, R 4 is -OH. In some embodiments, R 4 is C 1-4 alkyl, halo, C 1-4 haloalkyl, -X 3 -OH, cyano or -C(O)-C 1-4 It is an alkyl. In some embodiments, R 4 is C 1-4 It is an alkyl. In some embodiments, R 4 is a halo. In some embodiments, R 4 is chloro or fluoro. In some embodiments, R 4 is -OH. In some embodiments, R 4 is cyano. In some embodiments, -C(O)-C 1-4 It is an alkyl.
[0087] In some embodiments, Z in formula (I) represents 0-3 R 4 C replaced with 6-12 It is spirocyclyl. In some embodiments, Z in formula (I) represents 0-3 R 4 spiro[3.3]heptanyl substituted with In some embodiments, the above C 6-12 A spirocyclyl group has one R 4 has been replaced with In some embodiments, the above C 6-12 A spirocyclyl group consists of two R 4 has been replaced with In some embodiments, R 4 is -OH. In some embodiments, R 4 is C 1-4 alkyl, halo, C 1-4 haloalkyl, -X 3 -OH, cyano or -C(O)-C 1-4 It is an alkyl. In some embodiments, R 4 is C 1-4 It is an alkyl. In some embodiments, R 4 is a halo. In some embodiments, R 4 is chloro or fluoro. In some embodiments, R 4 is -OH. In some embodiments, R 4 is cyano. In some embodiments, -C(O)-C 1-4 It is an alkyl.
[0088] In some embodiments, Z in formula (I) is C 5-7 cycloalkyl, where adjacent ring vertices are joined to form a 5- to 6-membered heteroaryl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices; C substituted by two moieties, thereby forming a fused ring system 5-7 cycloalkyl, and the above fused ring system has 0 to 3 R 4 has been further replaced with . In some embodiments, the fused ring system has one R 4 has been replaced with In some embodiments, the fused ring system comprises two R 4 has been replaced with In some embodiments, R 4 is -OH. In some embodiments, R 4 is C 1-4 alkyl, halo, C 1-4 haloalkyl, -X 3 -OH, cyano or -C(O)-C 1-4 It is an alkyl. In some embodiments, R 4 is C 1-4 It is an alkyl. In some embodiments, R 4 is a halo. In some embodiments, R 4 is chloro or fluoro. In some embodiments, R 4 is -OH. In some embodiments, R 4 is cyano. In some embodiments, -C(O)-C 1-4 It is an alkyl.
[0089] In some embodiments, Z in formula (I) is a 5- to 7-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices; , two moieties whose adjacent ring vertices combine to form a 5- to 6-membered heteroaryl having 0 to 2 additional heteroatoms independently selected from N, O, and S as ring vertices. a 5- to 7-membered heterocycloalkyl substituted by R 4 has been further replaced with . In some embodiments, Z in formula (I) represents 0-3 R 4 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl substituted with In some embodiments, the fused ring system has one R 4 has been replaced with
[0090] In some embodiments, Z in formula (I) is a 5- to 6-membered heteroaryl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices, two adjacent ring vertices joined together to form a 5- to 6-membered ring containing as ring vertices 0 to 2 additional heteroatoms independently selected from the group consisting of N, O, and S; a 5- to 6-membered heteroaryl, substituted with 4 has been further replaced with . In some embodiments, Z in formula (I) has adjacent ring vertices joined thereto to form 0 to 2 additional heterozygous groups independently selected from the group consisting of N, O, and S. pyridyl substituted by two moieties forming a 5-6 membered ring containing atoms as ring vertices, thereby forming a fused ring system, the fused ring system comprising 0-3 R 4 has been further replaced with . In some embodiments, Z in formula (I) represents 0-3 R 4 4,5,6,7-tetrahydro-1H-indazolyl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 5,6,7,8-tetrahydroquinolinyl substituted with In some embodiments, Z in formula (I) represents 0-3 R 4 2,3-dihydro-[1,4]dioxino[2,3-b]pyridinyl or 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl substituted with . In some embodiments, Z in formula (I) represents 0-3 R 45,6,7,8-tetrahydro-1,6-naphthyridinyl substituted with In some embodiments, the 5-6 membered heteroaryl group has one R 4 has been replaced with In some embodiments, the 45-6 membered heteroaryl group has two R 4 has been replaced with In some embodiments, R 4 is -OH. In some embodiments, R 4 is C 1-4 alkyl, halo, C 1-4 haloalkyl, -X 3 -OH, cyano or -C(O)-C 1-4 It is an alkyl. In some embodiments, R 4 is C 1-4 It is an alkyl. In some embodiments, R 4 is a halo. In some embodiments, R 4 is chloro or fluoro. In some embodiments, R 4 is -OH. In some embodiments, R 4 is cyano. In some embodiments, -C(O)-C 1-4 It is an alkyl.
[0091] In some embodiments, Z in formula (I) is 0-3 R with 1-3 heteroatoms independently selected from N, O, and S as ring vertices. 4 C replaced with 5-7 It is a bridged heterocyclyl. In some embodiments, Z is 0-3 R 4 2-azabicyclo[2.2.1]heptanyl substituted with In some embodiments, the above C 5-7 A bridged heterocyclyl group has one R 4 has been replaced with In some embodiments, the above C 5-7 A bridged heterocyclyl group consists of two R 4 has been replaced with In some embodiments, R 4 is -OH. In some embodiments, R 4 is C 1-4 alkyl, halo, C 1-4 haloalkyl, -X 3 -OH, cyano or -C(O)-C 1-4 It is an alkyl. In some embodiments, R 4 is C 1-4 It is an alkyl. In some embodiments, R 4 is a halo. In some embodiments, R 4 is chloro or fluoro. In some embodiments, R 4 is -OH. In some embodiments, R 4 is cyano. In some embodiments, -C(O)-C 1-4 It is an alkyl.
[0092] In some embodiments, Z in formula (I) is 0-3 R with 1-3 heteroatoms independently selected from N, O, and S as ring vertices. 4 It is a 6- to 12-membered spiroheterocyclyl substituted with . In some embodiments, Z in formula (I) is 0-3 R 4 2-oxaspiro[3.3]heptanyl substituted with In some embodiments, Z in formula (I) is 0-3 R 4 2-oxaspiro[3.3]heptan-6-yl substituted with . In some embodiments, the 6-12 membered spiroheterocyclyl group has one R 4 has been replaced with In some embodiments, the 6-12 membered spiroheterocyclyl group has two R 4 has been replaced with In some embodiments, R 4 is -OH. In some embodiments, R 4 is C 1-4 alkyl, halo, C 1-4 haloalkyl, -X 3 -OH, cyano or -C(O)-C 1-4 It is an alkyl. In some embodiments, R 4 is C 1-4 It is an alkyl. In some embodiments, R 4 is a halo. In some embodiments, R 4 is chloro or fluoro. In some embodiments, R 4 is -OH. In some embodiments, R 4 is cyano. In some embodiments, -C(O)-C 1-4 It is an alkyl.
[0093] In some embodiments, Z in formula (I) is 0-3 R with 1-4 heteroatoms independently selected from N, O, and S as ring vertices. 4 is a 4- to 10-membered bicyclic heterocyclyl substituted with In some embodiments, Z in formula (I) is 0-3 R 4 oxabicyclo(3.1.0)hexanyl substituted with In some embodiments, the 4-10 membered bicyclic heterocyclyl group has one R 4 has been replaced with In some embodiments, the 4-10 membered bicyclic heterocyclyl group has two R 4 has been replaced with In some embodiments, R 4 is -OH. In some embodiments, R 4 is C 1-4 alkyl, halo, C 1-4 haloalkyl, -X 3 -OH, cyano or -C(O)-C 1-4 It is an alkyl. In some embodiments, R 4 is C 1-4 It is an alkyl. In some embodiments, R 4 is a halo. In some embodiments, R 4 is chloro or fluoro. In some embodiments, R 4 is -OH. In some embodiments, R 4 is cyano. In some embodiments, -C(O)-C 1-4 It is an alkyl.
[0094] In some embodiments, Z in formula (I) is R 4 is not replaced by . In some embodiments, Z in formula (I) is one R 4 has been replaced with In some embodiments, Z in formula (I) is 2 R 4 has been replaced with In some embodiments, R 4 is -OH. In some embodiments, R 4 is C 1-4 alkyl, halo, C 1-4 haloalkyl, -X 3 -OH, cyano or -C(O)-C 1-4 It is an alkyl. In some embodiments, R 4 is C 1-4 It is an alkyl. In some embodiments, R 4 is a halo. In some embodiments, R 4 is chloro or fluoro. In some embodiments, R 4 is -OH. In some embodiments, R 4 is cyano. In some embodiments, -C(O)-C 1-4 It is an alkyl.
[0095] In some embodiments, Formula (II): [ka] (In the formula, X 1 is CH 2 and C substituted with 0~1 -OH 2-4 selected from the group consisting of alkylene; Ring A is selected from the group consisting of phenyl and 5-10 membered heteroaryls having 1-3 heteroatoms independently selected from N, O and S as ring vertices; subscripts m and n are each independently 0 or 1; Each R 1 and R 2 are each independently, C 1-4 Alkyl, C 1-4 alkoxy, halo, C 1-4 haloalkyl, C 1-4 Haloalkoxy, C 1-4 selected from hydroxyalkyl, -C(O)OH and cyano; Ar 1 is phenyl, 5-6 membered heteroaryl having as ring vertices 1-3 heteroatoms independently selected from N, O and S, 1-3 independently selected from N, O and S 6- to 10-membered bicyclic heterocyclyl having 1 to 4 heteroatoms independently selected from N, O, and S as ring vertices; 6-10 membered bridged heterocyclyl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, and 1-3 heteroatoms independently selected from N, O and S selected from the group consisting of 6- to 12-membered spiroheterocyclyl having an atom as a ring apex, where Ar 1 is 0 to 3 R 3 is replaced with; Each R 3 is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4Haloalkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, -X 2 -OH, -X 2 -O-C 1-4 Alkyl, -C(O)-C 1-4 alkyl and -X 2 - selected from the group consisting of cyano; or two R on adjacent ring vertices 3 is combined with C 3-6 Form a cycloalkyl or two R on the same ring apex 3 combine to form oxo, where each 2 are independently combined and C 1-4 selected from alkylene; Ar 2 is a 5- to 10-membered heteroaryl having as ring vertices 1 to 3 heteroatoms independently selected from phenyl, N, O, and S, and C 3-6 selected from the group consisting of cycloalkyl, Each Ar 2 -X 3 -OH, -X 3 -O-C 1-4 Alkyl, C 3-6 cycloalkyl, -X 5 -C(O)OH, -C 2-4 Alkylene-cyano, -S(O)(NH)-C 1-4 Alkyl, -S(O) 2 -C 1-4 -X containing alkyl and 4 to 6 ring members and 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices 4 -R selected from the group consisting of heterocycloalkyl 4a Substituted with a substituent, Each cycloalkyl is independently -X 3 -O-C 1-4 Alkyl, -X 5 -C(O)OH and -X 3 substituted with 1 to 2 substituents independently selected from -OH; Each Ar 2 is 0 to 2 R 4 further substituted with substituents, each of which is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Alkoxy, C 1-4 haloalkoxy, -X 5 -OH,C 3-6 cycloalkyl, -X 5 -cyano and C 3-6 selected from the group consisting of cycloalkyloxy; each X 3 is independently C 1-4 is alkylene; each X 4 -O- and C 1-4 selected from alkylene; each X 5 are independently combined and C 1-4 selected from alkylene) Provided in this disclosure is a compound represented by: or a pharmaceutically acceptable salt thereof.
[0096] In some embodiments, Ar 2 and R 4a is combined [ka] (where the wavy line represents the point of attachment to the rest of the molecule) form.
[0097] In some embodiments, X in formula (II) 1 is CH 2 It is.
[0098] In some embodiments, R in formula (II) 4a -X 3 -OH. In some embodiments, R in formula (II) 4a is selected from the group consisting of hydroxymethyl, 1-hydroxylethyl, 2-hydroxyethyl and 2-hydroxylpropan-2-yl. In some embodiments, Ar 2 is pyridyl or piperazinyl and R 4a is hydroxymethyl or 2-hydroxylpropan-2-yl.
[0099] In some embodiments, R in formula (II) 4a -X 3 -O-C 1-4 It is an alkyl. In some embodiments, R in formula (II) 4a is selected from the group consisting of methoxymethyl, 2-methoxypropan-2-yl and 1-methoxyethyl. In some embodiments, Ar 2 is pyridyl or piperazinyl and R 4a is selected from the group consisting of methoxymethyl, 2-methoxypropan-2-yl and 1-methoxyethyl.
[0100] In some embodiments, R in formula (II) 4a is a C substituted with 1 to 2 substituents independently selected from the group consisting of -C(O)OH and hydroxymethyl 3-6 It is cycloalkyl. In some embodiments, R 4a is substituted with -C(O)OH or hydroxymethyl 6 It is cycloalkyl.
[0101] In some embodiments, R in formula (II) 4a -X 5 -C(O)OH. In some embodiments, R 4a is -C(O)OH. In some embodiments, Ar 2 and R 4a is combined [ka] form.
[0102] In some embodiments, R in formula (II) 4a -C 2-4 It is alkylene-cyano. In some embodiments, R 4a is selected from the group consisting of 1-cyanoethyl, 2-cyanoethyl and 2-cyanopropan-2-yl. In some embodiments, R 4a is 2-cyanopropan-2-yl.
[0103] In some embodiments, R in formula (II) 4a is -S(O)(NH)-C 1-4 It is an alkyl. In some embodiments, R 4a is -S(O)(NH)-methyl. In some embodiments, Ar 2 and R 4a is combined [ka] form.
[0104] In some embodiments, R in formula (II) 4a is -S(O) 2 -C 1-4 It is an alkyl. In some embodiments, R 4a is -S(O) 2 -Methyl. In some embodiments, Ar 2 and R 4a is combined [ka] form.
[0105] In some embodiments, R in formula (II) 4a -X contains as ring vertices 4 to 6 ring members and 1 to 3 heteroatoms independently selected from N, O and S 4 -Heterocycloalkyl. In some embodiments, R 4a is -methylene-heterocycloalkyl containing 4 to 6 ring members and 1 to 3 heteroatoms independently selected from N, O and S as ring vertices. In some embodiments, R 4a is -O-heterocycloalkyl containing 4 to 6 ring members and 1 to 3 heteroatoms independently selected from N, O and S as ring vertices. In some embodiments, the heterocycloalkyl containing 4 to 6 ring members and 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices is oxetanyl, azetidinyl, tetrahydro selected from the group consisting of pyran, tetrahydrofuran, pyrrolidine, pyrazolidine, piperidine, morpholine and piperazine. In some embodiments, the heterocycloalkyl containing 4 to 6 ring members and 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices is oxetanyl.
[0106] In some embodiments, Formula (III): [ka] (In the formula, X 1 is C substituted with -OH 2-4 is alkylene; Ring A is selected from the group consisting of phenyl and 5-10 membered heteroaryls having 1-3 heteroatoms independently selected from N, O and S as ring vertices; subscripts m and n are each independently 0 or 1; Each R 1 and R 2 are each independently, C 1-4 Alkyl, C 1-4 alkoxy, halo, C 1-4 haloalkyl, C 1-4 Haloalkoxy, C 1-4 selected from hydroxyalkyl, -C(O)OH and cyano; Ar 1 is selected from the group consisting of phenyl and 5- to 6-membered heteroaryls having as ring vertices 1 to 3 heteroatoms independently selected from N, O and S, where Ar 1 is 0 to 3 R 3 is replaced with; Each R 3 is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Haloalkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, -X 2 -OH, -X 2 -O-C 1-4 Alkyl, -C(O)-C 1-4 alkyl and -X 2 - selected from the group consisting of cyano; or two R on adjacent ring vertices 3 is combined with C 5-6 form a cycloalkyl, where each X 2 are independently combined and C 1-4 selected from alkylene; Ar 2 is a 5- to 10-membered heteroaryl having as ring vertices 1 to 3 heteroatoms independently selected from phenyl, N, O, and S, and C 3-6 selected from the group consisting of cycloalkyl, Each Ar 2 is 0 to 3 R 4 and each R 4 is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Haloalkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, -X 3 -OH, -X 3 -O-C 1-4 Alkyl, C 3-6 cycloalkyl, -X 5 -C(O)OH, -C 2-4 Alkylene-cyano, -S(O)(NH)-C 1-4 Alkyl, -S(O) 2 -C 1-4 -X containing alkyl and 4 to 6 ring members and 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices 4 -heterocycloalkyl, each cycloalkyl independently represents -X 3 -O-C 1-4 Alkyl, -X 5 -C(O)OH and -X 3 substituted with 1 to 2 substituents independently selected from -OH; each X 3 is independently C 1-4 is alkylene; each X 4 are independently -O- and C 1-4 selected from alkylene; each X 5 are independently combined and C 1-4 selected from alkylene) Provided in this disclosure is a compound represented by: or a pharmaceutically acceptable salt thereof.
[0107] In some embodiments, Formula (IV): [ka] (In the formula, X 1 is CH 2 and C substituted with 0~1 -OH 2-4 selected from the group consisting of alkylene; Ring A is selected from the group consisting of phenyl and 5-10 membered heteroaryls having 1-4 heteroatoms independently selected from N, O and S as ring vertices; subscripts m and n are each independently 0 or 1; R 1 and R 2 are each independently, C 1-4 Alkyl, C 1-4 alkoxy, halo, C 1-4 haloalkyl, C 1-4 Haloalkoxy, C 1-4 hydroxyalkyl, -X a -O-C 3-6 selected from the group consisting of cycloalkyl, -C(O)OH and cyano, where X a are independently combined and C 1-4 selected from alkylene; Ar 1 is phenyl, 5-6 membered heteroaryl having as ring vertices 1-4 heteroatoms independently selected from N, O and S, 1-3 independently selected from N, O and S 6- to 10-membered bicyclic heterocyclyl having 1 to 4 heteroatoms independently selected from N, O, and S as ring vertices; 6-10 membered bridged heterocyclyl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, and 1-3 heteroatoms independently selected from N, O and S selected from the group consisting of 6- to 12-membered spiroheterocyclyl having an atom as a ring apex, where Ar 1 is 0 to 3 R 3 is replaced with; Each R 3 is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Haloalkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, -X 2 -OH, -X 2 -O-C 1-4 Alkyl, -C(O)-C 1-4 alkyl and -X 2 - selected from the group consisting of cyano; or two R on adjacent ring vertices 3 is combined with C 3-6 Form a cycloalkyl or two R on the same ring apex 3 combine to form oxo, where each 2 is a combination and C 1-4 selected from alkylene; Z 1 is 1~3 R 5 C substituted with a substituent 3-6 cycloalkyl, Each R 5 are independently -OH, cyano, C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Alkoxy and C 1-4 selected from haloalkoxy) Provided in this disclosure is a compound represented by: or a pharmaceutically acceptable salt thereof.
[0108] In some embodiments, Formula (IV): [ka] (In the formula, X 1 is CH 2 and C substituted with 0~1 -OH 2-4 selected from the group consisting of alkylene; Ring A is selected from the group consisting of phenyl and 5-10 membered heteroaryls having 1-4 heteroatoms independently selected from N, O and S as ring vertices; subscripts m and n are each independently 0 or 1; R 1 and R 2 are each independently, C 1-4 Alkyl, C 1-4 alkoxy, halo, C 1-4 haloalkyl, C 1-4 Haloalkoxy, C 1-4 selected from the group consisting of hydroxyalkyl, -C(O)OH and cyano; Ar 1 is phenyl, 5-6 membered heteroaryl having as ring vertices 1-4 heteroatoms independently selected from N, O and S, 1-3 independently selected from N, O and S 6- to 10-membered bicyclic heterocyclyl having 1 to 4 heteroatoms independently selected from N, O, and S as ring vertices; 6-10 membered bridged heterocyclyl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, and 1-3 heteroatoms independently selected from N, O and S selected from the group consisting of 6- to 12-membered spiroheterocyclyl having an atom as a ring apex, where Ar 1 is 0 to 3 R 3 is replaced with; Each R 3 is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Haloalkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, -X 2 -OH, -X 2 -O-C1-4 Alkyl, -C(O)-C 1-4 alkyl and -X 2 - selected from the group consisting of cyano; or two R on adjacent ring vertices 3 is combined with C 3-6 Form a cycloalkyl or two R on the same ring apex 3 combine to form oxo, where each 2 is a combination and C 1-4 selected from alkylene; Z 1 is 1~3 R 5 C substituted with a substituent 3-6 cycloalkyl, Each R 5 are independently -OH, cyano, C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Alkoxy and C 1-4 selected from haloalkoxy) Provided in this disclosure is a compound represented by: or a pharmaceutically acceptable salt thereof.
[0109] In some embodiments, the compound of formula (IV) is of formula (IVa): [ka] or a pharmaceutically acceptable salt thereof.
[0110] In some embodiments, the compound of formula (IV) has formula (IVb): [ka] or a pharmaceutically acceptable salt thereof.
[0111] In some embodiments, the compound of formula (IV) has formula (IVc): [ka] or a pharmaceutically acceptable salt thereof.
[0112] In some embodiments, Z in formula (IV) 1 teeth, [ka] It is.
[0113] In some embodiments, Z in formula (IV) 1 teeth, [ka] It is.
[0114] In some embodiments, X in formula (IV) 1 is CH 2 It is.
[0115] In some embodiments, X in formula (IV) 1 is CH 2 CH 2 It is.
[0116] In some embodiments, R in formula (IV) 5 is a halo. In some embodiments, R in formula (IV) 5 is chloro. In some embodiments, R in formula (IV) 5 is fluoro.
[0117] In some embodiments, R in formula (IV) 5 is C 1-4 It is alkoxy. In some embodiments, R in formula (IV) 5 is methoxy. In some embodiments, R in formula (IV) 5 is ethoxy.
[0118] In some embodiments, R in formula (IV) 5 is -OH. In some embodiments, R in formula (IV) 5 is cyano.
[0119] In some embodiments, Z in formula (IV) 1 is permuted (i.e., Z 1 is 1 R 5 (substituted with a substituent). In some embodiments, Z in formula (IV) 1 is permuted (i.e., Z 1 is two R 5 (substituted with a substituent). In some embodiments, Z in formula (IV) 1 is permuted (i.e., Z 1 is 3 R 5 (substituted with a substituent).
[0120] In some embodiments, Z in formula (IV) 1 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In some embodiments, Z in formula (IV) 1 is cyclopropyl. In some embodiments, Z in formula (IV) 1 is cyclobutyl. In some embodiments, Z in formula (IV) 1 is cyclopentyl. In some embodiments, Z in formula (IV) 1 is cyclohexyl.
[0121] In some embodiments, Z in formula (IV) 1 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and each Z 1 is 1-2 R independently selected from cyano, hydroxy and halo 5 has been replaced with
[0122] In some embodiments, Z in formula (IV) 1 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and each Z 1 is 1-2 R independently selected from cyano, hydroxy and fluoro 5 has been replaced with
[0123] In some embodiments, Z in formula (IV) 1 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and each Z 1 is independently 1-2 R selected from hydroxy and fluoro 5 has been replaced with
[0124] In some embodiments, Z in formula (IV) 1 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and each Z 1 are independently substituted with cyano.
[0125] In some embodiments, Z in formula (IV) 1 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and each Z 1 are independently substituted with hydroxy.
[0126] In some embodiments, Z in formula (IV) 1 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and each Z 1 are independently substituted with halo. In some embodiments, Z in formula (IV) 1 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and each Z 1 are independently substituted with fluoro.
[0127] In some embodiments, Z in formula (IV) 1 is 1-2 R independently selected from halo and cyano 5 Cyclopropyl substituted with
[0128] In some embodiments, Z in formula (IV) 1 is 1-2 R independently selected from hydroxy and halo 5 Cyclobutyl substituted with
[0129] In some embodiments, Z in formula (IV) 1 is cyclopentyl substituted with hydroxy.
[0130] In some embodiments, Z in formula (IV) 1 is 1-2 R independently selected from hydroxy and halo 5 cyclohexyl substituted with
[0131] In some embodiments, X in formula (I), (II) or (IV) 1 is C substituted with -OH 2 It is alkylene. In some embodiments, X in formula (III) 0 is C substituted with -OH 2 It is alkylene.
[0132] In some embodiments, ring A in formula (I), (II), (III) or (IV) is phenyl, pyridinyl, pyridazinyl, imidazolyl, pyrazolyl, triazolyl, imidazo[1,2-a]pyridinyl , [1,2,3]triazolo[1,5-a]pyridinyl, imidazo[1,5-a]pyridinyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, pyrazolo[ 1,5-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl, 1,6-naphthyridinyl or 1,7-naphthyridinyl.
[0133] In some embodiments, ring A in formula (I), (II), (III) or (IV) is phenyl.
[0134] In some embodiments, ring A in formula (I), (II), (III), or (IV) is a 9- to 10-membered heteroaryl ring.
[0135] In some embodiments, ring A in formula (I), (II), (III) or (IV) is imidazo[1,2-a]pyridinyl, [1,2,3]triazolo[1, 5-a]pyridinyl, imidazo[1,5-a]pyridinyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2 ,4]triazolo[1,5-a]pyridinyl, 1,6-naphthyridinyl or 1,7-naphthyridinyl.
[0136] In some embodiments, ring A in formula (I), (II), (III), or (IV) is a 5- to 6-membered heteroaryl ring.
[0137] In some embodiments, Ring A in Formula (I), (II), (III) or (IV) is pyridinyl, pyridazinyl, pyrimidinyl, imidazolyl, pyrazolyl or triazolyl.
[0138] In some embodiments, ring A in formula (I), (II), (III) or (IV) is pyridyl.
[0139] In some embodiments, ring A in formula (I), (II), (III) or (IV) is [ka] selected from the group consisting of.
[0140] In some embodiments, ring A in formula (I), (II), (III) or (IV) is [ka] selected from the group consisting of.
[0141] In some embodiments, ring A in formula (I), (II), (III) or (IV) is [ka] selected from the group consisting of.
[0142] In some embodiments, ring A in formula (I), (II), (III) or (IV) is [ka] selected from the group consisting of.
[0143] In some embodiments, ring A in formula (I), (II), (III) or (IV) is [ka] It is.
[0144] In some embodiments, ring A in formula (I), (II), (III) or (IV) is [ka] It is.
[0145] In some embodiments, ring A in formula (I), (II), (III) or (IV) is [ka] It is.
[0146] In some embodiments, ring A in formula (I), (II), (III) or (IV) is [ka] It is.
[0147] In some embodiments, ring A in formula (I), (II), (III) or (IV) is [ka] It is.
[0148] In some embodiments, ring A in formula (I), (II), (III) or (IV) is not pyrimidine.
[0149] In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is selected from the group consisting of 5- to 6-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, and has formulas (I), (II), ( Ar in III) or (IV) 1 is 0 to 3 R 3 has been replaced with In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is piperidinyl, piperazinyl, morpholinyl, 2-oxopiperazinyl, 2-tetrahydropyranyl, 3,6-dihydro-2H-pyranyl, 2-oxo-1,2-dihydropyridinyl, thiomorpholinyl and 1,1- selected from the group consisting of dioxothiomorpholinyl, each Ar 1 is 0 to 3 R 3 has been replaced with In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is piperidin-1-yl, piperazin-1-yl, morpholin-4-yl, tetrahydropyran-4-yl, 3,6-dihydro-2H-pyran-4-yl, 6-oxo-1,6-dihydropyridine -3-yl, 6-oxo-1,6-dihydropyridin-4-yl, thiomorpholin-4-yl and 1,1-dioxothiomorpholin-4-yl, each Ar 1 is 0 to 3 R 3 has been replaced with In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is 0 to 3 R 3 morpholin-4-yl substituted with In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is morpholin-4-yl, 2-methylmorpholin-4-yl, 3-methylmorpholin-4-yl, 3R-methylmorpholin-4-yl, 3S-methylmorpholin-4-yl, 3-oxopiperazine-1 -yl, 4-methyl-3-oxopiperazin-1-yl, 2-methyl-3-oxopiperazin-1-yl, 6-methyl-3-oxopiperazin-1-yl, 5-methyl-3-oxopiperazine -1-yl, 4-dimethylaminocarbonylpiperazin-1-yl, tetrahydropyran-4-yl, 3,6-dihydro-2H-pyran-4-yl, 4-(2-hydroxyethyl)-3-oxopiperazine -1-yl, 6-oxo-1,6-dihydropyrazin-4-yl, 6-oxo-1,6-dihydropyridin-3-yl, 1-methyl-6-oxo-1,6-dihydropyridine-3- yl, 4-(2-morpholin-4-ylethyl)-3-oxopiperazin-1-yl, 4-methylcarbonylpiperazin-1-yl, 4-methylsulfonylpiperazin-1-yl, 1,1-dioxothio selected from the group consisting of morpholin-4-yl and 4,4-difluoropiperidin-1-yl.
[0150] In some embodiments, Ar in formula (I), (II) or (IV) 1 is 0 to 3 R 3 is a bicyclic heterocyclyl substituted with In some embodiments, Ar in formula (I), (II) or (IV) 1 is from the group consisting of 6-oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl and 2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl selected, each ring has 0 to 3 R 3 has been replaced with In some embodiments, Ar in formula (I), (II) or (IV) 1 is 6-oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, 3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl , benzo[d][1,3]dioxol-4-yl, (3,4-dihydro-2H-1,4-benzoxazin-8-yl), [5H,6H,7H-pyrazolo[1,5- a]pyrimidin-4-yl] and 2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl, each ring containing 0 to 3 R 3 has been replaced with In some embodiments, Ar in formula (I), (II) or (IV) 1 is 0 to 3 R 3each of which is independently substituted with methyl, ethyl, fluoro, cyano, difluoromethyl, trifluoromethyl, trifluoroethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, trifluoroethoxy, hydroxy, selected from the group consisting of methylsulfonyl, 2-hydroxyethyl and 2-methoxyethyl.
[0151] In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is 0 to 3 R 3 phenyl substituted with In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,4-dimethoxyphenyl, 2-chlorophenyl, 2-cyanophenyl or 2-cyclopropyl-oxyphenyl. In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is 2-methoxyphenyl. In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is 3-methoxyphenyl. In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is 2,4-dimethoxyphenyl. In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 teeth, [ka] It is.
[0152] In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 teeth, [ka] It is.
[0153] In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 teeth, [ka] It is.
[0154] In some embodiments, Ar in formula (I), (II) or (IV) 1 is a 6-10 membered bridged heterocyclyl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, or 1-3 heteroatoms independently selected from N, O and S It is a 6- to 12-membered spiroheterocyclyl having a heteroatom as the ring apex, and Ar 1 is 0 to 3 R 3 has been replaced with
[0155] In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is 0 to 3 R 3 is a heteroaryl substituted with In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is 0 to 3 R 3 pyridinyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl or triazolyl substituted with . In some embodiments, Ar 1 is 0 to 3 R 3 each of which is independently substituted with methyl, ethyl, fluoro, difluoromethyl, trifluoromethyl, trifluoroethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, trifluoroethoxy, hydroxy, 2- selected from the group consisting of hydroxyethyl and 2-methoxyethyl. In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 teeth, [ka] It is.
[0156] In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 teeth, [ka] It is.
[0157] In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 teeth, [ka] It is.
[0158] In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 teeth, [ka] It is.
[0159] In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 teeth, [ka] It is.
[0160] In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 teeth, [ka] It is.
[0161] In some embodiments, R in formula (I), (II), (III) or (IV) 1 and R 2 are each independently, C 1-4 Alkyl, C 1-4 Alkoxy, halo and C 1-4 selected from the group consisting of haloalkyl; In some embodiments, R in formula (I), (II), (III) or (IV) 1 and R 2 are each independently, C 1-4 It is an alkyl. In some embodiments, R in formula (I), (II), (III) or (IV) 1 and R 2 each, if present, is independently methyl. In some embodiments, R in formula (I), (II), (III) or (IV) 1 and R 2 -X if present a -O-C 1-4 alkyl and -X a -O-C 3-6 Cycloalkyl may also be included, X a are independently combined and C 1-4 selected from alkylene. In some embodiments, R in formula (I), (II), (III) or (IV) 2 -X if present a -O-C 1-4 is alkyl and X a are independently combined and C 1-4 selected from alkylene. In some embodiments, R in formula (I), (II), (III) or (IV) 2 -X if present a -O-C 3-6 cycloalkyl, X a are independently combined and C 1-4 selected from alkylene.
[0162] In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is 0 to 2 R 3 has been replaced with In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is 0 to 1 R 3 has been replaced with In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is R 3 is not replaced by . In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is 1 R 3 has been replaced with In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is two R 3 has been replaced with In some embodiments, Ar in formula (I), (II), (III) or (IV) 1 is 3 R 3 has been replaced with
[0163] In some embodiments, each R in formula (I), (II), (III) or (IV) 3 is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 3-6 selected from cycloalkyl and cyano. In some embodiments, each R in formula (I), (II), (III) or (IV) 3 is independently C1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Alkoxy and C 1-4 selected from haloalkoxy. In some embodiments, each R in formula (I), (II), (III) or (IV) 3 are independently selected from methoxy, methyl, ethyl, fluoro, chloro, difluoromethoxy, cyano and cyclopropyl.
[0164] In some embodiments, each R in formula (I), (II), (III) or (IV) 3 is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Alkoxy, C 1-4 haloalkoxy, and C 3-6 cycloalkyl, -X 2 -OH and -X 2 -Selected from Cyano. In some embodiments, each R in formula (I), (II), (III) or (IV) 3 is independently C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 3-6 selected from cycloalkyl and cyano. In some embodiments, each R in formula (I), (II), (III) or (IV) 3 are independently selected from methoxy, methyl, ethyl, fluoro, chloro, difluoromethoxy, cyano, hydroxymethyl and cyclopropyl. In some embodiments, each R in formula (I), (II), (III) or (IV) 3 is selected from methyl, fluoro, chloro and cyclopropyl. In some embodiments, each R in formula (I), (II), (III) or (IV) 3 is selected from difluoromethoxy, fluoro, chloro and cyano. In some embodiments, each R in formula (I), (II), (III) or (IV) 3 is selected from methoxy, fluoro and chloro.
[0165] In some embodiments, Z or Ar in formula (I) or (II) 2 is 0 to 2 R 4 Substituted with a substituent, each R 4 But independently, C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, -OH, cyano and -C(O)-C 1-4 selected from the group consisting of alkyl; In some embodiments, Z or Ar in formula (I) or (II) 2 is 0 to 2 R 4 Substituted with a substituent, each R 4 independently consists of methyl, ethyl, chloro, fluoro, methoxy, ethoxy, -OH, cyano, -C(O)-methyl, -C(O)-ethyl and -C(O)-2-propyl selected from the group. In some embodiments, Z or Ar in formula (I) or (II) 2 is 0 to 2 R 4 Substituted with a substituent, each R 4 are independently selected from the group consisting of chloro, fluoro, -OH, cyano and -C(O)-2-propyl.
[0166] In some embodiments, Z or Ar in formula (I) or (II) 2 is 0 to 1 R 4 Substituted with a substituent, each R 4 But independently, C 1-4 alkyl, halo, C 1-4 haloalkyl, -OH and -C(O)-C 1-4 selected from the group consisting of alkyl; In some embodiments, Z or Ar in formula (I) or (II) 2 is 0 to 1 R 4 Substituted with a substituent, each R 4 independently from the group consisting of methyl, ethyl, chloro, fluoro, methoxy, ethoxy, -OH, -C(O)-methyl, -C(O)-ethyl and -C(O)-2-propyl selected. In some embodiments, Z or Ar in formula (I) or (II) 2 is 0 to 1 R 4 Substituted with a substituent, each R 4 are independently selected from the group consisting of chloro, fluoro, -OH and -C(O)-2-propyl. In some embodiments, Z or Ar in formula (I) or (II) 2 is 0 to 2 R that combine to form an oxo moiety 4 Substituted with a substituent.
[0167] In some embodiments, Ar in formula (III) 2 is 0 to 2 R 4 Substituted with a substituent, each R 4 But independently, C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 Alkoxy and C 1-4 selected from the group consisting of haloalkoxy; In some embodiments, Ar in formula (III) 2 is 0 to 2 R 4 Substituted with a substituent, each R 4 are independently selected from the group consisting of methyl, ethyl, chloro, fluoro, methoxy and ethoxy. In some embodiments, Ar in formula (III) 2 is substituted with chloro.
[0168] In some embodiments, Z or Ar in formula (I), (II) or (III) 2 -X 3 -OH is substituted with X 3 is C 1-4 It is alkylene. In some embodiments, Z or Ar in formula (I), (II) or (III) 2 is substituted with hydroxymethyl. In some embodiments, Z or Ar in formula (I), (II) or (III) 2 is substituted with 2-hydroxyethyl. In some embodiments, Z or Ar in formula (I), (II) or (III) 2 is substituted with hydroxylpropan-2-yl.
[0169] In some embodiments, Z or Ar in formula (I), (II) or (III) 2 is unsubstituted (i.e. Z or Ar 2 is 0 R 4 (substituted with a substituent). In some embodiments, Z or Ar in formula (I), (II) or (III) 2 is 1 R 4 Substituted with a substituent. In some embodiments, Z or Ar in formula (I), (II) or (III) 2 is two R 4 Substituted with a substituent.
[0170] In some embodiments, the subscripts m and n in formula (I), (II), (III), or (IV) are both 0. In some embodiments, the subscripts m and n in formula (I), (II), (III), or (IV) are 1 and 0, respectively. In some embodiments, the subscripts m and n in formula (I), (II), (III), or (IV) are both 1.
[0171] Representative compounds of formula (I), (II), (III) or (IV) are listed in Table 1 below: [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13] [Table 1-14] [Table 1-15] [Table 1-16] [Table 1-17] [Table 1-18] [Table 1-19] [Table 1-20]
[0172] In some embodiments, the compound or pharmaceutically acceptable salt thereof is a compound of Table 1.
[0173] In some embodiments, the above compounds or pharmaceutically acceptable salts thereof are Compound Nos. 8, 9, 10, 11, 12, 13, 15, 16, 18, 19, 20, 21, 23, 31 , 36, 43, 44, 45, 46, 49, 52, 53, 64, 67, 74, 75, 77, 82, 85, 86, 91, 100, 101, 104, 113, 120, 127, 128, 129 , 130, 140 and 153.
[0174] In some embodiments, the compound or pharmaceutically acceptable salt thereof is Compound No. 1, 2, 3, 7, 35, 47, 51, 61, 65, 66, 71, 78, 92, 95 , 98, 99, 102, 103, 112, 116, 117, 121, 131, 132, 135, 136, 138, 139, 141, 142, 143, 151 and 156.
[0175] In some embodiments, the above compounds or pharmaceutically acceptable salts thereof are Compound Nos. 4, 5, 6, 14, 17, 22, 24, 25, 26, 32, 33, 34, 37, 38 , 39, 40, 41, 42, 48, 50, 54, 55, 56, 57, 58, 59, 60, 62, 63, 68, 69, 70, 72, 73, 76, 79, 80, 81, 83 , 84, 87, 88, 89, 90, 93, 94, 96, 97, 105, 106, 109, 110, 111, 114, 115, 119, 122, 123, 124, 125, 126, 133, 134, 144 , 145, 146, 147, 148, 149, 150, 152, 154 and 155.
[0176] In some embodiments, the compound or pharmaceutically acceptable salt thereof is a compound selected from the group consisting of Compound Nos. 27, 28, 29, and 30.
[0177] In some embodiments, the compound or pharmaceutically acceptable salt thereof is selected from the group consisting of compound numbers 100, 101, 104, 107, 108, 118, 127, 128, 129, 137 and 153. It is a compound that
[0178] In some embodiments, the compound or pharmaceutically acceptable salt thereof is Compound No. 156, 157, 158, 159, 160, 161, 161, 163, 164, 165, 166, 167, 168, 169 , 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194 , 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 109, 210, 211 and 212.
[0179] In some embodiments, the above compounds or pharmaceutically acceptable salts thereof are Compound Nos. 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226 , 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251 , 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272 and 273. It is a compound that
[0180] assay The ability of compounds of the disclosure to inhibit Polθ can be measured as described in the biological assays below.
[0181] pharmaceutical composition The compounds of formula (I), (II), (III), (IV) or the compounds of Table 1 provided herein, or a pharmaceutically acceptable salt thereof, are suitable for administration to a subject. It may be in the form of a suitable composition. Generally, such compositions include a compound of formula (I), (II), (III), (IV), or a compound of Table 1, or a pharmaceutically acceptable salt thereof and one or more pharmaceutical A pharmaceutical composition comprising a physiologically acceptable or physiologically acceptable excipient. In certain embodiments, a compound of formula (I), (II), (III), (IV), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, is administered in a therapeutically effective amount. exist. The pharmaceutical compositions may be used in any of the methods disclosed herein, and thus, for example, the pharmaceutical compositions may be used to carry out the treatments and uses described herein. Can be administered ex vivo or in vivo.
[0182] Pharmaceutical compositions can be formulated to suit the intended method or route of administration, and exemplary routes of administration are described herein. Additionally, the pharmaceutical compositions may be used in combination with other therapeutically effective agents or compounds as described herein to treat diseases, disorders and conditions contemplated by this disclosure. .
[0183] Pharmaceutical compositions containing active ingredients (e.g., compounds of formula (I), (II), (III), (IV), or compounds of Table 1, pharmaceutically acceptable salts thereof) can be administered orally. Forms suitable for use (e.g. tablets, capsules, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups, solutions, microbeads or elixir). Pharmaceutical compositions intended for oral use may be prepared according to any method known for the manufacture of pharmaceutical compositions, and such compositions may be prepared by: It may also contain one or more agents such as sweetening agents, flavoring agents, coloring agents and preservatives. Tablets, capsules and the like contain the active ingredient in association with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets, capsules and the like. These excipients include, for example, diluents (e.g. calcium carbonate, sodium carbonate, lactose, calcium or sodium phosphate); granulating and disintegrating agents (e.g. cornstarch, or alginic acid); binders (e.g. starch); , gelatin or gum arabic), and lubricants (eg, magnesium stearate, stearic acid or talc).
[0184] Tablets, capsules suitable for oral administration may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained release effect. good. For example, time delay materials such as glyceryl monostearate or glyceryl distearate may be used. These tablets may also be coated by techniques known in the art to form osmotic therapeutic tablets for controlled release. Additional agents may include biodegradable or biocompatible particles or polymeric materials (polyesters, polyamic acids, hydrogels, polyvinylpyrrolidone, polyanhydrides, polyglycolic acids, ethylene, etc.) to control the delivery of the administered composition. - vinyl acetate, methylcellulose, carboxymethylcellulose, protamine sulfate, or lactide and glycolide copolymers, polylactide and glycolide copolymers, or ethylene vinyl acetate copolymers). For example, oral agents can be encapsulated in microcapsules prepared by coacervation techniques or interfacial polymerization by the use of hydroxymethyl cellulose microcapsules or gelatin microcapsules or poly(methyl methacrylate) microcapsules, respectively, or in colloidal drug delivery systems. Can be done. Colloidal dispersion systems include macromolecular complexes, nanocapsules, microspheres, microbeads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes. Methods for the preparation of the above-mentioned formulations are known in the art.
[0185] Preparations for oral use may also be prepared as hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent (e.g. calcium carbonate, calcium phosphate, kaolin or microcrystalline cellulose) or in a water or oil medium ( For example, it may be provided as a soft gelatin capsule mixed with peanut oil, liquid paraffin or olive oil).
[0186] Aqueous suspensions contain the active materials together with excipients suitable for their manufacture. Such excipients include suspending agents (e.g. sodium carboxymethylcellulose, methylcellulose, (hydroxypropyl)methylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum arabic); dispersing or wetting agents (e.g. natural phosphatides); (for example, lecithin), or condensation products of alkylene oxides and fatty acids (for example, polyoxyethylene stearate), or condensation products of ethylene oxide and long-chain aliphatic alcohols (for example, in the case of heptodecaethyleneoxycetanol), or condensation products of ethylene oxide and partial esters derived from fatty acids and hexitol (e.g. polyoxyethylene sorbitol monooleate), or condensation products of ethylene oxide and partial esters derived from fatty acids and hexitol anhydride (e.g. , polyethylene sorbitan monooleate).Aqueous suspensions may also contain one or more preservatives.
[0187] Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin, or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.
[0188] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water are provided in admixture of the active ingredient with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified herein.
[0189] The pharmaceutical composition may also be in the form of an oil-in-water emulsion. The oil phase may be a vegetable oil (eg olive oil or arachis oil) or a mineral oil (eg liquid paraffin), or a mixture thereof. Suitable emulsifiers include natural gums (e.g. gum arabic or gum tragacanth); natural phosphatides (e.g. esters or partial esters derived from soy, lecithin, and fatty acids); hexitol anhydride (e.g. sorbitan monooleate); and It may also be a condensation product of a partial ester and ethylene oxide (for example, sorbitan polyoxyethylene monooleate).
[0190] The pharmaceutical composition generally comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), or a compound of Table 1, or a pharmaceutically acceptable salt thereof; It comprises one or more pharmaceutically acceptable excipients. Suitable pharmaceutically acceptable excipients include, but are not limited to, antioxidants (e.g. ascorbic acid and sodium bisulfate), preservatives (e.g. benzyl alcohol, methylparaben, ethyl or n-propyl , p-hydroxybenzoate), emulsifiers, suspending agents, dispersants, solvents, fillers, bulking agents, detergents, buffers, vehicles, diluents and / or adjuvants. For example, a suitable vehicle may be saline or citrate buffered saline, which may be supplemented with other ingredients common to pharmaceutical compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Those skilled in the art will readily recognize the variety of buffers that can be used in the pharmaceutical compositions and dosage forms contemplated herein. Typical buffers include, but are not limited to, pharmaceutically acceptable weak acids, weak bases, or mixtures thereof. By way of example, the buffer component can be a water-soluble material such as phosphoric acid, tartaric acid, lactic acid, succinic acid, citric acid, acetic acid, ascorbic acid, aspartic acid, glutamic acid, and salts thereof. Acceptable buffers include, for example, Tris buffer, N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES), 2-(N-morpholino)ethanesulfonic acid (MES). , 2-(N-morpholino)ethanesulfonic acid sodium salt (MES), 3-(N-morpholino)propanesulfonic acid (MOPS), and N-tris[hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS). can be mentioned.
[0191] After a pharmaceutical composition is formulated, it may be stored in a sterile vial as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder. Such formulations may be stored either in a ready-to-use form, in a lyophilized form requiring reconstitution before use, in a liquid form requiring dilution before use, or in any other acceptable form. Good too. In some embodiments, the pharmaceutical composition is provided in a single-use container (e.g., a single-use vial, ampoule, syringe, or autoinjector (e.g., similar to an EpiPen®)), but in other In embodiments of the invention, a multi-use container (eg, a multi-use vial) is provided.
[0192] The formulation can also include carriers to protect the composition from rapid degradation or elimination from the body, such as controlled release formulations including liposomes, hydrogels, prodrugs, and microencapsulated delivery systems. For example, time delay materials such as glyceryl monostearate or glyceryl stearate may be used alone or in combination with waxes. An implant (e.g., an implantable pump) is used to deliver a compound of formula (I), (II), (III), (IV), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. ) and catheter systems, slow infusion pumps and devices, all of which are well known to those skilled in the art.
[0193] Depot injections, generally administered subcutaneously or intramuscularly, may also be used to administer the compounds of formula (I), (II), (III), (IV) disclosed herein, or the compounds of Table 1, or their Pharmaceutically acceptable salts may be used to release over a defined period of time. Depot injections are usually either solid-based or oil-based and generally comprise at least one of the formulation components set forth herein. Those skilled in the art are familiar with the possible formulations and uses of depot injections.
[0194] The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. Suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents mentioned herein. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol. Acceptable diluents, solvents and dispersion media that may be employed include water, Ringer's solution, isotonic sodium chloride solution, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). , ethanol, polyols (eg, glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Additionally, fatty acids such as oleic acid are used in injectables. Prolonged absorption of certain injectables can be accomplished by including agents that delay absorption, such as aluminum monostearate or gelatin.
[0195] Compounds of formula (I), (II), (III), (IV), or compounds of Table 1, or pharmaceutically acceptable salts thereof, may also be administered as suppositories for rectal administration or for nasal or inhalation use. It may also be administered in the form of a spray. Suppositories can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at room temperature and liquid at rectal temperature, thus melting in the rectum to release the drug. Such materials include, but are not limited to, cocoa butter and polyethylene glycols.
[0196] All of the compounds and pharmaceutical compositions provided herein can be used in all of the methods provided herein. For example, the compounds and pharmaceutical compositions provided herein can be used in any of the methods for the treatment and / or prevention of any disease or disorder provided herein. Accordingly, the compounds and pharmaceutical compositions provided herein are for use as medicaments.
[0197] Route of administration Compounds of formula (I), (II), (III), (IV) or compounds of Table 1, or pharmaceutically acceptable salts thereof and compositions containing the same, may be prepared in any suitable manner. may be administered in any manner. Suitable routes of administration include oral, parenteral (e.g., intramuscular, intravenous, subcutaneous (e.g., injection or implant), intraperitoneal, intracisternal, intraarticular, intraperitoneal, intracerebral (intraparenchymal), and intracerebral). intranasal, vaginal, sublingual, intraocular, rectal, topical (eg, transdermal), oral, and inhalation. Depot injections, generally administered subcutaneously or intramuscularly, also include compounds of formula (I), (II), (III), (IV), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. may be used to administer over a defined period of time. Certain embodiments of the invention contemplate oral administration.
[0198] combination therapy The present invention provides compounds of formula (I), (II), (III), (IV) in combination with one or more effective therapeutic agents (e.g., chemotherapeutic agents) or other prophylactic or therapeutic modalities (e.g., radiation). or a compound of Table 1, or a pharmaceutically acceptable salt thereof. In such combination therapy, the various active agents often have different and complementary mechanisms of action. Such combination therapy may be particularly advantageous by allowing dose reduction of one or more of the drugs, thereby reducing or eliminating adverse effects associated with one or more of the drugs. Furthermore, such combination therapy may have a synergistic therapeutic or prophylactic effect on the underlying disease, disorder, or condition.
[0199] As used herein, "combination" refers to therapies that may be administered separately (e.g., may be formulated separately for separate administration (e.g., may be provided in a kit)), and a single It is meant to include therapies that may be administered together in a formulation (ie, a “combination”).
[0200] In certain embodiments, a compound of formula (I), (II), (III), (IV), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, is used, e.g. Administered or applied sequentially, such as before one or more other drugs. In other embodiments, a compound of formula (I), (II), (III), (IV), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, is used, e.g. The agents may be administered simultaneously, such as at or near the same time; the two or more agents may be present in two or more separate formulations or in a single formulation (i.e., co-formulation). ). Whether two or more agents are administered sequentially or simultaneously, they are considered to be administered in combination for purposes of this disclosure.
[0201] A compound of formula (I), (II), (III), (IV) or a compound of Table 1, or a pharmaceutically acceptable salt thereof, may be prepared in any manner appropriate under the circumstances. It may also be used in combination with at least one other (active) drug. In one embodiment, at least one active agent and at least one compound of formula (I), (II), (III), (IV) or a compound of Table 1, or a pharmaceutically acceptable salt thereof Treatment with is maintained over a period of time. In another embodiment, treatment with at least one active agent is reduced or discontinued (e.g., if the subject is stable) while formula (I), (II), (III), (IV) Treatment with the indicated compound, or a compound of Table 1, or a pharmaceutically acceptable salt thereof, is maintained on a fixed dosing regimen. In further embodiments, treatment with at least one active agent is reduced or discontinued (e.g., if the subject is stable) while or a compound of Table 1, or a pharmaceutically acceptable salt thereof, is reduced (eg, lower dose, less frequency, or shorter treatment regimen). In yet another embodiment, treatment with at least one active agent is reduced or discontinued (e.g., if the subject is stable) and is represented by formula (I), (II), (III), (IV) Treatment with a compound, or a compound of Table 1, or a pharmaceutically acceptable salt thereof, is enhanced (eg, higher doses, higher frequency, or longer treatment regimen). In yet another embodiment, treatment with at least one active agent is maintained and the compound of formula (I), (II), (III), (IV), or a compound of Table 1, or a pharmaceutically active agent thereof, is maintained. Treatment with acceptable salts is reduced or discontinued (eg, lower doses, less frequency, or shorter treatment regimens). In yet another embodiment, treatment with at least one active agent and a compound of formula (I), (II), (III), (IV), or a compound of Table 1, or a pharmaceutically acceptable Salt therapy is reduced or discontinued (eg, lower dose, less frequency or shorter treatment regimen).
[0202] The present disclosure describes a compound of formula (I), (II), (III), (IV), or a compound of Table 1, or a pharmaceutically acceptable salt thereof and at least one additional therapeutic agent or Provides a method for treating cancer with a diagnostic agent.
[0203] In some embodiments, the compound of formula (I), (II), (III), (IV) or a compound of Table 1, or a pharmaceutically acceptable salt thereof, is a compound of formula (I), (II), (III), (IV), or a pharmaceutically acceptable salt thereof. Liposomal doxorubicin (Doxyl), eribulin (Halaben), ixabepilone (Ixempra), protein-bound paclitaxel (Abraxane), oxaliplatin, irinotecan, benatocrux (BCL2 inhibitor), 5-azacytadine, anti-CD20 therapeutics (e.g., Rituxan) and obinutuzumab), hormonal agents (anastrozole, exemestand, letrozole, zoladex, lupon eligard), CDK4 / 6 inhibitors, palbociclib, abemaciclib, CPIs (avelumab, cemiplimab-rwlc and bevacizumab) administered in combination with at least one additional therapeutic agent selected from:
[0204] In certain embodiments, the present disclosure provides a method for treating cancer, comprising formula (I), (II) as described herein to achieve additive or synergistic inhibition of tumor growth. ), (III), (IV), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, and a signal transduction inhibitor (STI). As used herein, the term "signal transduction inhibitor" refers to an agent that selectively inhibits one or more steps of a signal transduction pathway. Examples of signal transduction inhibitors (STIs) useful in the methods described herein include, but are not limited to, (i) bcr / abl kinase inhibitors (e.g., Gleevec); (ii) kinase inhibitors; and epidermal growth factor (EGF) receptor inhibitors, including antibodies; (iii) her-2 / neu receptor inhibitors (e.g., Herceptin); (iv) inhibitors of Akt family kinases or the Akt pathway (e.g., rapamycin); ); (v) cell cycle kinase inhibitors (eg, flavopiridol); and (vi) phosphatidylinositol kinase inhibitors. Agents involved in immunomodulation may also include one or more of the compounds of formula (I), (II), (III), (IV) described herein for the suppression of tumor growth in cancer patients; or a compound of Table 1, or a pharmaceutically acceptable salt thereof.
[0205] In certain embodiments, the present disclosure provides a method for treating cancer, comprising a compound of formula (I), (II), (III), (IV), or a compound described herein. 1, or a pharmaceutically acceptable salt thereof, and a chemotherapeutic agent. Examples of chemotherapeutic agents include, but are not limited to, alkylating agents such as thiotepa and cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; benzodopa, carbocone, metledopa, and uredopa. Aziridine; ethyleneimine and methylmelamine, including altretamine, triethylene melamine, triethylene phosphoramide, triethylenethio-phosphaoramide and trimethylolomelamime; thiorambucil, chlornafadine, colophosphamide Nitrogen mustards such as , estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novenvitin, fenesterine, prednimustine, trophosfamide, uracil mustard; carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine, etc. Nitroureas; aclacinomycin, actinomycin, autotramycin, azaserine, bleomycin, cactinomycin, calicheamicin, carabicin, caminomycin, cardinophilin, chromomycin, dactinomycin, daunorubicin, detruubicin, 6- Diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin, mycophenolic acid, nogaramycin, olibomycin, pepromycin, potophilomycin, puromycin, keramycin, rhodorubicin, streptonigrin, streptococcus Antibiotics such as Zosin, Tubercidin, Ubenimex, Dinostatin, Zorubicin; Antimetabolites such as methotrexate and 5-fluorouracil (5-FU); Folic acid analogs such as denopterin, methotrexate, pteropterin, trimetrexate; Fludarabine, 6-mercapto Purine analogs such as purines, thiamipurine, thioguanine; pyrimidine analogs such as ancitabine, azacytidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; carsterone, dromostanolone propionate, epi Androgens such as thiostanol, mepithiostane, testolactone; anti-adrenergic agents such as aminoglutethimide, mitotane, trilostane; folic acid supplements such as fluoric acid; acegratone; aldophosphamide glycosides; aminolevulinic acid; amsacrine; bestrabucil Bisanthrene; Edatrexate; Defofamine; -Ethyl hydrazide; procarbazine; razoxane; schizophyllan; spirogermanium; thenuazonic acid; triaziquone; 2,2',2''-trichlorotriethylamine; urethane; vindesine; C); cyclophosphamide; thiotepa; taxoids, such as paclitaxel and doxetaxel; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum and platinum complexes, such as cisplatin and carboplatin; vinblastine; etoposide (VP-16) ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; ; as well as pharmaceutically acceptable salts, acids or derivatives of any of the above. In certain embodiments, compounds of the present disclosure are administered in combination with a cytostatic compound selected from the group consisting of cisplatin, doxorubicin, taxol, taxotere, and mitomycin C. In certain embodiments, the cytostatic compound is doxorubicin.
[0206] Chemotherapeutic agents also include, for example, anti-estrogenic agents (including moxifen, raloxifene, aromatase inhibitor 4(5)-imidazole, 4-hydroxy tamoxifen, trioxifene, keoxifene, onapristone, and toremifene); androgen agonists (such as flutamide, nilutamide, bicalutamide, enzalutamide, apalutamide, abiraterone acetate, leuprolide and goserelin); and pharmaceutically acceptable salts, acids or derivatives of any of the above to modulate or inhibit hormonal action on tumors It also contains anti-hormonal drugs that act as In certain embodiments, combination therapy includes administration of hormones or related hormonal agents.
[0207] The present disclosure also provides a compound of formula (I), (II), (III), (IV) as described herein, or a compound of Table 1, or a pharmaceutically acceptable salt thereof and an immunoassay. Combination use with point inhibitors is also contemplated. The vast number of genetic and epigenetic changes characteristic of all cancers provides a diverse set of antigens that the immune system can use to distinguish tumor cells from normal ones. For T cells, the final magnitude (e.g., level of cytokine production or proliferation) and quality (e.g., pattern of cytokine production) of the response initiated by antigen recognition by the T cell receptor (TCR) The type of immune response (e.g., the type of immune response that occurs) is regulated by the balance between costimulatory and inhibitory signals (immune checkpoints). Under normal physiological conditions, immune checkpoints are important for suppressing autoimmunity (i.e., maintaining self-tolerance) and protecting tissues from damage when the immune system is responding to pathogenic infections. It is also important to The expression of immune checkpoint proteins can be deregulated by tumors as an important immune resistance mechanism. Examples of immune checkpoint inhibitors include, but are not limited to, CTLA-4, PD-1, PD-L1, BTLA, TIM3, LAG3, OX40, 41BB, VISTA, CD96, TGFβ, CD73, CD39, A2AR , A2BR, IDO1, TDO2, arginase, B7-H3, and B7-H4. Cell-based modulators of anti-cancer immunity are also contemplated. Examples of such modulators include, but are not limited to, chimeric antigen receptor T cells, tumor-infiltrating T cells, and dendritic cells.
[0208] The present disclosure relates to compounds of formula (I), (II), (III), (IV) as described herein, or compounds of Table 1, or pharmaceutically acceptable salts thereof and Combinations with inhibitors of immune checkpoint receptors and ligands (eg, ipilimumab, abatacept, nivolumab, pembrolizumab, atezolizumab, nivolumab and durvalumab) are also contemplated.
[0209] Additional treatments that may be used in combination with a compound of formula (I), (II), (III), (IV) or a compound of Table 1 disclosed herein, or a pharmaceutically acceptable salt thereof. Modalities include radiation therapy, monoclonal antibodies directed against tumor antigens, monoclonal antibody and toxin conjugates, T cell adjuvants, bone marrow transplantation, or antigen presenting cells (eg, dendritic cell therapy).
[0210] The present disclosure provides compounds of formula (I), (II), (III), (IV) as described herein, or compounds of Table 1, or the pharmaceutical composition thereof, for the treatment of glioblastoma. Contemplated is the use of the commercially acceptable salts alone or in combination with radiation and / or temozolomide (TMZ), Avastin or lomustine.
[0211] The present disclosure encompasses pharmaceutically acceptable salts, acids or derivatives of any of the above.
[0212] administration The compounds of formula (I), (II), (III), (IV) or the compounds of Table 1 provided herein, or a pharmaceutically acceptable salt thereof, may be used, for example, for administration. purpose (e.g., degree of desired resolution); age, weight, sex, and health / physical condition of the subject to whom the formulation is administered; route of administration; and the nature of the disease, disorder, condition, or symptom thereof. The amount may be administered to a subject. Dosage regimens can also take into account the existence, nature, and extent of any side effects associated with the administered drug. Effective doses and dosing regimens can be readily determined, for example, from safety and dose escalation studies, in vivo studies (eg, animal models), and other methods known to those of skill in the art.
[0213] In general, dosing parameters are such that the dose is below the amount that could cause irreversible toxicity to the subject (maximum tolerated dose (MTD)) and above the amount needed to produce a measurable effect in the subject. It stipulates that Such amounts are determined by, for example, pharmacokinetic and pharmacodynamic parameters relevant to ADME, taking into account the route of administration and other factors.
[0214] An effective dose (ED) is a dose or amount of a drug that produces a therapeutic response or desired effect in a percentage of subjects to whom it is administered. The “median effective dose” or ED of a drug 50 is the dose or amount of a drug that produces a therapeutic response or desired effect in 50% of the population to which the drug is administered. ED 50is commonly used as a measure of the reasonable expectation of a drug's effectiveness, but it is not necessarily the dose that a clinician would consider appropriate given all relevant factors. Therefore, in some cases the effective amount is the calculated ED 50 more, otherwise the effective dose is the calculated ED 50 In still other cases the effective amount is less than the calculated ED 50 is the same as
[0215] Additionally, an effective amount of a compound of formula (I), (II), (III), (IV), or a compound of Table 1, or a salt thereof, as provided herein, may be administered to a subject in one dose. It may be an amount that, when administered above, produces a desired result compared to a healthy subject. For example, in a subject suffering from a particular disorder, an effective amount may reduce the diagnostic parameters, measurements, markers, etc. of the disorder by at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90%; , 100% is defined as the diagnostic parameters, measurements, markers, etc. exhibited by normal subjects.
[0216] In certain embodiments, a compound of formula (I), (II), (III), (IV) disclosed herein or a compound of Table 1, or a pharmaceutically acceptable salt thereof is administered once or more daily (e.g., orally) at a dose level of about 0.01 mg / kg to about 50 mg / kg, or about 1 mg / kg to about 25 mg / kg subject body weight / day to achieve the desired therapeutic effect. ) may be done.
[0217] For oral drug administration, the composition may contain from 1.0 to 1000 milligrams of active ingredient, in particular 1.0, 3.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0 , 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of active ingredient.
[0218] In certain embodiments, this dose of a compound of formula (I), (II), (III), (IV), or a compound of Table 1, or a pharmaceutically acceptable salt thereof, is administered in a "unit dosage form." ” Contained in. The phrase "unit dosage form" means that each unit contains a predetermined amount of a compound of formula (I), (II), (III), (IV) or a compound of Table 1 sufficient to produce the desired effect. , or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional agents. It will be appreciated that the parameters of the unit dosage form will vary depending on the particular drug and the effect to be achieved.
[0219] kit The present invention also includes compounds of formula (I), (II), (III), (IV) or compounds of Table 1, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. We are also planning a kit. Kits are generally in the form of physical structures containing various components, as described below, that may be utilized, for example, in carrying out the methods described above.
[0220] The kit may contain a compound of formula (I), (II), (III), or (IV) disclosed herein, which may be in the form of a pharmaceutical composition suitable for administration to a subject. 1, or a pharmaceutically acceptable salt thereof (eg, provided in a sterile container). A compound of formula (I), (II), (III), (IV) or a compound of Table 1, or a pharmaceutically acceptable salt thereof, can be prepared in ready-to-use form (e.g., tablets or capsules). ) or may be provided in a form (eg, a powder) that requires, eg, reconstitution or dilution before administration. A compound of formula (I), (II), (III), (IV) or a compound of Table 1, or a pharmaceutically acceptable salt thereof, may need to be reconstituted or diluted by the user. When in one form, the kit is also packaged with a compound of formula (I), (II), (III), (IV), or a compound of Table 1, or a pharmaceutically acceptable salt thereof. It may also contain diluents (eg, sterile water), buffers, pharmaceutically acceptable excipients, etc., either packaged separately or separately. If combination therapy is contemplated, the kit may contain several agents separately or they may already be combined within the kit. Each component of the kit may be enclosed in an individual container, or the various containers may all be within a single package. Kits of the invention may be designed for the conditions necessary to properly maintain the components contained therein (eg, refrigeration or freezing).
[0221] The kit shall include a label or packaging containing identification information of the components therein and instructions for use (e.g., administration parameters, mechanism of action, clinical pharmacology of the active ingredient including pharmacokinetics and pharmacodynamics, side effects, contraindications, etc.) May include package inserts. The label or package insert may also include manufacturer information such as lot number and expiration date. The label or insert may, for example, be integrated into the physical structure containing the components, or may be contained separately within the physical structure, or attached to the components of the kit (e.g., ampoules, tubes, etc.). or vial).
[0222] The label or package insert may further include disks (e.g. hard disks, cards, memory disks), optical disks (CD- or DVD-ROM / RAM, DVD, MP3, etc.), magnetic tape or electrical storage media (such as RAM and ROM), or a computer readable medium such as a magnetic / optical storage medium, a FLASH medium or a hybrid thereof such as a memory type card. In some embodiments, actual instructions are not present within the kit, but a means is provided for obtaining instructions from a remote source, such as via the Internet.
Example
[0223] The following Examples and References (Intermediates) are presented to provide those skilled in the art with a complete disclosure and description of how to make and use the invention and limit the scope of what the inventors regard as the invention. It is not intended to represent that the following experiments have been performed or that they are all of the experiments that may be performed. Exemplary descriptions written in the present tense are to be understood as not necessarily being implemented, but rather that those descriptions can be implemented to produce data etc. of the nature described therein. . Efforts have been made to ensure accuracy with respect to numbers used (eg, amounts, temperature, etc.) but some experimental errors and deviations should be accounted for.
[0224] Compounds of formula (I), (II), (III), (IV) are prepared by synthetic methods known in the art of organic chemistry or by the methods described below, with modifications and transformations well known to those skilled in the art. be able to. The starting materials used herein are commercially available or prepared using standard methods known in the art [e.g., the Compendium of Organic Synthetic Methods, Vol. I-XII (published by Wiley-Interscience)]. It can be prepared by the method disclosed in the reference book].
[0225] Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius (° C.), and pressure is near atmospheric. Standard abbreviations are used including: THF=tetrahydrofuran; DIEA=diisopropylethylamine; EtOAc=ethyl acetate; NMP=N-methylpyridine, TFA=trifluoroacetic acid; DCM=dichloromethane; Cs 2 C.O. 3 =Cesium carbonate; Palladium-(II) methanesulfonate; LiCl=lithium chloride; POCl 3 =phosphoryl chloride;PE=petroleum ether;DMSO=dimethyl sulfoxide;HCl=hydrochloric acid;Na 2 S.O. 4 =Sodium sulfate;DMF=Dimethylformamide;NaOH=Sodium hydroxide;K 2 C.O. 3 =potassium carbonate;MeCN=acetonitrile;BOC=tert-butoxycarbonyl;MTBE=methyl tert-butyl ether;MeOH=methanol;NaHCO 3 =Sodium bicarbonate;NaBH 3 CN=sodium cyanoborohydride; EtOH=ethanol; PCl 5 =phosphorus pentachloride;NH 4 OAc=ammonium acetate; Et 2 O=ether;HOAc=acetic acid;Ac 2 O=acetic anhydride;i-PrOH=isopropanol;NCS=N-chlorosuccinimide;K 3 P.O. 4 =potassium phosphate;Pd(dtbpf)Cl 2 =1,1’-bis(di-tert-butylphosphino)ferrocene)dichloro-palladium(II);Zn(CN) 2 =zinc cyanide;Pd(PPh 3 ) 4 =tetrakis(triphenylphosphine)palladium(0);Et 3N=triethylamine;CuCN=copper cyanide;t-BuONO=tert-butyl nitrite;HATU=1-(bis(dimethylamino)methylene)-1H-1,2,3-triazolo(4,5-b)pyridinium 3-Oxidohexafluorophosphate; DBU=1,8-diazabicyclo(5.4.0)undec-7-ene; LiAlH 4 = lithium aluminum hydride; NH 3 =Ammonia;H 2 S.O. 4 =Sulfuric acid;H 2 O 2 =Hydrogen peroxide;EDCI=N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride;HOBT=1-hydroxybenzotriazole hydrate;DHP=dihydropyran;TsOH=p-toluenesulfonic acid;FA =Formic acid;TCFH=N,N,N,N'-tetramethylchloroformamidium hexafluorophosphate;NMI=N-methylimidazole;Pd(dppf)Cl 2 =(1,1’-bis(diphenylphosphino)ferrocene)dichloropalladium(II);Pd(dppf)Cl 2 -DCM=(1,1’-bis(diphenylphosphino)ferrocene)dichloropalladium(II), dichloromethane complex
[0226] Certain compounds of the present disclosure have asymmetric carbon atoms. Where the absolute stereochemistry of the exemplified compounds has not yet been determined, this is noted in the text and a name is assigned to each isolated isomer. Further study may reveal that the isomer to which the name is assigned has a different absolute stereochemistry.
[0227] Synthesis example Intermediate A 5-((4-chlorobenzyl)oxy)-1,3,4-thiadiazol-2-amine [ka] To a solution of NaH (42.0 g, 1.05 mol, 60.0% purity) in THF (750 mL) was added dropwise a solution of (4-chlorophenyl)methanol (100 g, 701 mmol) in THF (250 mL) at 5°C. This mixture was stirred at 5°C for 4 hours. Then, 2-amino-5-bromo-1,3,4-thiadiazole (152 g, 842 mmol) was added to this mixture at 5°C. This mixture was stirred at 5°C for 3 hours. This mixture is 2 Poured into O and extracted with EtOAc (3x). The combined organic layer was diluted with Na 2 S.O. 4 dried, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography, eluting with 9%-66% EtOAc in PE to give a residue. The residue was diluted with MeOH and the slurry was stirred at 25° C. for 0.5 h. The solid was collected and diluted with MeOH. The slurry was stirred at 80°C for 16 hours. The solid was collected to give 5-((4-chlorobenzyl)oxy)-1,3,4-thiadiazol-2-amine (61.0 g, 18% yield) as a gray solid.
[0228] Intermediate B 3-(2-methoxyphenyl)pyridine-4-carboxylic acid [ka] A solution of 3-bromopyridine-4-carboxylic acid (2.0 g, 9.9 mmol) in dioxane (10 mL) and water (10 mL) was added with 2-methoxyphenylboronic acid (2.3 g, 14.9 mmol), Na 2 C.O. 3 (1.1g, 9.9mmol) and Pd(PPh 3 ) 4 (1.1 g, 0.99 mmol) was added at room temperature under nitrogen. This mixture was stirred at 100°C overnight. The mixture was cooled to room temperature and diluted with water. This mixture was extracted with EtOAc (2x). The aqueous layer was acidified to pH 6 with HCl (1M). The resulting solid and mixture were filtered to give 3-(2-methoxyphenyl)pyridine-4-carboxylic acid as a white solid, which was used in the next step without further purification.
[0229] Intermediate C 5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-amine [ka]
[0230] Step 1. Preparation of (5-chloropyridin-2-yl)methanol [ka] A solution of methyl 5-chloropicolinate (95 g, 554 mmol) in MeOH (950 mL) was added with NaBH 4 (42.0 g, 1.11 mol) was added portionwise at 0°C. This mixture was then stirred at room temperature for 2 hours. This mixture is 2 Pour into O. The mixture was cooled to 0°C and 6N HCl was added until the pH of the solution was 1-2. The temperature of the solution was 0~10℃. The mixture was then concentrated under reduced pressure to remove MeOH. 6N NaOH was added until the pH of the solution was 8-10. This mixture was extracted with EtOAc (3x). The combined organic layer was diluted with Na 2 S.O. 4 , filtered and concentrated under reduced pressure to give the title compound (158g) as a yellow oil, which was used in the next step without further purification.
[0231] Step 2. Preparation of 5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-amine [ka] A solution of NaH (65.7 g, 1.64 mol, 60.0% purity) in THF (1.20 L) was added with (5-chloropyridin-2-yl)methanol (158 g, 1.10 mol) in THF (400 mL) at 5°C. The solution was added dropwise. This mixture was stirred at 5°C for 1 hour. Next, 2-amino-5-bromo-1,3,4-thiadiazole (237 g, 1.31 mol) was added portionwise at 5°C. This mixture was stirred at 5°C for 4 hours. This mixture is 2 Poured into O and extracted with EtOAc (4x). The combined organic layer was diluted with Na 2 S.O. 4 dried, filtered and concentrated under reduced pressure. The residue was diluted with MeOH and the slurry was stirred at 25° C. for 0.5 h. The solid was collected and diluted with MeOH. The slurry was stirred at 80°C for 2 hours. The solid was collected to give 5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-amine (57.6 g, 21% yield) as a gray solid.
[0232] Intermediate D 4-(2-methoxyphenyl)-6-methylnicotinic acid [ka]
[0233] Step 1: Preparation of methyl 4-(2-methoxyphenyl)-6-methylnicotinate [ka] To a solution of methyl 4-chloro-6-methylpyridine-3-carboxylate (300 mg, 1.61 mmol) in 1,4-dioxane (4 mL) and water (0.5 mL) was added 2-methoxyphenylboronic acid (491 mg, 3.23 mmol), K 2 C.O. 3 (446mg, 3.23mmol), Pd(dtbpf)Cl 2 (105mg, 0.162mmol) was added. This mixture was stirred at 80°C for 2 hours. The mixture was diluted with water and extracted with EtOAc (3x). The combined organic extracts were concentrated under reduced pressure. The residue was purified by Prep-TLC (eluent: 10% MeOH in DCM) to give the title compound (330 mg, 72% yield) as a brown oil.
[0234] Step 2: Preparation of 4-(2-methoxyphenyl)-6-methylnicotinic acid [ka] The title compound was prepared according to General Procedure F using methyl 4-chloro-6-methylpyridine-3-carboxylate. The mixture was diluted with water and MeOH was removed under reduced pressure. The mixture was acidified to pH 5 with HCl (1M). The precipitated solid was collected by filtration and washed with water (2x) to give 4-(2-methoxyphenyl)-6-methylnicotinic acid (140 mg, 41% yield) as a white solid.
[0235] Intermediate E 4-(2-(difluoromethoxy)-6-fluorophenyl)-6-methylnicotinic acid [ka] The title compound was prepared according to the procedure for Intermediate D to give 4-(2-(difluoromethoxy)-6-fluorophenyl)-6-methylnicotinic acid as a white solid, which was used without further purification.
[0236] Intermediate F 4-(2-fluoro-6-methoxyphenyl)-6-methylnicotinic acid [ka] The title compound was prepared according to the procedure for Intermediate D using methyl 3-bromoisonicotinate and 2-fluoro-6-methoxyphenylboronic acid to give 4-(2-fluoro-6-methoxyphenyl)-6-methyl Nicotinic acid was obtained as a white solid, which was used without further purification.
[0237] intermediate G 5’-Methoxy-2’,6-dimethyl-(4,4’-bipyridine)-3-carboxylic acid [ka]
[0238] Step 1 Benzyl 4-chloro-6-methylnicotinate [ka] 4-chloro-6-methylpyridine-3-carboxylic acid (10.00g, 58.3mmol) and Cs in DMF (100mL) 2 C.O. 3 (37.98g, 116.6mmol) was added benzyl bromide (14.95g, 87.45mmol). The resulting mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-30% ethyl acetate in petroleum ether to give benzyl 4-chloro-6-methylnicotinate (12.94 g, 84.8%) as a yellow oil. (C 14 H 12 ClNO 2 )(M+1) + MS(ESI) calculated value of 262.0, measured value of 262.1.
[0239] Step 2 Benzyl 2’-chloro-5’-methoxy-6-methyl-(4,4’-bipyridine)-3-carboxylate [ka] 1,4-dioxane (50mL) and H 2 of methylbenzyl 4-chloro-6-methylpyridin-3-carboxylate (6.00 g, 22.926 mmol) and 2-chloro-5-methoxypyridin-4-ylboronic acid (4.30 g, 22.926 mmol) in O (5 mL). In the degassed mixture, K 2 C.O. 3 (9.51g, 0.069mmol) and Pd(DtBPF)Cl 2 (1.49g, 2.29mmol) was added. The resulting mixture was stirred at 80° C. for 2 hours under nitrogen atmosphere. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-50% ethyl acetate in petroleum ether to give 2'-chloro-5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carvone. Benzyl acid (4g, 47.3%) was obtained as a yellow oil. (C 20 H 17 ClN 2 O 3 )(M+1) + MS (ESI) calculated value of 369.1, actual value of 369.0.
[0240] Step 3 Benzyl 5’-methoxy-2’,6-dimethyl-(4,4’-bipyridine)-3-carboxylate [ka] Benzyl 2-chloro-5-methoxy-6-methyl-(4,4-bipyridine)-3-carboxylate (4.00 g, 10.845 mmol) and K in DME (30 mL). 2 C.O. 3 (4.50g, 33.0mmol) of Pd(dppf)Cl 2 (0.79 g, 1.0 mmol) and trimethyl-1,3,5,2,4,6-trioxatriborinane (1.50 g, 12.0 mmol) were added. The resulting mixture was stirred at 120° C. for 2 hours under nitrogen atmosphere. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by reverse phase flash chromatography using 5-70% acetonitrile in water to give benzyl 5'-methoxy-2',6-dimethyl-(4,4'-bipyridine)-3-carboxylate (2.8 g, 74.1 %) as a yellow oil. (C 21 H 20 N 2 O 3 )(M+1) + MS (ESI) calculated value of 349.1, actual value of 349.0.
[0241] Step 4 5’-methoxy-2’,6-dimethyl-(4,4’-bipyridine)-3-carboxylic acid [ka] Pd / C (2.80 g, 10% ) was added. The resulting mixture was stirred at room temperature for 1 hour under a hydrogen atmosphere. The resulting mixture was filtered. The filtrate was concentrated in vacuo to give 5'-methoxy-2',6-dimethyl-(4,4'-bipyridine)-3-carboxylic acid (2.5 g, crude product) as a yellow solid, which was subjected to further purification. It was used directly in the next step. (C 14 H 14 N 2 O 3 )(M+1) + MS (ESI) calculated value of 259.1, actual value of 259.0.
[0242] Intermediate H 2’-chloro-5’-methoxy-6-methyl-(4,4’-bipyridine)-3-carboxylic acid [ka]
[0243] Step-7: 2-chloro-5-methoxypyridin-4-ylboronic acid [ka] To a stirred solution of 2-chloro-5-methoxypyridine (10.0 g, 69.65 mmol) in THF (500 mL) was added LDA (14.9 g, 139.30 mmol) at -78°C, N 2 Dropped under atmosphere. The resulting mixture was stirred at -78°C for 2 hours. Triisopropyl borate (26.2 g, 139.30 mmol) was then added to this mixture at -78°C. The resulting mixture was stirred at -78°C for 2 hours. The resulting mixture was then stirred at room temperature for 16 hours. The resulting mixture was quenched with HCl (2N) and stirred at room temperature for 30 minutes. The resulting mixture was extracted with ethyl acetate. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. 2-chloro-5-methoxypyridin-4-ylboronic acid (9 g, 68.9%) was obtained as a brown solid. (C 6 H 7 BClNO 3 )(M+1) + MS(ESI) calculated value for 188.0; measured value 188.0.
[0244] Step-8: Methyl 2’-chloro-5’-methoxy-6-methyl-[4,4’-bipyridine]-3-carboxylate [ka] Dioxane (6mL) and H 2 A degassed solution of methyl 4-chloro-6-methylpyridin-3-carboxylate (700 mg, 3.77 mmol) and 2-chloro-5-methoxypyridin-4-ylboronic acid (918 mg, 4.90 mmol) in O (2 mL). In, Pd(dppf)Cl 2 (275mg, 0.37mmol) and K 2 C.O. 3 (1563 mg, 11.31 mmol) was added under nitrogen atmosphere. The resulting mixture was stirred at 80° C. for 16 hours under nitrogen atmosphere. The resulting mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography using 0-60% ethyl acetate in petroleum ether to give methyl 2'-chloro-5'-methoxy-6-methyl-[4,4'-bipyridine]-3-carboxylate ( 220 mg, 19.9%) was obtained as a white solid. (C 14 H 13 ClN 2 O 3 )(M+1) + MS(ESI) calculated value for 293.1; measured value 293.1.
[0245] Step-9: 2’-chloro-5’-methoxy-6-methyl-(4,4’-bipyridine)-3-carboxylic acid [ka] To a stirred solution of methyl 2'-chloro-5'-methoxy-6-methyl-[4,4'-bipyridine]-3-carboxylate (220 mg, 0.75 mmol) in THF (2 mL) and water (2 mL) was added LiOH.H 2 O (126 mg, 3.01 mmol) was added. The resulting mixture was stirred at room temperature for 2 hours. The mixture was acidified to pH 3 with citric acid. The resulting mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated in vacuo, and purified with 2'-chloro-5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carvone. The acid (160 mg, 76.3%) was obtained as a white solid. (C 13 H 11 ClN 2 O 3 )(M+1) + MS(ESI) calculated value for 279.0; measured value 279.0.
[0246] Example 1 3-(2-methoxyphenyl)-N-(5-((tetrahydro-2H-pyran-4-yl)methoxy)-1,3,4-thiadiazol-2-yl)isonicotinamide [ka]
[0247] Step 1 (methylsulfanyl)((oxan-4-yl)methoxy)methanethione [ka] In a 100 mL three-necked round bottom flask, a stirred solution of (oxan-4-yl)methanol (3.00 g, 25.826 mmol, 1.00 eq.) in THF (30 mL) was added with NaH (1.24 g, 51.713 mmol, 2.00 eq. ) was added dropwise at 0°C under a nitrogen atmosphere. CS at 0 °C in the above mixture 2 (2.95g, 38.744mmol, 1.50eq) was added. The mixture was stirred for 10 minutes and MeI (4.39g, 30.985mmol, 1.20eq) was added at 0°C. The mixture was stirred for 3 hours at room temperature under nitrogen atmosphere. The reaction was monitored by TLC. Saturate the reaction at room temperature with NH 4 Quenched by adding Cl(aq) (50 mL). The aqueous layer was extracted with EtOAc (4 x 50 mL). The resulting mixture was concentrated in vacuo. The residue was purified by a silica gel column (PE:EtOAc=5:1) to obtain (methylsulfanyl)((oxan-4-yl)methoxy)methanethione (1.4 g) as a pale yellow oil.
[0248] Step 2 O-((tetrahydro-2H-pyran-4-yl)methyl)hydrazinecarbothioate [ka] In a 50 mL three-neck round bottom flask, (methylsulfanyl)((oxan-4-yl)methoxy)methanethione (1.40 g, 6.785 mmol, 1.00 eq.) and hydrazine (326.00 mg, 10.178 mmol, 1.50 eq) was added. The mixture was evaporated, the residue was redissolved in 4 mL of MeOH and the solution was evaporated again. The crude hydrazinecarbothioate O-((tetrahydro-2H-pyran-4-yl)methyl) was used directly in the next step without further purification.
[0249] Step 3 5-((tetrahydro-2H-pyran-4-yl)methoxy)-1,3,4-thiadiazol-2-amine [ka] In a 50 mL three-neck round bottom flask, (((oxan-4-yl)methoxy)methanethioyl)amino)amine (1.29 g, 6.780 mmol, 1.00 eq.) and BrCN (865.80 mg, 8.140 mmol, 1.20 eq) of Et 3 N (1.37g, 13.560mmol, 2.00eq) was added. The mixture was stirred for 1 hour at room temperature under nitrogen atmosphere. The reaction was monitored by TLC. The solution was evaporated and precipitated by adding MeOH. This gave 5-((tetrahydro-2H-pyran-4-yl)methoxy)-1,3,4-thiadiazol-2-amine (560 mg) as a white solid.
[0250] Step 4 3-(2-methoxyphenyl)-N-(5-((tetrahydro-2H-pyran-4-yl)methoxy)-1,3,4-thiadiazol-2-yl)isonicotinamide [ka] 5-(oxan-4-ylmethoxy)-1,3,4-thiadiazol-2-amine (34.00mg, 0.158mmol, 1.00eq) and 3-(2-methoxyphenyl)pyridine-4 in DMF (400.00uL) -To a stirred solution of carboxylic acid (36.21 mg, 0.158 mmol, 1.00 eq.) at room temperature was added DIEA (40.83 mg, 0.316 mmol, 2.00 eq.) and HATU (72.06 mg, 0.190 mmol, 1.20 eq.). The resulting mixture was stirred for 1 hour at room temperature. The reaction was diluted with EA (20 mL). The resulting mixture was washed with 2 x 10 mL of water. The organic layer was concentrated in vacuo. Prep-TLC (CH 2 Cl 2 / MeOH 15:1) and 3-(2-methoxyphenyl)-N-(5-((tetrahydro-2H-pyran-4-yl)methoxy)-1,3,4-thiadiazol-2-yl ) Isonicotinamide (68.2 mg, 101.15%) was obtained as a white solid. MS (ESI) (M+1) + , 427. 1 H NMR (300MHz, DMSO): δ 12.83 (s, 1H), 8.72 - 8.70 (d, 1H), 8.61 (s, 1H), 7.63 - 7.60 (d, 1H), 7.40 - 7.35 (m, 2H), 7.12 - 6.95 (m, 2H), 4.29 - 4.27 (d, 2H), 3.89 - 3.84 (m, 2H), 3.51 (s, 3H), 3.31-3.31 (m, 2H), 2.06-1.98 (m, 1H) ), 1.65 - 1.60 (d, 2H), 1.37 - 1.24 (m, 2H) ppm.
[0251] Example 2 3-(2-methoxyphenyl)-N-(5-((tetrahydro-2H-pyran-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)isonicotinamide [ka]
[0252] Step 1. S-methyl O-((tetrahydro-2H-pyran-2-yl)methyl)carbodithioate [ka] A solution of tetrahydropyran-2-methanol (5.00 g, 43.044 mmol, 1.00 eq.) and NaH (2.06 g, 51.653 mmol, 1.2 eq., 60%) in THF (50 mL) was added for 30 min at 0°C under nitrogen atmosphere. It was stirred with CS at 0 °C in the above mixture 2 (3.93g, 51.653mmol, 1.2eq) was added. The resulting mixture was stirred for an additional 20 minutes at 0°C. CH to the above mixture at 0 °C 3 I (7.33g, 51.653mmol, 1.2eq) was added. The resulting mixture was stirred for 20 minutes at 0° C. under nitrogen atmosphere. The reaction was carried out at room temperature with (100 mL) NH 4 Quenched with Cl (aq). The aqueous layer was extracted with EtOAc (3 x 30 mL). The resulting mixture was concentrated in vacuo. The residue was purified by silica gel column chromatography and CH 2 Cl 2 / MeOH (90:1) to give S-methyl O-((tetrahydro-2H-pyran-2-yl)methyl)carbodithioate (6 g, yield 67.56%).
[0253] Step 2. 2-methylhydrazine-1-carbothioic acid O-((tetrahydro-2H-pyran-2-yl)methyl) [ka] S-Methyl O-((tetrahydro-2H-pyran-2-yl)methyl)carbodithioate (6.00 g, 29.081 mmol, 1.00 equiv.) and hydrazine hydrate in MeOH (70 mL) under nitrogen atmosphere at 0 °C. (1.53g, 30.535mmol, 1.05eq) into a stirred solution. The resulting mixture was stirred at 0° C. for 2 hours under nitrogen atmosphere. The resulting mixture was concentrated in vacuo. The residue was purified by trituration with EtOAc (20 mL). This gave S-methyl O-((tetrahydro-2H-pyran-2-yl)methyl)carbodithioate (5 g, yield 90.37%) as a white solid.
[0254] Step 3. 5-((tetrahydro-2H-pyran-2-yl)methoxy)-1,3,4-thiadiazol-2-amine [ka] S-methyl O-((tetrahydro-2H-pyran-2-yl)methyl)carbodithioate (5.80 g, 30.485 mmol, 1.00 eq.) and Et in MeOH (60 mL). 3 To a stirred solution of N (6.17 g, 60.969 mmol, 2.00 eq.) was added cyanogen bromide (3.87 g, 36.582 mmol, 1.20 eq.) at 0° C. under an air atmosphere. The resulting mixture was stirred for 2 hours. The resulting mixture was concentrated in vacuo. The residue was purified by trituration with MeOH (20 mL). This gave 5-((tetrahydro-2H-pyran-2-yl)methoxy)-1,3,4-thiadiazol-2-amine (2.5 g, yield 38.10%) as a pink solid.
[0255] Step 4. 3-(2-methoxyphenyl)-N-(5-((tetrahydro-2H-pyran-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)isonicotinamide [ka] 5-((tetrahydro-2H-pyran-2-yl)methoxy)-1,3,4-thiadiazol-2-amine (100.00 mg, 0.465 mmol, 1.00 mg) in DMF (2 mL) at room temperature under air atmosphere. 3-(2-methoxyphenyl)pyridine-4-carboxylic acid (127.78mg, 0.557mmol, 1.20eq), DIEA (120.08mg, 0.929mmol, 2.00eq) and HATU (264.94mg, 0.697mmol, 1.50eq) ) stirred solution. The resulting mixture was stirred overnight at room temperature under an air atmosphere. The resulting mixture was diluted with brine (50 mL). The aqueous layer was extracted with EtOAc (2x20ml). The resulting mixture was concentrated in vacuo. Prep-TLC (CH 2 Cl 2 / MeOH 12:1) and 3-(2-methoxyphenyl)-N-(5-((tetrahydro-2H-pyran-2-yl)methoxy)-1,3,4-thiadiazol-2-yl ) Isonicotinamide (100.2 mg, yield 50.58%) was obtained as a white solid. MS (ESI) (M+1) + , 427. 1 H NMR (400 MHz, DMSO) δ12.82 (s, 1H), 8.71 - 8.70 (d, 1H), 8.60 (s, 1H), 7.63 - 7.61 (d, 1H), 7.37 - 7.35 (m, 2H) , 7.07-7.06 (t, 1H), 6.99 - 6.97 (d, 1H), 4.36 - 4.30 (m, 2H), 3.89 - 3.86 (m, 1H), 3.68 - 3.63 (t, 1H), 3.51 (s, ppm.
[0256] Example 3 3-(2-methoxyphenyl)-N-(5-(4,5,6,7-tetrahydro-1H-indazol-4-ylmethoxy)-1,3,4-thiadiazol-2-yl)pyridin-4- carboxamide [ka]
[0257] Step 1. 1-((2-(trimethylsilyl)ethoxy)methyl)-6,7-dihydro-5H-indazol-4-one [ka] To a stirred solution of 1,5,6,7-tetrahydroindazol-4-one (5.00 g, 36.723 mmol, 1.00 eq.) in DMF (50 mL) was added NaH (1.76 g, 0.073 mmol, 2 eq.) at 0 °C. It was added in portions under a nitrogen atmosphere. The resulting mixture was stirred for 2 hours at 0°C. SEMCl (7.35g, 0.044mmol, 1.20eq) was added dropwise to the above mixture at 0°C. The resulting mixture was further stirred overnight at room temperature. Bring the reaction to room temperature with 200 mL of NH 4 Quenched with Cl (aq). The aqueous layer was extracted with EtOAc (2 x 200 mL). The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with hexane / EtOAc (10:1) to give 1-((2-(trimethylsilyl)ethoxy)methyl)-6,7-dihydro-5H-indazol-4-one ( 8.3g, 83.14%) was obtained as a light brown oil.
[0258] Step 2. 4-methylidene-1-((2-(trimethylsilyl)ethoxy)methyl)-6,7-dihydro-5H-indazole [ka] To a stirred solution of methyltriphenylphosphanium bromide (16.49 g, 0.046 mmol, 1.5 eq.) in DMSO (200 mL) was added NaH (2.48 g, 0.062 mmol, 2 eq., 60% in oil) at room temperature under nitrogen atmosphere. I added it little by little at the bottom. The resulting mixture was stirred at room temperature for 2 hours. 1-((2-(trimethylsilyl)ethoxy)methyl)-6,7-dihydro-5H-indazol-4-one (8.20 g, 0.031 mmol, 1.00 equivalent) was added dropwise to the above mixture at room temperature. The resulting mixture was stirred for an additional 4 hours at room temperature. The reaction was carried out at room temperature with NH 4 Quenched with Cl (aq). The aqueous layer was extracted with EtOAc (2 x 100 mL). The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with hexane / EtOAc (100:1~15:1) to give 4-methylidene-1-((2-(trimethylsilyl)ethoxy)methyl)-6,7-dihydro- 5H-indazole (6.1 g, 73.45%) was obtained as a colorless oil.
[0259] Step 3. (1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydroindazol-4-yl)methanol [ka] A stirred solution of 4-methylidene-1-((2-(trimethylsilyl)ethoxy)methyl)-6,7-dihydro-5H-indazole (3.10 g, 11.723 mmol, 1.00 eq.) in THF (30 mL) was added with 1 M BH 3 -THF (100.00 mL, 46.892 mmol, 4 equivalents) was added dropwise at 0° C. under nitrogen atmosphere. The resulting mixture was stirred for 3 hours at 55° C. under nitrogen atmosphere. H in the above mixture 2 In O, 1M K 2 C.O. 3 (5.67g, 0.041mmol, 3.50eq) at 0°C, then H 2 O 2 (3.67g, 41.000mmol, 3.50eq, 38%) was added dropwise. The resulting mixture was stirred for an additional 3 hours at room temperature. The aqueous layer was extracted with EtOAc (2 x 100 mL). The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with hexane / EtOAc (50:1~1:1) to give (1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro Indazol-4-yl)methanol (2 g, 59.19%) was obtained as a colorless oil.
[0260] Step 4. (Methylsulfanyl)((1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydroindazol-4-yl)methoxy)methanethione [ka] A stirred solution of (1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydroindazol-4-yl)methanol (3.10 g, 10.975 mmol, 1.00 eq.) in THF (30 mL) / To the mixture was added NaH (0.88 g, 21.950 mmol, 2.00 eq., 60% in oil) portionwise at 0° C. under nitrogen atmosphere. The resulting mixture was stirred for 2 hours at 0°C. CS to the above mixture 2 (1.00g, 13.170mmol, 1.20eq) was added dropwise at 0°C. After 10 minutes, MeI (1.87g, 0.013mmol, 1.2eq) was added to the above mixture. The resulting mixture was stirred for an additional 5 minutes at 0°C. React at room temperature with NH 4 Quenched by adding Cl(aq) (20 mL). The aqueous layer was extracted with EtOAc (1 x 20 mL). The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with hexane / EtOAc (100:1~10:1) to give (methylsulfanyl)((1-((2-(trimethylsilyl)ethoxy)methyl)-4,5, 6,7-tetrahydroindazol-4-yl)methoxy)methanethione (2 g, 47.93%) was obtained as a colorless oil.
[0261] Step 5. Hydrazinecarbothioate O-((1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-1H-indazol-4-yl)methyl) [ka] In a 50-mL three-neck round-bottom flask purged with nitrogen and maintained under an inert atmosphere of nitrogen, add MeOH (20.00 mL), (methylsulfanyl)((1-((2-(trimethylsilyl)ethoxy)methyl) -4,5,6,7-tetrahydroindazol-4-yl)methoxy)methanethione (2.00g, 5.367mmol, 1.00eq) and hydrazine hydrate (98%) (0.54g, 10.787mmol, 2.01eq) were added. Ta. The resulting solution was stirred for 20 minutes at room temperature. The resulting mixture was diluted with water (50 mL). The aqueous layer was extracted with EtOAc (2 x 20 mL). The resulting mixture was concentrated under reduced pressure. This produced hydrazinecarbothioate O-((1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-1H-indazol-4-yl)methyl) (1.7 g, 88.83 %) as an off-white solid.
[0262] Step 6. 5-((1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydroindazol-4-yl)methoxy)-1,3,4-thiadiazol-2-amine [ka] ((((1-((2-(trimethylsilyl)ethoxy)ethoxy)methyl)-4,5,6,7-tetrahydroindazol-4-yl)methoxy)methanethioyl)amino)amine (1.70 g, BrCN (1.01 g, 9.535 mmol, 2.00 eq.) was added portionwise at room temperature under a nitrogen atmosphere to a stirred solution of TEA (0.96 g, 9.536 mmol, 2 eq.). The resulting mixture was stirred for 1 hour at room temperature. The reaction was quenched with water at room temperature. The aqueous layer was extracted with EtOAc (2 x 50 mL). The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and CH 2 Cl 2 / MeOH (20:1) and 5-((1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydroindazol-4-yl)methoxy)-1,3 ,4-Thiadiazol-2-amine (1.5 g, 79.15%) was obtained as an off-white solid.
[0263] Step 7. 3-(2-methoxyphenyl)-N-(5-((1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydroindazol-4-yl)methoxy) -1,3,4-thiadiazol-2-yl)pyridine-4-carboxamide [ka] HATU (597.89 mg, 1.572 mmol, 1.20 eq.) was added at room temperature under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 2 hours. Add 5-((1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydroindazol-4-yl)methoxy)-1,3,4-thiadiazole- to the above mixture at room temperature. 2-amine (500.00mg, 1.310mmol, 1.00eq) was added. The resulting mixture was stirred for an additional 3 hours at room temperature. The resulting mixture was diluted with water (50 mL). The aqueous layer was extracted with EtOAc (2 x 20 mL). The resulting mixture was concentrated under reduced pressure. Prep-TLC (CH 2 Cl 2 / MeOH 30:1) and 3-(2-methoxyphenyl)-N-(5-((1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydroindazole). -4-yl)methoxy)-1,3,4-thiadiazol-2-yl)pyridine-4-carboxamide (440 mg, 56.64%) was obtained as a white solid.
[0264] Step 8. 3-(2-methoxyphenyl)-N-(5-(4,5,6,7-tetrahydro-1H-indazol-4-ylmethoxy)-1,3,4-thiadiazol-2-yl)pyridine -4-carboxamide [ka] In a 20-mL sealed tube purged with nitrogen and maintained under an inert atmosphere of nitrogen, THF (10.00 mL), 3-(2-methoxyphenyl)-N-(5-((1-((2-( Trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydroindazol-4-yl)methoxy)-1,3,4-thiadiazol-2-yl)pyridine-4-carboxamide (220.00mg, 0.371mmol, 1.00 equivalent), CsF (1127.51 mg, 7.423 mmol, 20.00 equivalent), and TBAF (970.35 mg, 3.711 mmol, 10 equivalent) were added. The resulting solution was stirred at 70°C for 1 hour. The resulting mixture was diluted with water (30 mL). The aqueous layer was extracted with EtOAc (1 x 20 mL). The resulting mixture was concentrated under reduced pressure. Prep-TLC (CH 2 Cl 2 / MeOH 20:1) and 3-(2-methoxyphenyl)-N-(5-(4,5,6,7-tetrahydro-1H-indazol-4-ylmethoxy)-1,3,4- Thiadiazol-2-yl)pyridine-4-carboxamide (49.6 mg, 28.72%) was obtained as a white solid. MS (ESI) (M+1) + , 463. 1 H NMR (300 MHz, DMSO-d6) δ12.80(s, 1H), 12.31(s, 1H), 8.71 - 8.70 (d, 1H), 8.60 (s, 1H), 7.63 - 7.62 (d, 1H) , 7.44-7.35 (m, 3H), 7.09 - 7.07 (m, 1H), 7.00-6.98 (d, 1H), 4.51 - 4.45 (m, 1H), 4.39 - 4.33 (m, 1H), 3.52 (s, ppm.
[0265] Example 4 1-(6-(((5-(4-(2-methoxyphenyl)-6-methylnicotinamide)-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridin-3-yl)cyclo Propane-1-carboxylic acid [ka]
[0266] Step-1: 1-(6-chloropyridin-3-yl)cyclopropane-1-carbonitrile [ka] H 2 To a solution of NaOH (100 g) in O (100 mL) was added 2-(6-chloropyridin-3-yl)acetonitrile (20 g, 131.079 mmol) and dibromoethane (27 g, 142.658 mmol). This mixture was stirred at 50°C for 16 hours. The resulting mixture was extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-50% ethyl acetate in petroleum ether to give 1-(6-chloropyridin-3-yl)cyclopropane-1-carbonitrile (18 g, 77%). Obtained as a yellow solid. (C 9 H 7 ClN 2 )(M+1) + MS (ESI) calculated value of 179.0, measured value of 179.2.
[0267] Step-2: 1-(6-vinylpyridin-3-yl)cyclopropane-1-carbonitrile [ka] Dioxane (100mL) and H 2 To a solution of potassium ethenyltrifluoro-λ4-borane (11.5 g, 0.084 mmol) in O (20 mL) was added 1-(6-chloropyridin-3-yl)cyclopropane-1-carbonitrile (10 g, 55.985 mmol). ,K 2 C.O. 3 (23.2g, 0.168mmol) and Pd(dppf)Cl 2 (4.1g, 0.006mmol) was added. The resulting mixture was stirred at 80° C. for 12 hours under nitrogen. The resulting mixture was extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-50% ethyl acetate in petroleum ether to give 1-(6-ethenylpyridin-3-yl)cyclopropane-1-carbonitrile (6.84 g, 72% ) was obtained as a yellow solid. (C 11 H 10 N 2 )(M+1) + MS(ESI) calculated value of 171.0, measured value of 171.0.
[0268] Step-3: 1-(6-formylpyridin-3-yl)cyclopropane-1-carbonitrile [ka] THF (120mL) and H 2 A solution of 1-(6-ethenylpyridin-3-yl)cyclopropane-1-carbonitrile (6.84 g, 40.184 mmol) in O (40 mL) was added with OsO 4 (1.02g, 4.018mmol) and NaIO 4 (34.5g, 160.73mmol) was added. The resulting mixture was stirred at room temperature for 16 hours. The resulting mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-50% ethyl acetate in petroleum ether to give 1-(6-formylpyridin-3-yl)cyclopropane-1-carbonitrile (2.11 g, 40%). was obtained as a yellow solid. (C 10 H 8 N 2 O)(M+1) + MS (ESI) calculated value of 173.0, measured value of 173.0.
[0269] Step-4: 1-(6-(hydroxymethyl)pyridin-3-yl)cyclopropane-1-carbonitrile [ka] A solution of 1-(6-formylpyridin-3-yl)cyclopropane-1-carbonitrile (2.12 g, 12.254 mmol) in MeOH (20 mL) was added with NaBH at 0 °C. 4 (0.46g, 12.254mmol) was added. This mixture was stirred at room temperature for 1 hour. The reaction was then quenched by adding water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give 1-(6-(hydroxymethyl)pyridin-3-yl)cyclopropane-1-carbonitrile (1.11 g, 70%) was obtained as a yellow solid. (C 10 H 10 N 2 O)(M+1) + MS (ESI) calculated value of 175.1, measured value of 175.0.
[0270] Step-5: 1-(6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridin-3-yl)cyclopropane-1-carbonitrile [ka] To a solution of NaH (0.73 g, 17.502 mmol, 60%) in THF (10 mL) was added 1-(6-(hydroxymethyl)pyridin-3-yl)cyclopropane-1-carbonitrile (2.11 g, 12.112 mmol). was added little by little at 0 to 5°C, and the mixture was stirred at 5°C for 1 hour. Next, 5-bromo-1,3,4-thiadiazol-2-amine (2.62 g, 14.534 mmol) was added little by little to this mixture at 5°C, and the mixture was stirred at 5°C for 5 hours. The reaction mixture was then quenched by adding water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane to give 1-(6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl) Pyridin-3-yl)cyclopropane-1-carbonitrile (1.11 g, 33%) was obtained as a white solid. (C 12 H 11 N 5 OS)(M+1) + MS(ESI) calculated value of 274.1, actual value of 274.0.
[0271] Step-6: Methyl 1-(6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridin-3-yl)cyclopropane-1-carboxylate [ka] H 2 A solution of 1-(6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridin-3-yl in sulfuric acid (8 mL, 98%) in O (8 mL) ) Cyclopropane-1-carbonitrile (362 mg, 1.325 mmol) was added little by little at 0 to 5°C, and the mixture was stirred at 80°C for 12 hours. Next, MeOH (32 mL) was added little by little to the above mixture at room temperature, and the mixture was stirred at 80°C for 3 hours. The mixture was concentrated in vacuo. This aqueous solution was then saturated with NaHCO 3 It was neutralized with an aqueous solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give 1-(6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy) Methyl)pyridin-3-yl)cyclopropane-1-carboxylate (280 mg, 77.3%) was obtained as a pale yellow solid. (C 13 H 14 N 4 O 3 S)(M+1) + MS(ESI) calculated value for 307.1; measured value 307.0.
[0272] Step-7: 1-(6-(((5-(4-(2-methoxyphenyl)-6-methylnicotinamide)-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-3 -yl)cyclopropane-1-carboxylic acid methyl [ka] Methyl 1-(6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridin-3-yl)cyclopropane-1-carboxylate (450 mg) in DMF (20 mL). , 1.466 mmol), DIEA (379 mg, 2.938 mmol), HATU (557 mg, 1.466 mmol) and 4-(2-methoxyphenyl)-6-methylpyridine-3-carboxylic acid (238 mg, 0.979 mmol, intermediate D) was added. The resulting mixture was stirred at room temperature for 2 hours. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane using the following conditions: (Column: Sunfire prep C18 column, 30 * by prep-HPLC using 150, 5 um; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 25B to 55B in 8 min; 220 nm; RT1: 7.23 min) Further purification resulted in 1-(6-(((5-(4-(2-methoxyphenyl)-6-methylnicotinamide)-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-3 -yl)cyclopropane-1-carboxylate (340 mg, 76%) was obtained as a yellow solid. (C 27 H 25 FN 5 O 5 S)(M+1) + MS(ESI) calculated value for 532.2; measured value 532.2.
[0273] Step-8: 1-(6-(((5-(4-(2-methoxyphenyl)-6-methylnicotinamide)-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-3 -yl)cyclopropane-1-carboxylic acid [ka] MeOH (0.5mL) and H 2 1-(6-(((5-(4-(2-methoxyphenyl)-6-methylpyridin-3-amido)-1,3,4-thiadiazol-2-yl)oxy in O (0.5 mL). ) To a solution of methyl)pyridin-3-yl)cyclopropane-1-carboxylate (25 mg, 0.047 mmol) was added NaOH (5 mg, 0.094 mmol). The resulting mixture was stirred at room temperature for 8 hours. The mixture was acidified with HCl (1N) to pH ~4 and then subjected to the following conditions: (Column: Xselect CSH OBD Column 30 * prep-HPLC using 150mm 5um; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 15B to 40B in 8 min; 220 / 254 nm; RT: 6.99 min) 1-(6-(((5-(4-(2-methoxyphenyl)-6-methylpyridin-3-amido)-1,3,4-thiadiazol-2-yl)oxy)methyl) Pyridin-3-yl)cyclopropane-1-carboxylic acid (8.1 mg, 25%) was obtained as a white solid. (C 26 H 23 N 5 O 5 S)(M+1) + MS(ESI) calculated value for 518.1; measured value 518.2. 1 H NMR (400 MHz, CD 3 OD) δ 8.66 (s, 1H), 8.58 (s, 1H), 7.89 - 7.87 (m, 1H), 7.58 - 7.56 (m, 1H), 7.44 - 7.38 (m, 3H), 7.13 - 7.11 (m, 1H), 6.99 - 6.97 (m, 1H), 5.56 (s, 2H), 3.61 (s,3H), 2.65 (s, 3H), 1.68 - 1.65 (m, 2H), 1.33 - 1.25 (m, 2H) .
[0274] Example 5 N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide [ka]
[0275] Step-1: Methyl 6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)nicotinate [ka] To a solution of NaH (358.9 mg, 25.92 mmol, 60%) in THF (15.00 mL) was added methyl 6-(hydroxymethyl)nicotinate (1 g, 6.0 mmol) in portions at 0° C. under nitrogen. The resulting mixture was stirred at 0°C for 1 hour. 5-bromo-1,3,4-thiadiazol-2-amine (1.3 g, 7.2 mmol) was added dropwise to the above mixture at 0°C. The resulting mixture was stirred at 0-5°C for 5 hours. The resulting mixture was quenched with water and extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated in vacuo. The residue was purified by reverse phase flash column chromatography using 5-50% acetonitrile in water to give methyl 6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)nicotinate (320 mg , 20%) as a yellow solid. (C 10 H 10 N 4 O 3 S)(M+1) + MS(ESI) calculated value for 267.0; measured value 267.0.
[0276] Step-2: 6-(((5-(4-(2-methoxyphenyl)-6-methylpyridine-3-amido)-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-3 -methyl carboxylate [ka] DIEA ( 436.0mg, 3.373mmol) was added. The resulting mixture was stirred at room temperature for 30 minutes. To the above mixture was added methyl 6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-3-carboxylate (300.0 mg, 1.127 mmol). The mixture was stirred at 50° C. for 16 hours under nitrogen atmosphere. The resulting mixture was quenched with water. The aqueous layer was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated in vacuo. The residue was purified by reverse phase flash column chromatography using 5-50% acetonitrile in water to give 6-(((5-(4-(2-methoxyphenyl)-6-methylpyridine-3-amide)-1,3 ,4-thiadiazol-2-yl)oxy)methyl)pyridine-3-carboxylate (60 mg, 11%) was obtained as a white solid. (C 24 H 21 N 5 O 5 S)(M+1) + MS(ESI) calculated value for 492.1; measured value 492.0.
[0277] Step-3: N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6- Methylpyridine-3-carboxamide [ka] 6-(((5-(4-(2-methoxyphenyl)-6-methylpyridine-3-amido)-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine in THF (5 mL). A mixture of methyl -3-carboxylate (160.0 mg, 0.326 mmol) was 4 (12.3 mg, 0.326 mmol) was added portionwise at 0°C. The mixture was stirred at 0° C. for 1 hour under nitrogen. The resulting mixture was quenched with water. This suspension was filtered. The filtrate was collected and concentrated in vacuo. The residue was purified by reverse phase flash column chromatography using 5-50% acetonitrile in water using the following conditions: (Column: XBridge Shield RP18 OBD column, 30% * 150mm, 5um; Mobile phase A: Water (10MMOL / L NH 4 HCO 3 +0.1%NH 3 .H 2 O), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 9B to 28B in 8 min; 254 / 220 nm; RT1: 8.52 min) and further purified by prep-HPLC using N-(5-( (5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylpyridine-3-carboxamide (7.9 mg, 5%) was obtained as a white solid. (C 23 H 21 N 5 O 4 S)(M+1) + MS(ESI) calculated value for 464.1; measured value 464.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.75 (s, 1H), 8.66 (s, 1H), 8.53 (d, J = 2.4 Hz, 1H), 7.82 - 7.75 (m, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.44 - 7.32 (m, 2H), 7.30 (s, 1H), 7.12 - 7.03 (m, 1H), 6.98 (d, J = 8.4 Hz, 1H), 5.52 (s, 2H), 5.39 - 5.32 (m, 1H) ), 4.55 (d, J = 5.6 Hz, 2H), 3.51 (s, 3H), 2.56 (s, 3H).
[0278] Example 6 N-(5-((6-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylpyridine-3 -Carboxamide [ka]
[0279] Step-1: Methyl 6-((((methylsulfanyl)methanethioyl)oxy)methyl)pyridine-2-carboxylate [ka] To a solution of methyl 6-(hydroxymethyl)pyridine-2-carboxylate (500.00 mg, 2.991 mmol) in THF (5 mL) was added NaH (238.3 mg, 5.982 mmol, 60%) at 0 °C, nitrogen Stir under and then add the above mixture to the CS at 0 °C. 2 (341.62 mg, 4.487 mmol) and MeI (636.83 mg, 4.487 mmol) were added sequentially. The resulting solution was stirred at 0° C. for 1 hour under nitrogen atmosphere. The reaction mixture was quenched by adding water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography using 0-10% ethyl acetate in petroleum ether to give methyl 6-((((methylsulfanyl)methanethioyl)oxy)methyl)pyridine-2-carboxylate (290 mg, 35%). Obtained as a yellow solid. (C 10 H 11 NO. 3 S 2 )(M+1) + MS(ESI) calculated value for 258.0; measured value 258.0.
[0280] Step-2: Methyl 6-(((aminocarbamothioyl)oxy)methyl)pyridine-2-carboxylate [ka] A solution of methyl 6-((((methylsulfanyl)methanethioyl)oxy)methyl)pyridine-2-carboxylate (290.00 mg, 1.127 mmol) in MeOH (5 mL) was added with NH 2 N.H. 2 ·H 2 O (62.06 mg, 1.240 mmol) was added at 0°C. The resulting solution was stirred at 0° C. for 0.5 h under nitrogen. The resulting mixture was quenched with water and extracted with ethyl acetate. Combined organic layers with H 2 Wash with O, anhydrous Na 2 S.O. 4 dried with. After filtration, the filtrate was concentrated in vacuo to give methyl 6-(((aminocarbamothioyl)oxy)methyl)pyridine-2-carboxylate (254 mg, crude product) as a yellow solid. (C 9 H 11 N 3 O 3 S)(M+1) + MS(ESI) calculated value for 242.0; measured value 242.0.
[0281] Step-3: Methyl 6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-2-carboxylate [ka] A solution of methyl 6-(((aminocarbamothioyl)oxy)methyl)pyridine-2-carboxylate (254.00 mg, 1.053 mmol) in MeOH (10 mL) was added with BrCN (122.66 mg, 1.158 mmol) and Et 3 N (213.06 mg, 2.108 mmol) was added at 0°C. The resulting mixture was stirred for 30 minutes at 0°C. The resulting mixture was quenched with water and extracted with ethyl acetate. Combined organic layers with H 2 Wash with O, anhydrous Na 2 S.O. 4 dried with. After filtration, the filtrate was concentrated in vacuo to give methyl 6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-2-carboxylate (248 mg, 82%) as a light brown Obtained as a solid. (C 10 H 10 N 4 O 3 S)(M+1) + MS(ESI) calculated value for 267.0; measured value 267.0.
[0282] Step-4: 6-(((5-(4-(2-methoxyphenyl)-6-methylpyridine-3-amido)-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-2 -methyl carboxylate [ka] A solution of 4-(2-methoxyphenyl)-6-methylpyridine-3-carboxylic acid (139.77 mg, 0.575 mmol, intermediate D) in DMF (2 mL), HATU (327.71 mg, 0.862 mmol), DIEA ( 222.78 mg, 1.724 mmol) and methyl 6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-2-carboxylate (153.00 mg, 0.575 mmol) were added. The resulting mixture was stirred at 50° C. for 2 hours under nitrogen atmosphere. The residue was purified by reverse phase flash column chromatography using 5-40% acetonitrile in water to give 6-(((5-(4-(2-methoxyphenyl)-6-methylpyridine-3-amide)-1,3 ,4-thiadiazol-2-yl)oxy)methyl)pyridine-2-carboxylate (155 mg, 38%) was obtained as a yellow oil. (C 24 H 21 N 5 O 5 S)(M+1) + MS(ESI) calculated value for 492.1; measured value 492.1.
[0283] Step-5: N-(5-((6-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6- Methylpyridine-3-carboxamide [ka] 6-(((5-(4-(2-methoxyphenyl)-6-methylpyridin-3-amido)-1,3,4-thiadiazol-2-yl)oxy)methyl) in THF (8.00 mL). A solution of pyridine-2-carboxylic acid (189.00 mg, 0.396 mmol) was 4 (30.05 mg, 0.792 mmol) was added in small portions at 0°C under nitrogen atmosphere. The resulting mixture was stirred for 0.5 h at 0° C. under nitrogen atmosphere. The resulting mixture was quenched by adding water and extracted with ethyl acetate. The combined organic layers were washed with brine and anhydrous Na 2 S.O. 4 dried with. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash column chromatography using 5-40% acetonitrile in water to give methyl N-(5-((6-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4- Thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylpyridine-3-carboxamide (27.1 mg, 14%) was obtained as a white solid. (C 23 H 21 N 5 O 4 S)(M+1) + MS(ESI) calculated value for 464.1; measured value 464.1. 1 H NMR (400 MHz, DMSO-d6) δ 12.76 (s, 1H), 8.67 (s, 1H), 7.86 (t, J = 7.6 Hz, 1H), 7.47 (d, J = 7.6 Hz, 1H), 7.44 - 7.32 (m, 3H), 7.30 (s, 1H), 7.12 - 7.03 (m, 1H), 6.98 (d, J = 8.4 Hz, 1H), 5.52 - 5.43 (m, 3H), 4.57 (d, J = 6.0 Hz, 2H), 3.51 (s, 3H), 2.57 (s, 3H).
[0284] Example 7 N-(5-((5-(1-(hydroxymethyl)cyclopropyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)- 6-methylnicotinamide [ka]
[0285] Step-1: Methyl 1-(6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridin-3-yl)cyclopropane-1-carboxylate [ka] H 2 A solution of 1-(6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridin-3-yl in sulfuric acid (8 mL, 98%) in O (8 mL) ) Cyclopropane-1-carbonitrile (362 mg, 1.325 mmol) was added little by little at 0 to 5°C, and the mixture was stirred at 80°C for 12 hours. Next, MeOH (32 mL) was added little by little to the above mixture at room temperature, and the mixture was stirred at 80°C for 3 hours. The mixture was concentrated in vacuo. This aqueous solution was then saturated with NaHCO 3 It was neutralized with an aqueous solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give 1-(6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy) Methyl)pyridin-3-yl)cyclopropane-1-carboxylate (280 mg, 77.3%) was obtained as a pale yellow solid. (C 13 H 14 N 4 O 3 S)(M+1) + MS(ESI) calculated value for 307.1; measured value 307.0.
[0286] Step-2: 1-(6-(((5-(4-(2-methoxyphenyl)-6-methylnicotinamide)-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-3 -yl)cyclopropane-1-carboxylic acid methyl [ka] Methyl 1-(6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridin-3-yl)cyclopropane-1-carboxylate (450 mg) in DMF (20 mL). , 1.466 mmol), DIEA (379 mg, 2.938 mmol), HATU (557 mg, 1.466 mmol) and 4-(2-methoxyphenyl)-6-methylpyridine-3-carboxylic acid (238 mg, 0.979 mmol, intermediate D)) was added. The resulting mixture was stirred at room temperature for 2 hours. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane using the following conditions: (Column: Sunfire prep C18 column, 30 * by prep-HPLC using 150, 5 um; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 25B to 55B in 8 min; 220 nm; RT1: 7.23 min) Further purification resulted in 1-(6-(((5-(4-(2-methoxyphenyl)-6-methylnicotinamide)-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-3 -yl)cyclopropane-1-carboxylate (340 mg, 76%) was obtained as a yellow solid. (C 27 H 25 FN 5 O 5 S)(M+1) + MS(ESI) calculated value for 532.2; measured value 532.2.
[0287] Step-3: N-(5-((5-(1-(hydroxymethyl)cyclopropyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2- Methoxyphenyl)-6-methylnicotinamide [ka] 1-(6-(((5-(4-(2-methoxyphenyl)-6-methylpyridin-3-amido)-1,3,4-thiadiazol-2-yl)oxy) in THF (5 mL). Add LiAlH in small portions to a solution of methyl)pyridin-3-yl)cyclopropane-1-carboxylate (140 mg, 0.263 mmol) at 0-5°C. 4(10 mg, 0.263 mmol) was added and then stirred at room temperature for 1 hour. The reaction mixture was then quenched by adding water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane to give N-(5-((5-(1-(hydroxymethyl)cyclopropyl)pyridin-2-yl)methoxy)- 1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide (25.2 mg, 18%) was obtained as a white solid. (C 26 H 25 N 5 O 4 S)(M+1) + MS(ESI) calculated value for 504.2; measured value 504.2. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.74 (s, 1H), 8.66 (s, 1H), 8.54 (s, 1H), 7.74 - 7.73 (m, 1H), 7.46 - 7.44 (m, 1H), 7.40 (s, 1H), 7.35 - 7.34 (m, 1H), 7.30 - 7.28 (m, 1H), 7.08 - 7.05 (m, 1H), 7.02 - 6.95 (m, 1H), 5.49 (s, 2H), 4.80 (s,1H), 3.52 - 3.51 (m, 5H), 2.33 (s, 3H), 0.91 - 0.85 (m, 2H), 0.85 - 0.78 (m, 2H).
[0288] Example 8 2'-Chloro-N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5'-methoxy-6-methyl-[4,4 '-Bipyridine]-3-carboxamide [ka]
[0289] Step-1: Methyl 2’-chloro-5’-methoxy-6-methyl-(4,4’-bipyridine)-3-carboxylate [ka] A solution of 4-chloro-6-methylnicotinic acid (244 mg, 1.31 mmol) in dioxane (5 mL) and water (1 mL) was added with (2-chloro-5-methoxypyridin-4-yl)boronic acid (320 mg, 1.70 mg). mmol), K 2 C.O. 3 (363mg, 2.62mmol) and PdCl 2 (DTBPF) (171 mg, 0.26 mmol) was added. The mixture was stirred at 90° C. for 2 hours under nitrogen atmosphere. The resulting mixture was diluted with water. The aqueous layer was extracted with EtOAc. The combined organic phases were washed with brine, dried over sodium sulfate and filtered. The filtrate was concentrated in vacuo. The residue was purified by reverse phase flash chromatography using 5-45% ACN in water to give methyl 2'-chloro-5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carboxylate (94 mg, 18%) was obtained as a yellow solid. (C 14 H 13 ClN 2 O 3 )(M+1) + MS (ESI) calculated value of 293.0, measured value of 292.9.
[0290] Step-2: 2’-chloro-5’-methoxy-6-methyl-(4,4’-bipyridine)-3-carboxylic acid [ka] Methyl 2'-chloro-5'-methoxy-6-methyl-[4,4'-bipyridine]-3-carboxylate (50.0 mg, 0.17 mmol) and LiOH ( A solution of 5.3 mg, 0.22 mmol) was stirred at room temperature for 16 hours. The aqueous solution was acidified to pH 5-6 with citric acid. The aqueous layer was extracted with EtOAc. The combined organic solution was dried over sodium sulfate, filtered, and concentrated in vacuo to give 2'-chloro-5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carboxylic acid (40.0 mg, crude The product) was obtained as a yellow solid. (C 13 H 11 ClN 2 O 3 )(M+1) + MS (ESI) calculated value of 279.0, actual value of 279.0.
[0291] Step-3: 2'-chloro-N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5'-methoxy-6-methyl- [4,4'-bipyridine]-3-carboxamide [ka] In DMF (1 mL), 2'-chloro-5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carboxylic acid (25.0 mg, 0.09 mmol), 5-((5-chloropyridine- 2-yl)methoxy)-1,3,4-thiadiazol-2-amine (23.9 mg, 0.09 mmol), HOBt (15.7 mg, 0.11 mmol), EDCI (22.3 mg, 0.11 mmol) and DIEA (23.1 mg, 0.17 mmol) solution was stirred at room temperature for 16 hours. This solution was purified by reverse phase flash chromatography using 5-62% ACN in water to obtain the crude product (19.0 mg). The crude product (19.0 mg) was purified under the following conditions: (Column: X Bridge Prep OBD C18 column, 30 x 150 mm 5 um; Mobile phase A: Water (10 MMOL / L NH 4 HCO 3 +0.1%NH 3 .H 2 Further purification by Prep-HPLC using mobile phase B: ACN; flow rate: 60 mL / min; gradient: 20% B to 45% B in 8 min; 220 nm; RT 1: 7.23 min) and 2'-chloro -N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5'-methoxy-6-methyl-[4,4'-bipyridine] -3-carboxamide (6.3 mg, 13%) was obtained as a white solid. (C 21 H 16 C l2 N 6 O 3 S)(M+1) + MS (ESI) calculated value of 503.0, measured value of 502.9. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.95 (s, 1H), 8.81 (s, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.17 (s, 1H), 8.05 - 7.97 (m, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.55 (s, 1H), 7.44 (s, 1H), 5.55 (s, 2H), 3.63 (s, 3H), 2.59 (s, 3H).
[0292] Example 9 N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-2-(2-methoxyphenyl)-1,5-naphthyridine-3-carboxamide [ka]
[0293] Step-1: Methyl 3-(3-ethoxy-3-oxopropanamido)picolinate [ka] To a stirred solution of methyl 3-aminopicolinate (5000.0 mg, 32.86 mmol) in dichloromethane (40.0 mL) was added ethyl 3-chloro-3-oxopropanoate (4947.6 mg, 32.86 mmol) at room temperature. The resulting mixture was heated at 80 °C for 2 h with N 2 Stir at the bottom. The resulting mixture was saturated with NaHCO 3 Quenched with aqueous solution and extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give methyl 3-(3-ethoxy-3-oxopropanamido)picolinate (7750 mg, crude product) as a yellow solid. (C 12 H 14 N 2 O 5 )(M+1) + MS(ESI) calculated value of 267.1, actual value of 267.0.
[0294] Step-2: Ethyl 4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate [ka] To a stirred solution of methyl 3-(3-ethoxy-3-oxopropanamido)picolinate (7750.0 mg, 29.10 mmol) in EtOH (50.0 mL) was added EtONa (2376.9 mg, 34.92 mmol). The resulting mixture was heated at 50 °C for 1 h in N 2 Stir at the bottom. The resulting mixture was concentrated in vacuo and washed with ethyl acetate to give ethyl 4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate (6500 mg crude product) as a yellow solid. Obtained. (C11 H 10 N 2 O 4 )(M+1) + MS(ESI) calculated value of 235.1, actual value of 235.0.
[0295] Step-3: Ethyl 2,4-dichloro-1,5-naphthyridine-3-carboxylate [ka] POCl 3 (250 mL) was added portionwise at room temperature. The resulting mixture was heated at 30 °C for 48 h in N 2 Stir at the bottom. The mixture was allowed to cool to room temperature and concentrated in vacuo. Pour the residue into ice water and add saturated Na 2 C.O. 3 (aqueous solution) to pH 10. The resulting mixture was extracted with ethyl acetate. The combined organic layers were washed with brine and anhydrous Na 2 S.O. 4 dried with. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography using 0-27% ethyl acetate in petroleum ether to give ethyl 2,4-dichloro-1,5-naphthyridine-3-carboxylate (1120 mg, 20%) as a dark yellow solid. . (C 11 H 8 Cl 2 N 2 O 2 )(M+1) + MS(ESI) calculated value of 271.0, actual value of 270.0.
[0296] Step-4: Ethyl 4-chloro-2-(2-methoxyphenyl)-1,5-naphthyridine-3-carboxylate [ka] 1,4-dioxane (5mL) and H 2 To a stirred mixture of ethyl 2,4-dichloro-1,5-naphthyridine-3-carboxylate (135.0 mg, 0.49 mmol) in O (1 mL) was added (2-methoxyphenyl)boronic acid (75.6 mg, 0.49 mmol). ,K 2 C.O. 3 (206.4mg, 1.49mmol) and Pd(dppf)Cl 2 (36.4 mg, 0.05 mmol) was added. The resulting mixture was heated at 80 °C for 2 h with N 2 Stir at the bottom. The resulting mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine and anhydrous Na 2 S.O. 4 dried with. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography using 0-32% ethyl acetate in petroleum ether to give ethyl 4-chloro-2-(2-methoxyphenyl)-1,5-naphthyridine-3-carboxylate and 2-chloro-4 A mixture of ethyl -(2-methoxyphenyl)-1,5-naphthyridine-3-carboxylate (510 mg, 66%) was obtained as an off-white solid. (C 17 H 17 ClN 2 O 3 )(M+1) + MS(ESI) calculated value of 333.1, measured value of 333.0.
[0297] Step-5: Ethyl 2-(2-methoxyphenyl)-1,5-naphthyridine-3-carboxylate [ka] Ethyl 4-chloro-2-(2-methoxyphenyl)-1,5-naphthyridine-3-carboxylate and 2-chloro-4-(2-methoxyphenyl)-1,5-naphthyridine in DMF (3.0 mL). A stirred solution of a mixture of ethyl -3-carboxylate (240.0 mg, 0.70 mmol) was added with TEA (212.5 mg, 2.10 mmol), CHOOH (161.0 mg, 3.50 mmol) and Pd(dppf)Cl 2 (51.2 mg, 0.07 mmol) (dppf) was added. The resulting mixture was heated at 60 °C for 3 h with N 2 Stir at the bottom. The resulting mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine and anhydrous Na 2 S.O. 4 dried with. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography using 0-37% ethyl acetate in petroleum ether to give ethyl 2-(2-methoxyphenyl)-1,5-naphthyridine-3-carboxylate and 4-(2-methoxyphenyl). A mixture of ethyl-1,5-naphthyridine-3-carboxylate (210 mg, 97%) was obtained as a yellow oil. (C 18 H 16 N 2 O 3 )(M+1) + MS (ESI) calculated value of 309.1, measured value of 309.0.
[0298] Step-6: 2-(2-methoxyphenyl)-1,5-naphthyridine-3-carboxylic acid [ka] EtOH (4 mL) and H 2 A mixture of ethyl 2-(2-methoxyphenyl)-1,5-naphthyridine-3-carboxylate and ethyl 4-(2-methoxyphenyl)-1,5-naphthyridine-3-carboxylate in O (4.0 mL). To a stirred solution of (230.0 mg, 0.74 mmol) was added NaOH (149.1 mg, 3.73 mmol). The resulting mixture was stirred at room temperature for 1.5 hours. The residue was acidified to pH 7 with HCl (1N). The resulting mixture was extracted with ethyl acetate and anhydrous Na 2 S.O. 4 dried with. After filtration, the filtrate was concentrated under reduced pressure to obtain 2-(2-methoxyphenyl)-1,5-naphthyridine-3-carboxylic acid and 4-(2-methoxyphenyl)-1,5-naphthyridine-3-carboxylic acid. and ethyl 4-(2-methoxyphenyl)-1,5-naphthyridine-3-carboxylate (100 mg, 48%) was obtained as an off-white solid. (C 16 H 12 N 2 O 3 )(M+1) + MS(ESI) calculated value of 281.1, actual value of 281.0.
[0299] Step-7: N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-2-(2-methoxyphenyl)-1,5-naphthyridine -3-carboxamide [ka] In acetonitrile (3.0 mL), 2-(2-methoxyphenyl)-1,5-naphthyridine-3-carboxylic acid and 4-(2-methoxyphenyl)-1,5-naphthyridine-3-carboxylic acid and 4-( To a stirred solution of a mixture of ethyl 2-methoxyphenyl)-1,5-naphthyridine-3-carboxylate (80.0 mg, 0.28 mmol) was added TCFH (88.0 mg, 0.31 mmol), 5-((5-chloropyridine-2 -yl)methoxy)-1,3,4-thiadiazol-2-amine (83.1 mg, 0.34 mmol, Intermediate C) and NMI (49.2 mg, 0.59 mmol) were added. The resulting mixture was stirred at room temperature for 1.5 hours. The resulting mixture was concentrated in vacuo. The crude product was purified under the following conditions: (Column: XBridge Prep OBD C18 column, 30×150mm 5um; Mobile phase A: Water (10MMOL / L NH 4 HCO 3 +0.1%NH 3 .H 2 O), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 20B to 45B in 7 min; 220 nm; 5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-2-(2-methoxyphenyl)-1,5-naphthyridine-3-carboxamide (8.0 mg) was obtained. . (C 24 H 17 ClN 6 O 3 S)(M+1) + MS (ESI) calculated value of 505.1, measured value of 505.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 13.09 (s, 1H), 9.11 - 9.10 (m, 1H), 8.70 - 8.66 (m, 2H), 8.51 (d, J = 8.0 Hz, 1H), 8.03 - 8.01 (m, 1H), 7.92 - 7.89 (m, 1H), 7.67 - 7.62 (m, 2H), 7.48 - 7.43 (m, 1H), 7.15 - 7.11 (m, 1H), 7.01 (d, J = 8.4 Hz, 1H), 5.57 (s, 2H), 3.53 (s, 3H).
[0300] Example 10 N-(5-((1H-pyrazolo(4,3-c)pyridin-4-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6- methylnicotinamide [ka]
[0301] Step-1: 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo(4,3-c)pyridine [ka] To a solution of NaH (392 mg, 9.802 mmol, 60%) in THF (10 mL) at 0 °C was added 4-chloro-1H-pyrazolo(4,3-c)pyridine (1 g, 6.535 mmol) and at 5 °C. It was stirred for 0.5 hours, and then SEM-Cl (1.3 g, 7.842 mmol) was added dropwise to this mixture at 5°C, and the mixture was stirred at 5°C for 5 hours. The reaction mixture was then quenched by adding water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane to give 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo(4,3-c) Pyridine (900 mg, 50%) was obtained as a white solid. (C 12 H 18 ClN 3 OSi)(M+1) + MS(ESI) calculated value for 284.1; measured value 284.1.
[0302] Step-2: Methyl 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo(4,3-c)pyridine-4-carboxylate [ka] A degassed solution of 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)pyrazolo(4,3-c)pyridine (1 g, 3.523 mmol) in MeOH (10 mL) was added with TEA (2 mL) and Pd. (PPh 3 ) 2 Cl 2 (0.25g, 0.352mmol) was added. The resulting solution was stirred at 80° C. for 24 hours under CO (10 atm). The resulting mixture was concentrated. The residue was purified by flash chromatography on silica gel using 0-50% ethyl acetate in petroleum ether to give 1-((2-(trimethylsilyl)ethoxy)methyl)pyrazolo(4,3-c)pyridine-4-carvone. Methyl acid (1 g, 83.1%) was obtained as a yellow oil. (C 14 H 21 N 3 O 3 Si)(M+1) + MS(ESI) calculated value for 308.1; measured value 308.1.
[0303] Step-3: (1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo(4,3-c)pyridin-4-yl)methanol [ka] LiAlH 4 (248 mg, 6.514 mmol) was added portionwise at 0°C. The resulting solution was stirred at 0°C for 1 hour. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated in vacuo and purified with (1-((2-(trimethylsilyl)ethoxy)ethoxy)methyl)-1H-pyrazolo(4,3-c)pyridine. -4-yl)methanol (800 mg, 80%) was obtained as a yellow solid. (C 13 H 21 N 3 O 2 Si)(M+1) + MS(ESI) calculated value for 280.1; measured value 280.1.
[0304] Step-4: 5-((1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo(4,3-c)pyridin-4-yl)methoxy)-1,3,4-thiadiazole-2 -amine [ka] A solution of NaH (108 mg, 2.684 mmol, 60%) in THF (8 mL) was added with (1-((2-(trimethylsilyl)ethoxy)methyl)pyrazolo(4,3-c)pyridin-4-yl)methanol ( 500 mg, 1.789 mmol) was added at 0°C and stirred for 1 hour at 0-5°C, and then 5-bromo-1,3,4-thiadiazol-2-amine (387 mg, 2.147 mmol) was added to this mixture at 5°C. The mixture was added little by little and stirred at 5°C for 5 hours. The reaction mixture was then quenched by adding water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane to give 5-((1-((2-(trimethylsilyl)ethoxy)methyl)pyrazolo(4,3-c)pyridine-4 -yl)methoxy)-1,3,4-thiadiazol-2-amine (200 mg, 29.5%) was obtained as a yellow solid. (C 13 H 21 N 3 O 2 Si)(M+1) + MS(ESI) calculated value for 379.1; measured value 379.1.
[0305] Step-5: 4-(2-methoxyphenyl)-6-methyl-N-(5-((1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo(4,3-c)pyridine- 4-yl)methoxy)-1,3,4-thiadiazol-2-yl)nicotinamide [ka] 5-((1-((2-(trimethylsilyl)ethoxy)methyl)pyrazolo(4,3-c)pyridin-4-yl)methoxy)-1,3,4-thiadiazole-2- in DMF (10 mL). A solution of amine (180 mg, 0.476 mmol) contains HATU (361 mg, 0.951 mmol), DIEA (185 mg, 1.427 mmol) and 4-(2-methoxyphenyl)-6-methylpyridine-3-carboxylic acid (174 mg, 0.713 mmol). , intermediate D) was added. The resulting solution was stirred at room temperature for 2 hours. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane to give 4-(2-methoxyphenyl)-6-methyl-N-(5-((1-((2-(trimethylsilyl) )ethoxy)methyl)-1H-pyrazolo(4,3-c)pyridin-4-yl)methoxy)-1,3,4-thiadiazol-2-yl)nicotinamide (150 mg, 25%) was obtained as a yellow solid. Ta. (C 15 H 22 N 6 O 2 SSi)(M+1) + MS(ESI) calculated value for 604.2; measured value 604.2.
[0306] Step-6: N-(5-((1H-pyrazolo(4,3-c)pyridin-4-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl )-6-Methylnicotinamide [ka] 4-(2-methoxyphenyl)-6-methyl-N-(5-((1-((2-(trimethylsilyl)ethoxy)methyl)pyrazolo(4,3-c)pyridine-4 in THF (3 mL)) -yl)methoxy)-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide (100 mg, 0.166 mmol) was added TBAF (260 mg, 0.994 mmol) and CsF (252 mg, 1.656 mmol). Ta. The resulting solution was stirred at 60°C for 12 hours and then concentrated in vacuo. The residue was purified by flash column chromatography using 0-10% methanol in dichloromethane using the following conditions: (Column: XBridge Prep OBD C18 column, 30 x 150 mm 5 um; Mobile phase A: water (10 MMOL / L NH 4 HCO 3 +0.1%NH 3 .H 2 4-(2-methoxyphenyl)-6- Methyl-N-(5-(1H-pyrazolo(4,3-c)pyridin-4-ylmethoxy)-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide (4 mg, 10.7%) in white Obtained as a solid. (C 23 H 19 N 7 O 3 S)(M+1) + MS(ESI) calculated value for 474.1; measured value 474.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 13.80 (s, 1H), 12.87 (s, 1H), 8.66 (s, 1H), 8.47 (s, 1H), 8.39 (s, 1H), 7.55 (s, 1H), 7.41 - 7.33 (m, 2H), 7.11 - 7.05 (m, 3H), 5.85 (s, 2H), 3.50 (s, 3H), 2.51 (s, 3H).
[0307] Examples 11 and 12 (S)-N-(5-(1-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methyl Nicotinamide (Example 11) and (R)-N-(5-(1-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2 -methoxyphenyl)-6-methylnicotinamide (Example 12) [ka]
[0308] Step-1: 1-(5-chloropyridin-2-yl)ethane-1-ol [ka] A solution of 1-(5-chloropyridin-2-yl)ethanone (3.0 g, 9.3 mmol) in MeOH (30 mL) was added with NaBH 4 (763 mg, 20.2 mmol) was added portionwise at 0°C. This mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched by adding water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 1-(5-chloropyridin-2-yl)ethane-1-ol (2.5 g, 82.2%) to a yellow Obtained as an oil. (C 7 H 8 ClNO)(M+1) + MS (ESI) calculated value of 158.0, actual value of 158.0.
[0309] Step-2: 5-(2-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-amine [ka] A solution of NaH (77 mg, 1.9 mmol, 60%) in THF (5 mL) was added with 1-(5-chloropyridin-2-yl)ethane-1-ol (200 mg, 1.2 mmol) in THF (1 mL). The solution was added at 0°C and stirred at 0°C for 30 minutes under nitrogen. To the above solution was added 5-bromo-1,3,4-thiadiazol-2-amine (455 mg, 2.5 mmol) at 0° C. under nitrogen. This mixture was stirred at room temperature for 4 hours. The reaction mixture was quenched by adding water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-50% ethyl acetate in petroleum ether to give 5-(1-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazole- The 2-amine (60 mg, 18.4%) was obtained as a yellow solid. (C 9 H 9 ClN 4 OS)(M+1) + MS (ESI) calculated value of 257.0, actual value of 257.0.
[0310] Step-3 and Step-4: (S)-N-(5-(1-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2 -methoxyphenyl)-6-methylnicotinamide and (R)-N-(5-(1-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-yl)-4 -(2-methoxyphenyl)-6-methylnicotinamide [ka] A solution of 5-(1-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-amine (52 mg, 0.2 mmol) in DMF (2 mL) was added with DIEA (78 mg, 0.6 mmol), HATU (116 mg, 0.3 mmol) and 4-(2-methoxyphenyl)-6-methylnicotinic acid (50 mg, 0.2 mmol, Intermediate D) were added. This mixture was stirred at room temperature for 16 hours. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane to give the racemic product, which was purified using the following conditions: (Column: Chiral PAK ID, 2 * 25cm, 5um; Mobile phase A: Hex(0.2%DEA) -- HPLC, Mobile phase B: EtOH:DCM=1:1 -- HPLC; Flow rate: 20 mL / min; Gradient: 45B to 45B in 13 minutes; 220 (S)-N-(5-(1-(5-chloropyridin-2-yl)ethoxy) as a white solid with short retention time on chiral-HPLC) -1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide (7.8 mg, 8%) and (as a white solid with a long retention time on chiral-HPLC) R)-N-(5-(1-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotine The amide (5.7 mg, 7%) was obtained.
[0311] (S)-N-(5-(1-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methyl Nicotinamide:(C 23 H 20 ClN 5 O 3 S)(M+1) + MS(ESI) calculated value for 482.1; measured value 482.2. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.71 (s, 1H), 8.64 (s, 2H), 7.98 - 7.96 (m, 1H), 7.58 - 7.55 (m, 1H), 7.41 - 6.96 (m, 5H), 6.04 - 5.99 (m, 1H) ), 3.49 ( s, 3H), 2.52 (s, 3H), 1.66 (d, J = 6.4 Hz, 3H).
[0312] (R)-N-(5-(1-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methyl Nicotinamide:(C 23 H 20 ClN 5 O 3 S)(M+1) + MS(ESI) calculated value for 482.1; measured value 482.2. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.71 (s, 1H), 8.64 (s, 2H), 7.98 - 7.96 (m, 1H), 7.58 - 7.55 (m, 1H), 7.41 - 7.30 (m, 3 H), 7.09 - 6.96 (m, 2H), 6.04 - 5.99 (m, 1H), 3.49 (s, 3H), 2.52 (s, 3H), 1.66 (d, J = 6.4 Hz, 3H).
[0313] Example 13 N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(5-fluoro-2-methoxyphenyl)-6-methylnicotinamide [ka]
[0314] Step-1: 4-chloro-N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methylnicotinamide [ka] To a mixture of 4-chloro-6-methylnicotinic acid (5.0 g, 29.23 mmol) in DCM (50 mL) was added oxalyl chloride (4.42 g, 35.08 mmol) and DMF (1 mL). This mixture was stirred at room temperature for 2 hours. The solvent was removed under reduced pressure to obtain 4-chloro-6-methylnicotinoyl chloride.
[0315] In DCM (100 mL), 5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-amine (5.11 g, 21.050 mmol, Intermediate C) and DIEA (8.16 g, 63.151 mmol) was added dropwise at 0° C. with the above solution of 4-chloro-6-methylnicotinoyl chloride in DCM (50 mL). The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography using 0-10% methanol in dichloromethane to give 4-chloro-N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazole- 2-yl)-6-methylpyridine-3-carboxamide (1.8 g, 21.58%) was obtained as a yellow solid. (C 15 H 11 Cl 2 N 5 O 2 S)(M+1) + MS (ESI) calculated value for 396.0; measured value 396.0.
[0316] Step-2: N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(5-fluoro-2-methoxyphenyl)-6 -Methylnicotinamide [ka] Dioxane (7mL) and H 2 4-chloro-N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methylnicotinamide (156 mg) in O (1.4 mL) , 0.394 mmol) in a degassed solution of (5-fluoro-2-methoxyphenyl)boronic acid (201 mg, 1.182 mmol), K 3 P.O. 4 (418mg, 1.972mmol) and Pd(dtbpf)Cl 2 (30 mg, 0.046 mmol) was added. The resulting solution was stirred at 100°C for 8 hours. This aqueous solution was concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane using the following conditions: (Column: Sunfire prep C18 column, 30 * by prep-HPLC using 150, 5 um; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 40 mL / min; gradient: 25B to 55B in 8 min; 220 nm; RT1: 7.23 min) Further purification resulted in N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(5-fluoro-2-methoxyphenyl)-6 -Methylnicotinamide (13 mg, 8.3%) was obtained as a white solid. (C 22 H 17 ClFN 5 O 3 S)(M+1) + MS(ESI) calculated value for 486.1; measured value 486.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.70 (s, 1H), 8.70 - 8.65 (m, 2H), 8.01 - 7.99 (m, 1H), 7.62 - 7.60 (m, 1H), 7.34 - 7.20 (m, 3H), 7.00 - 6.97 (m , 1H), 5.54 (s, 2H), 3.53 (s, 3H), 2.57 (s, 3H).
[0317] Example 14 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6- Methylpyridine-3-carboxamide [ka]
[0318] Step-1: 6-(((5-(4-(2-fluoro-6-methoxyphenyl)-6-methylpyridin-3-amido)-1,3,4-thiadiazol-2-yl)oxy)methyl ) Methyl pyridine-3-carboxylate [ka] Methyl 6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-3-carboxylate (150 mg, 0.563 mmol, Example 5, Step 1) in MeCN (4 mL). ) and 4-(2-fluoro-6-methoxyphenyl)-6-methylpyridine-3-carboxylic acid (191 mg, 0.732 mmol, Intermediate F), NMI (162 mg, 1.972 mmol) and TCFH (205 mg, 0.732 mmol) was added. The resulting mixture was stirred at room temperature for 1 hour under nitrogen atmosphere. The resulting mixture was diluted with water. The precipitated solid was collected by filtration, washed with CAN, and 6-(((5-(4-(2-fluoro-6-methoxyphenyl)-6-methylpyridine-3-amide)-1,3,4- Thiadiazol-2-yl)oxy)methyl)pyridine-3-carboxylate (220 mg, 76.6%) was obtained as a white solid. (C 24 H 20 FN 5 O 5 S)(M+1) + MS(ESI) calculated value for 509.5; measured value 509.5.
[0319] Step-2: 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl )-6-methylpyridine-3-carboxamide [ka] 6-(((5-(4-(2-fluoro-6-methoxyphenyl)-6-methylpyridin-3-amido)-1,3,4-thiadiazol-2-yl)oxy in THF (3 mL). ) methyl)pyridine-3-carboxylate (150 mg, 0.294 mmol) was added with LiAlH 4 (22 mg, 0.588 mmol) was added little by little at 0°C under nitrogen atmosphere. The resulting mixture was stirred for 1 hour at 0° C. under nitrogen atmosphere. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Remove the residue under the following conditions: (Column: XBridge Shield RP18 OBD column, 30 * 150mm, 5um; Mobile phase A: Water (10mmol / L NH 4 HCO 3 +0.1%NH 3 .H 2 O), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 17B to 30B in 8 min; -N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methylpyridine-3-carboxamide (52.8 mg, 37.2% ) was obtained as a yellow solid. (C 23 H 20 FN 5 O 4 S)(M+1) + MS(ESI) calculated value for 482.0; measured value 482.0. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.89 (s, 1H), 8.81 (s, 1H), 8.53 (d, J = 2.0 Hz, 1H), 7.82 - 7.75 (m, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.46 - 7.36 (m, 1H), 7.33 (d, J = 1.6 Hz, 1H), 6.97 - 6.86 (m, 2H), 5.52 (s, 2H), 5.39 - 5.32 (m, 1H), 4.55 (d, J = 5.6 Hz, 2H), 3.59 (s, 3H), 2.57 (s, 3H).
[0320] Example 15 4-(2-fluoro-6-methoxyphenyl)-6-methyl-N-(5-((1-methylpyrazol-3-yl)methoxy)-1,3,4-thiadiazol-2-yl)pyridine- 3-carboxamide [ka]
[0321] Step-1: 5-((1-methylpyrazol-3-yl)methoxy)-1,3,4-thiadiazol-2-amine [ka] To a stirred solution of NaH (214 mg, 8.92 mmol) in THF (6 mL) was added dropwise a solution of (1-methylpyrazol-3-yl)methanol (500 mg, 4.46 mmol) in THF (2 mL) at 0 °C; Stirred at 0°C for 40 minutes under nitrogen atmosphere. 5-Bromo-1,3,4-thiadiazol-2-amine (959 mg, 5.33 mmol) was added portionwise to the above mixture at 0°C. The resulting mixture was stirred at 0° C. for 4 hours under nitrogen atmosphere. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by reverse phase flash column chromatography using 5-80% ACN in water and purified with 5-((1-methylpyrazol-3-yl)methoxy)-1,3,4-thiadiazol-2-amine (280 mg, 29.73%) was obtained as a white solid. (C 7 H 9 N 5 OS)(M+1) + MS (ESI) calculated value of 212.1, measured value of 211.9.
[0322] Step-2: 4-(2-fluoro-6-methoxyphenyl)-6-methyl-N-(5-((1-methylpyrazol-3-yl)methoxy)-1,3,4-thiadiazole-2- yl)pyridine-3-carboxamide [ka] In MeCN (4.00 mL), 5-((1-methylpyrazol-3-yl)methoxy)-1,3,4-thiadiazol-2-amine (250 mg, 1.18 mmol) and 4-(2-fluoro-6- To a stirred solution of methoxyphenyl)-6-methylpyridine-3-carboxylic acid (206 mg, 0.79 mmol, Intermediate F) were added NMI (259 mg, 3.15 mmol) and TCFH (288 mg, 1.03 mmol). The residue was purified by reverse-phase flash column chromatography using 5-80% ACN in water using the following conditions: (Column: XBridge Prep OBD C18 column, 30 × 150 mm 5um; Mobile phase A: water (10MMOL / L NH 4 HCO 3 +0.1%NH 3 .H 2 Further purification by Prep-HPLC using mobile phase B: ACN; flow rate: 60 mL / min; gradient: 10B to 45B in 7 min; 220 nm; RT 1: 6.6 min) and 4-(2-fluoro-6 -methoxyphenyl)-6-methyl-N-(5-((1-methylpyrazol-3-yl)methoxy)-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide (30 mg, 8.3% ) was obtained as a white solid. (C 21 H 19 FN 6 O 3 S)(M-1) - MS(ESI) calculated value of 453.1, measured value of 453.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.88 (s, 1H), 7.68 (d, J = 2.0 Hz, 1H), 7.42 - 7.32 (m, 1H), 7.23 (s, 1H), 6.90 - 6.85 (m, 2H), 6.35 (d, J = 2.4 Hz, 1H), 5.32 (s, 2H), 3.84 (s, 3H), 3.59 (s, 3H), 2.55 (s, 3H).
[0323] Example 16 N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(3-fluoro-2-methoxyphenyl)-6-methylnicotinamide [ka] Dioxane (3mL) and H 2 4-chloro-N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methylnicotinamide (150 mg) in O (0.6 mL) , 0.379 mmol, (3-fluoro-2-methoxyphenyl)boronic acid (194 mg, 1.141 mmol), K 3 P.O. 4 (301 mg, 1.419 mmol) and Pd(dtbpf)Cl 2 (50mg, 0.077mmol) was added under nitrogen. The resulting solution was stirred at 100° C. for 8 hours under nitrogen. The aqueous solution was concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane using the following conditions: (Column: Sunfire prep C18 column, 30 * by prep-HPLC using 150, 5 um; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 40 mL / min; gradient: 25B to 55B in 8 min; 220 nm; RT1: 7.23 min) Further purification resulted in N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(3-fluoro-2-methoxyphenyl)-6 -Methylnicotinamide (22.6 mg, 15.1%) was obtained as a white solid. (C 22 H 17 ClFN 5 O 3 S)(M+1) + MS(ESI) calculated value for 486.1; measured value 486.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.94 (s, 1H), 8.78 (s, 1H), 8.65 (s, 1H), 8.01 - 7.99 (m, 1H), 7.61 - 7.59 (m, 1H), 7.35 - 7.30 (m, 2H), 7.21 - 7.13 (m, 2H), 5.54 (s, 2H), 3.56 (s, 3H), 2.68 (s, 3H).
[0324] Example 17 4-(2-(difluoromethoxy)phenyl)-N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methyl Pyridine-3-carboxamide [ka]
[0325] Step-1: 5-(methoxycarbonyl)-2-methylpyridin-4-ylboronic acid [ka] Methyl 4-chloro-6-methylpyridine-3-carboxylate (1.00 g, 5.388 mmo) and Pd(dppf)Cl in dioxane (10.00 mL) 2 AcOK (1.59 g, 16.163 mmol) and B 2 Pin (2.73g, 10.775mmol) was added. The resulting solution was stirred in a sealed tube at 80° C. for 3 hours under a nitrogen atmosphere. The resulting mixture was used directly in the next step without further purification. (C 8 H 10 BNO 4 )(M+1) + MS(ESI) calculated value 196.0; measured value 196.0.
[0326] Step-2: Methyl 4-(2-(difluoromethoxy)phenyl)-6-methylpyridine-3-carboxylate [ka] Dioxane (10.00mL) and H 2 A solution of 5-(methoxycarbonyl)-2-methylpyridin-4-ylboronic acid (347.00 mg, 1.780 mmol) and 1-bromo-2-(difluoromethoxy)benzene (396.90 mg, 1.780 mmol) in O (2 mL). In, Pd(dppf)Cl 2 (130.22mg, 0.178mmol) and K 2 C.O. 3 (737.88mg, 5.339mmol) was added. The resulting solution was stirred in a sealed tube at 80° C. for 16 hours under a nitrogen atmosphere. The resulting mixture was concentrated in vacuo. The residue was purified by flash column chromatography using 0-10% MeOH in DCM to give methyl 4-(2-(difluoromethoxy)phenyl)-6-methylpyridine-3-carboxylate (551 mg, 68.62%) as a yellow oil. I got it as a thing. (C 15 H 13 F 2 NO. 3 )(M+1) + MS(ESI) calculated value for 294.0; measured value 294.0.
[0327] Step-3: 4-(2-(difluoromethoxy)phenyl)-6-methylpyridine-3-carboxylic acid: [ka] THF (5.00mL) and H 2 A solution of methyl 4-(2-(difluoromethoxy)phenyl)-6-methylpyridine-3-carboxylate (350.00 mg, 1.193 mmol, 1 eq.) in O (1.00 mL) was added with NaOH (190.94 mg, 4.772 mmol). , 4 equivalents) were added. The resulting mixture was stirred for 4 hours at 50° C. under nitrogen atmosphere. The mixture was acidified to pH 2 with citric acid. The residue was purified by flash column chromatography using 5-50% water in acetonitrile to give 4-(2-(difluoromethoxy)phenyl)-6-methylpyridine-3-carboxylic acid (129 mg, 37.55%) as a pale yellow solid. obtained as. (C 14 H 11 F 2 NO. 3 )(M+1) + MS(ESI) calculated value for 280.0; measured value 280.0.
[0328] Step-4: 6-(((5-(4-(2-(difluoromethoxy)phenyl)-6-methylpyridin-3-amido)-1,3,4-thiadiazol-2-yl)oxy)methyl) Pyridine-3-carboxylate [ka] In DMF (2.00 mL), 4-(2-(difluoromethoxy)phenyl)-6-methylpyridine-3-carboxylic acid (180.00 mg, 0.643 mmol) and 6-(((5-amino-1,3,4 HOBt (104.5 mg, 0.771 mmol) and EDCI (148.3 mg, 0.771 mmol) were added to a mixture of methyl -thiadiazol-2-yl)oxy)methyl)pyridine-3-carboxylate (171.6 mg, 0.643 mmol, 1.00 eq.). added. The resulting mixture was stirred at room temperature for 16 hours. The residue was purified by flash column chromatography using 5-50% water in acetonitrile to give 6-(((5-(4-(2-(difluoromethoxy)phenyl)-6-methylpyridine-3-amide)-1 ,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-3-carboxylate (90 mg, 26.47%) was obtained as a yellow solid. (C24H19F2N5O5S)(M+1) + MS(ESI) calculated value for 527.1; measured value 527.1.
[0329] Step-5: 4-(2-(difluoromethoxy)phenyl)-N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl) -6-methylpyridine-3-carboxamide [ka] 6-(((5-(4-(2-(difluoromethoxy)phenyl)-6-methylpyridin-3-amido)-1,3,4-thiadiazol-2-yl)oxy in THF (3.00 mL). ) To a mixture of pyridine-3-carboxylate (90.00 mg, 0.171 mmol) was added LiAlH4 (19.4 mg, 0.171 mmol) portionwise at 0°C. This mixture was stirred at 0°C for 1 hour. The resulting mixture was quenched with water. This suspension was filtered. Filter the filtrate under the following conditions: Column: YMC-Actus Triart C18, 20 * 250MM, 5um, 12nm; Mobile phase A: not determined, Mobile phase B: not determined; Flow rate: 60mL / min; Gradient: 20B to 50B in 8 minutes; prep-HPLC / prep using 220 / 254nm -Chiral-purified by HPLC, 4-(2-(difluoromethoxy)phenyl)-N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazole- 2-yl)-6-methylpyridine-3-carboxamide (11.3 mg, 13.26%) was obtained as a white solid. (C23H19F2N5O4S)(M+1) + MS(ESI) calculated value for 499.1; measured value 499.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.91 (s, 1H), 8.82 (s, 1H), 8.53 (s, 1H), 7.81 - 7.75 (m, 1H), 7.49 (dd, J = 14.4, 8.0 Hz, 2H), 7.40 (d, J = 7.6 Hz, 1H), 7.37 - 7.29 (m, 2H), 7.25 - 7.15 (m, 1H), 7.04 (s, 1H), 5.51 (s, 2H), 5.38 - 5.31 (m, J = 5.6 Hz , 1H), 4.55 (d, J = 5.2 Hz, 2H), 2.58 (s, 3H).
[0330] Example 18 N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methyl-4-(tetrahydro-2H-pyran-4-yl)nicotine Amide [ka]
[0331] Step-1: Methyl 4-(3,6-dihydro-2H-pyran-4-yl)-6-methylpyridine-3-carboxylate [ka] Methyl 4-chloro-6-methylpyridine-3-carboxylate (500.0 mg, 2.694 mmol) and 2-(3,6-dihydro-2H-pyran-4-yl) in dioxane (5 mL) and water (1 mL). In a mixture of -4,4,5,5-tetramethyl-1,3,2-dioxaborolane (848.8 mg, 4.041 mmol), K 2 C.O. 3 (1116.9mg, 8.082mmol) and Pd(dppf)Cl 2 (197.1 mg, 0.269 mmol) was added. The resulting mixture was stirred at 80° C. for 16 hours under nitrogen atmosphere. The resulting mixture was quenched with water and the aqueous phase was extracted with ethyl acetate. The combined organic solutions were dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by reverse phase flash column chromatography using 5-50% acetonitrile in water to give methyl 4-(3,6-dihydro-2H-pyran-4-yl)-6-methylpyridine-3-carboxylate (404 mg , 64.2%) as a yellow solid. (C 13 H 15 NO. 3 )(M+1) + MS (ESI) calculated value of 234.0, actual value of 234.0.
[0332] Step-2: Methyl 6-methyl-4-(oxan-4-yl)pyridine-3-carboxylate [ka] A solution of methyl 4-(3,6-dihydro-2H-pyran-4-yl)-6-methylpyridine-3-carboxylate (200.0 mg, 0.857 mmol) in MeOH was added to %) was added. The resulting mixture was stirred at room temperature for 2 hours under an atmosphere of hydrogen. The solids were filtered and the filtrate was concentrated in vacuo to give methyl 6-methyl-4-(oxan-4-yl)pyridine-3-carboxylate (164 mg, crude product) as a white solid. (C 13 H 17 NO. 3 )(M+1) + MS(ESI) calculated value of 233.1, measured value of 233.1.
[0333] Step-3: 6-methyl-4-(oxan-4-yl)pyridine-3-carboxylic acid [ka] A solution of methyl 6-methyl-4-(oxan-4-yl)pyridine-3-carboxylate (164.0 mg, 0.697 mmol) in THF (2.0 mL, 0.028 mmol) was added with NaOH (83.6 mg, 2.091 mmol) and H 2 O (2.0 mL) was added. The resulting mixture was stirred at room temperature for 16 hours. The aqueous solution was acidified to pH ~2 with citric acid. The residue was purified by reverse phase flash column chromatography using 5-55% acetonitrile in water to give 6-methyl-4-(oxan-4-yl)pyridine-3-carboxylic acid (73 mg, 47.3%) as a white solid. Ta. (C 12 H 15 NO. 3 )(M+1) + MS(ESI) calculated value of 222.1, measured value of 222.1.
[0334] Step-4: N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methyl-4-(tetrahydro-2H-pyran-4 -yl)nicotinamide [ka] 5-( (5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-amine (60.33 mg, 0.249 mmol, intermediate C) and TCFH (82.43 mg, 0.294 mmol) and NMI (92.77 mg, 1.130 mmol) was added. The resulting mixture was stirred at room temperature for 16 hours. The residue was purified by reverse phase flash column chromatography using 5-30% acetonitrile in water using the following conditions: (Column: XBridge Prep OBD C18 column, 30 x 150 mm 5um; Mobile phase A: water (10MMOL / L NH 4 HCO 3 +0.1%NH 3 .H 2 further purified by prep-HPLC using mobile phase B: ACN; flow rate: 60 mL / min; gradient: 5B to 40B in 7 min; 220 nm; RT 1: 6.5 min) and N-(5-((5 -chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methyl-4-(oxan-4-yl)pyridine-3-carboxamide (23.6 mg, 23.4%) Obtained as a white solid. (C 20 H 20 ClN 5 O 3 S)(M+1) + MS(ESI) calculated value of 446.1, measured value of 446.1. 1H NMR (400 MHz, chloroform-d) δ 12.38 (s, 1H), 8.81 (s, 1H), 8.61 (d, J = 2.4 Hz, 1H), 7.76 - 7.69 (m, 1H), 7.47 (d, J = 8.4 Hz, 1H), 7.24 (s, 1H), 5.51 (s, 2H), 4.11 - 4.04 (m, 2H), 3.61 - 3.50 (m, 2H), 3.48 - 3.36 (m, 1H), 2.63 (s, 3H), 1.91 - 1.77 (m, 4H).
[0335] Example 19 N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-3-(2-fluoro-6-methoxyphenyl)picolinamide [ka]
[0336] Step-1: Methyl 3-(2-fluoro-6-methoxyphenyl)pyridine-2-carboxylate [ka] Dioxane (15mL) and H 2 To a degassed mixture of methyl 3-bromopyridine-2-carboxylate (1.0 g, 4.629 mmol) and 2-fluoro-6-methoxyphenylboronic acid (1.2 g, 6.943 mmol) in 2 C.O. 3 (1.9g, 13.887mmol) and Pd(dppf)Cl2 (338.7mg, 0.463mmol) were added. The resulting mixture was stirred at 80° C. for 16 hours under nitrogen atmosphere. The resulting mixture was quenched with water and the aqueous phase was extracted with ethyl acetate. The combined organic solutions were dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography, eluting with 0-50% ethyl acetate in petroleum ether to give methyl 3-(2-fluoro-6-methoxyphenyl)pyridine-2-carboxylate (698 mg, 57.7%) in yellow. Obtained as a solid. (C 14 H 12 FNO 3 )(M+1) + MS(ESI) calculated value of 262.0, actual value of 262.0.
[0337] Step-2: 3-(2-fluoro-6-methoxyphenyl)picolinic acid [ka] A solution of methyl 3-(2-fluoro-6-methoxyphenyl)pyridine-2-carboxylate (200.0 mg, 0.766 mmol) in THF (2 mL) in water (2 mL), NaOH (91.8 mg, 2.297 mmol) solution was added. The resulting mixture was stirred at 50°C for 16 hours. The resulting mixture was diluted with water and acidified to pH 2 with HCl (2N). The aqueous layer was extracted with ethyl acetate. The combined organic solutions were dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by reverse phase flash column chromatography using 5-45% acetonitrile in water to give 3-(2-fluoro-6-methoxyphenyl)pyridine-2-carboxylic acid (182 mg, 96.1%) as a white solid. . (C 13 H 10 FNO 3 )(M+1) + MS (ESI) calculated value of 248.0, actual value of 248.0.
[0338] Step-3: N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-3-(2-fluoro-6-methoxyphenyl)pyridine- 2-carboxamide [ka] A solution of 3-(2-fluoro-6-methoxyphenyl)pyridine-2-carboxylic acid (100.0 mg, 0.404 mmol) in MeCN (3.0 mL, 0.073 mmol) was added with NMI (166.05 mg, 2.022 mmol), 5- ((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-amine (107.9 mg, 0.444 mmol, Intermediate C) and TCFH (147.5 mg, 0.525 mmol) were added. The resulting mixture was stirred at room temperature for 16 hours under nitrogen atmosphere. The precipitated solid was collected by filtration, washed with water and methanol, and N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-3-( 2-Fluoro-6-methoxyphenyl)pyridine-2-carboxamide (90.3 mg, 47.3%) was obtained as a white solid. (C 21 H 15 ClFN 5 O 3 S)(M+1) + MS(ESI) calculated value of 472.0, measured value of 472.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.62 (s, 1H), 8.76 - 8.70 (m, 1H), 8.65 (d, J = 2.4 Hz, 1H), 8.04 - 7.97 (m, 1H), 7.96 - 7.89 (m, 1H), 7.74 ( dd, J = 8.0, 4.4 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.46 - 7.36 (m, 1H), 6.97 - 6.88 (m, 2H), 5.55 (s, 2H), 3.62 (s, 3H).
[0339] Example 20 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-methoxypyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methylpyridine- 3-carboxamide [ka]
[0340] Step-1: 5-((5-methoxypyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-amine [ka] To a solution of NaH (66.6 mg, 1.66 mmol) in THF (5.00 mL) was added a solution of (5-methoxypyridin-2-yl)methanol (185.5 mg, 1.33 mmol) in THF (1 mL) at 0 °C. , and stirred at 0°C for 1 hour. 5-Bromo-1,3,4-thiadiazol-2-amine (200.00 mg, 1.11 mmol) was added to the above mixture at 0°C. The resulting mixture was stirred at room temperature for 5 hours. The resulting mixture was quenched with water. The aqueous layer was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated in vacuo. The residue was purified by flash column chromatography using 5-50% acetonitrile in water and purified with 5-((5-methoxypyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-amine (60 mg, 22.6% ) was obtained as a yellow solid. (C 9 H 10 N 4 O 2 S)(M+1) + MS(ESI) calculated value for 238.1; measured value 238.1.
[0341] Step-2: 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-methoxypyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6 -Methylpyridine-3-carboxamide [ka] 5-((5-methoxypyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-amine (60.00 mg, 0.252 mmol) and 4-(2-fluoro-6 -Methoxyphenyl)-6-methylpyridine-3-carboxylic acid (55 mg, 0.21 mmol, Intermediate F) was added TCFH (65.00 mg, 0.231 mmol) and NMI (52.00 mg, 0.63 mmol). The mixture was stirred at room temperature for 6 hours under nitrogen atmosphere. This mixture was purified by reverse-phase flash column chromatography using 5-50% acetonitrile in water and purified with 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-methoxypyridin-2-yl)). methoxy)-1,3,4-thiadiazol-2-yl)-6-methylpyridine-3-carboxamide (17.2 mg, 14.1%) was obtained as a pale yellow solid. (C 23 H 20 FN 5 O 4 S)(M+1) + MS(ESI) calculated value for 481.1; measured value 481.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.88 (s, 1H), 8.81 (s, 1H), 8.30 (d, J = 3.2 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.48 - 7.35 (m, 2H), 7.33 (s, 1H), 6.97 - 6.86 (m, 2H), 5.46 (s, 2H), 3.85 (s, 3H), 3.33 (s, 3H), 2.57 (s, 3H).
[0342] Example 21 N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(3-cyano-2-methoxyphenyl)-6-methylnicotinamide [ka]
[0343] Step-1: Methyl 4-(3-cyano-2-methoxyphenyl)-6-methylnicotinate [ka] Dioxane (10mL) and H 2 A degassed solution of methyl 4-chloro-6-methylnicotinate (200 mg, 1.081 mmol) in O (2 mL) was added to 2-methoxy-3-(4,4,5,5-tetramethyl-1,3, 2-dioxaborolan-2-yl)benzonitrile (432 mg, 1.662 mmol), K 2 C.O. 3 (459mg, 3.326mmol) and Pd(PPh 3 ) 4 (129 mg, 0.112 mmol) was added under nitrogen. The resulting solution was stirred at 80° C. for 8 hours under nitrogen. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-50% ethyl acetate in petroleum ether to give methyl 4-(3-cyano-2-methoxyphenyl)-6-methylnicotinate (212 mg, 80%). Obtained as a white solid. (C 16 H 14 N 2 O 3 )(M+1) + MS(ESI) calculated value for 283.1; measured value 283.0.
[0344] Step-2: 4-(3-cyano-2-methoxyphenyl)-6-methylnicotinic acid [ka] MeOH (10mL) and H 2 To a solution of methyl 4-(3-cyano-2-methoxyphenyl)-6-methylnicotinate (250 mg, 0.883 mmol) in O (5 mL) was added LiOH (45 mg, 1.875 mmol). This mixture was stirred at 50°C for 2 hours. This aqueous solution was acidified to pH 5-6 with HCl. This aqueous solution was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated in vacuo to give 4-(3-cyano-2-methoxyphenyl)-6-methylnicotinic acid (213 mg, 85%) as a white solid. (C 15 H 12 N 2 O 3 )(M+1) + MS(ESI) calculated value for 269.1; measured value 269.0.
[0345] Step-3: N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(3-cyano-2-methoxyphenyl)-6 -Methylnicotinamide [ka] A solution of 4-(3-cyano-2-methoxyphenyl)-6-methylnicotinic acid (213 mg, 0.792 mmol) in ACN (10 mL) was added with NMI (195 mg, 2.378 mmol), 5-((5-chloropyridine -2-yl)methoxy)-1,3,4-thiadiazol-2-amine (200 mg, 0.823 mmol, Intermediate C) and TCFH (268 mg, 0.954 mmol) were added. This mixture was stirred at room temperature for 2 hours. The mixture was concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane using the following conditions: (Column: Sunfire prep C18 column, 30 * by prep-HPLC using 150, 5 um; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 40 mL / min; gradient: 25B to 55B in 8 min; 220 nm; RT1: 7.23 min) Further purification resulted in N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(3-cyano-2-methoxyphenyl)-6 -Methylnicotinamide (23.2 mg, 10.9%) was obtained as a white solid. (C 23 H 17 ClN 6 O 3 S)(M+1) + MS(ESI) calculated value for 493.1; measured value 493.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 13.02 (s, 1H), 8.85 (s, 1H), 8.66 (s, 1H), 8.02 - 7.99 (m, 1H), 7.98 - 7.85 (m, 1H), 7.69 - 7.60 (m, 2H), 7.43 - 7.38 (m, 2H), 5.55 (s, 2H), 3.56 (s, 3H), 2.61 (s, 3H).
[0346] Examples 22, 40 and 41 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-(1-hydroxyethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)- 6-Methylnicotinamide (Example 22) [ka]
[0347] 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-((S)-1-hydroxyethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazole-2 -yl)-6-methylnicotinamide (Example 40) and 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-((R)-1-hydroxyethyl)pyridine-2 -yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methylnicotinamide (Example 41) [ka]
[0348] Step-1: (5-(1-ethoxyvinyl)pyridin-2-yl)methanol [ka] To a degassed mixture of (5-bromopyridin-2-yl)methanol (10.0 g, 53.18 mmol) in toluene (50.00 mL) was added tributyl(1-ethoxyethenyl)stannane (38.42 g, 0.11 mmol) and Pd ( PPh 3 ) 2 Cl 2 (3.73g, 5.31mmol) was added. The resulting solution was stirred at 100° C. for 2 hours under a nitrogen atmosphere and then concentrated in vacuo. The residue was purified by flash column chromatography using 0-50% ethyl acetate in petroleum ether to give (5-(1-ethoxyvinyl)pyridin-2-yl)methanol (5.0 g, 52.4%) as a yellow solid. . (C 10 H 13 NO. 2 )(M+1) + MS(ESI) calculated value for 180.1; measured value 180.0.
[0349] Step-2: (5-(1-ethoxyethenyl)pyridin-2-yl)methanol [ka] A solution of (5-(1-ethoxyethenyl)pyridin-2-yl)methanol ( A solution of 8.00 g, 44.63 mmol) was added dropwise at 0 to 5°C, and the mixture was stirred at 0 to 5°C for 1 hour under a nitrogen atmosphere. 5-bromo-1,3,4-thiadiazol-2-amine (9.64 g, 53.56 mmol) was added to the above solution at 0°C. The resulting mixture was stirred at room temperature for 12 hours under nitrogen. The reaction mixture was quenched by adding ice / water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane to give 5-((5-(1-ethoxyethenyl)pyridin-2-yl)methoxy)-1,3,4- Thiadiazol-2-amine (4.0 g, 32.2%) was obtained as a yellow solid. (C 12 H 14 N 4 O 2 S)(M+1) + MS (ESI) calculated value of 279.1, actual value of 279.0.
[0350] Step-3: 1-(6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridin-3-yl)ethenone [ka] A mixture of 5-((5-(1-ethoxyethenyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-amine (5.03 g, 18.07 mmol) in HCl (50 mL, 4M in dioxane) ) was stirred at room temperature for 2 hours. Solvent was removed under reduced pressure. Saturate the residue with NaHCO 3 (aqueous solution) and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane to give 1-(6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl) Pyridin-3-yl)ethanone (3.46 g, 68.8%) was obtained as a yellow solid. (C 10 H 10 N 4 O 2 S)(M+1) + MS(ESI) calculated value of 251.0, actual value of 251.0.
[0351] Step-4: N-(5-((5-acetylpyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-fluoro-6-methoxyphenyl)-6 -Methylpyridine-3-carboxamide [ka] In acetonitrile (5 mL), 1-(6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridin-3-yl)ethanone (300 mg, 1.19 mmol) and 4- To a stirred solution of (2-fluoro-6-methoxyphenyl)-6-methylpyridine-3-carboxylic acid (313.1 mg, 1.19 mmol, Intermediate F) was added TCFH (504 mg, 1.79 mmol) and N-methylimidazole (393 mg , 4.79 mmol) was added at room temperature under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 2 hours under nitrogen atmosphere. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by reverse phase flash column chromatography using 5-70% acetonitrile in water to give N-(5-((5-acetylpyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl. )-4-(2-fluoro-6-methoxyphenyl)-6-methylpyridine-3-carboxamide (350 mg, 59.1%) was obtained as a yellow oil. (C 24 H 20 FN 5 O 4 S)(M+1) + MS(ESI) calculated value for 494.1; measured value 494.1.
[0352] Step-5: 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-((1S)-1-hydroxyethyl)pyridin-2-yl)methoxy)-1,3,4 -thiadiazol-2-yl)-6-methylpyridine-3-carboxamide [ka] N-(5-((5-acetylpyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-fluoro-6-methoxyphenyl) in MeOH (3 mL). A stirred solution of -6-methylpyridine-3-carboxamide (234 mg, 0.47 mmol) was added with NaBH 4 (35mg, 0.94mmol) was added. The resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified under the following conditions: (Column: XBridge Prep OBD C18 column, 30×150mm 5um; Mobile phase A: Water (10mmol / L NH 4 HCO 3 ), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 25B to 45B in 7 min; 5-((5-(1-hydroxyethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methylnicotinamide (22.2 mg, 10.2%) as a white solid. Obtained. (C 24 H 22 FN 5 O 4 S)(M+1) + MS(ESI) calculated value for 496.1; measured value 496.0. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.89 (s, 1H), 8.82 (s, 1H), 8.56 (s, 1H), 7.85 - 7.75 (m, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.45 - 7.35 (m, 1H), 7.32 (d, J = 1.6 Hz, 1H), 6.97 - 6.86 (m, 2H), 5.51 (s, 2H), 5.36 (s, 1H), 4.83 - 4.78 (m, 1H), 3.59 (s , 3H), 2.56 (s, 3H), 1.37 (d, J = 6.4 Hz, 3H).
[0353] Step-6: 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-((S)-1-hydroxyethyl)pyridin-2-yl)methoxy)-1,3,4 -thiadiazol-2-yl)-6-methylnicotinamide and 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-((R)-1-hydroxyethyl)pyridine-2- yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methylnicotinamide: [ka] 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-((1S)-1-hydroxyethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazole-2 -yl)-6-methylpyridine-3-carboxamide (160 mg) was added under the following conditions: (Column: DZ-CHIRALPAK IG-3, 2 * 25cm, 5um; Mobile phase A:Hex(0.2%FA):(EtOH:DCM=1:1)=50:50, Mobile phase B:;Flow rate: 20mL / min;Gradient: 30B to 30B in 25 minutes; 4-(2- Fluoro-6-methoxyphenyl)-N-(5-((5-((S)-1-hydroxyethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6 -Methylnicotinamide (47.4 mg, 29.6%) and 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-((R)- 1-Hydroxyethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methylnicotinamide (46.2 mg, 28.9%) was obtained.
[0354] 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-((S)-1-hydroxyethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazole-2 -yl)-6-methylnicotinamide:(C 24 H 22 FN 5 O 4 S)(M+1) + MS(ESI) calculated value for 496.1; measured value 496.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.99 (s, 1H), 8.82 (s, 1H), 8.56 (s, 1H), 7.85 - 7.75 (m, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.45 - 7.35 (m, 1H), 7.32 (d, J = 1.6 Hz, 1H), 6.97 - 6.86 (m, 2H), 5.51 (s, 2H), 5.36 (s, 1H), 4.83 - 4.78 (m, 1H), 3.59 (s , 3H), 2.56 (s, 3H), 1.37 (d, J = 6.4 Hz, 3H).
[0355] 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-((R)-1-hydroxyethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazole-2 -yl)-6-methylnicotinamide:(C 24 H 22 FN 5 O 4 S)(M+1) + MS(ESI) calculated value for 496.1; measured value 496.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.89 (s, 1H), 8.82 (s, 1H), 8.56 (s, 1H), 7.85 - 7.75 (m, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.45 - 7.35 (m, 1H), 7.32 (d, J = 1.6 Hz, 1H), 6.97 - 6.86 (m, 2H), 5.51 (s, 2H), 5.36 (s, 1H), 4.83 - 4.78 (m, 1H), 3.59 (s , 3H), 2.56 (s, 3H), 1.37 (d, J = 6.4 Hz, 3H).
[0356] Example 23 N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-fluoro-5-(hydroxymethyl)phenyl)-6- methylnicotinamide [ka]
[0357] Step-1: Methyl 4-(2-fluoro-5-(hydroxymethyl)phenyl)-6-methylnicotinate [ka] Dioxane (10mL) and H 2 In O (1 mL), methyl 4-chloro-6-methylpyridine-3-carboxylate (500.0 mg, 2.694 mmol), 2-fluoro-5-(hydroxymethyl)phenylboronic acid (457.8 mg, 2.694 mmol), K 2 C.O. 3 (1116.9mg, 8.082mmol) and Pd(dppf)Cl 2 A degassed solution of (197.11 mg, 0.269 mmol) was stirred at 80°C for 2 hours. Solvent was removed under reduced pressure. The residue was purified by flash column chromatography using 0-10% methanol in dichloromethane to give methyl 4-(2-fluoro-5-(hydroxymethyl)phenyl)-6-methylnicotinate (480 mg, 65%) as a yellow oil. I got it as a thing. (C 15 H 14 FNO 3 )(M+1) + MS(ESI) calculated value for 276.1; measured value 276.0.
[0358] Step-2: Methyl 4-(2-fluoro-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)phenyl)-6-methylnicotinate [ka] A solution of methyl 4-(2-fluoro-5-(hydroxymethyl)phenyl)-6-methylnicotinate (380.00 mg, 1.38 mmol) in DCM (5 mL) was added with DHP (233 mg, 2.76 mmol) and pTsOH (119 mg , 0.69 mmol) was added. The resulting mixture was stirred at room temperature for 16 hours. Reaction mixture with NaHCO 3 (aqueous solution). The aqueous solution was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated in vacuo to give an off-yellow methyl 4-(2-fluoro-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)phenyl)-6-methylnicotinate (370 mg, 74.6%). Obtained as a solid. (C 20 H 22 FNO 4 )(M+1) + MS(ESI) calculated value for 360.1; measured value 360.0.
[0359] Step-3: 4-(2-fluoro-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)phenyl)-6-methylnicotinic acid [ka] MeOH (10mL) and H 2 A solution of methyl 4-(2-fluoro-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)phenyl)-6-methylnicotinate (370 mg, 1.03 mmol) in O (5 mL) , NaOH (82 mg, 2.06 mmol) was added. This mixture was stirred at 50°C for 2 hours. The aqueous solution was acidified to pH ˜6 with HCl (1N). This aqueous solution was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated in vacuo to give 4-(2-fluoro-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)phenyl)-6-methylnicotinic acid (280 mg, 78%) as a white solid. Obtained. (C 19 H 20 FNO 4 )(M+1) + MS(ESI) calculated value for 346.1; measured value 346.0.
[0360] Step-4: N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-fluoro-5-(((tetrahydro- 2H-pyran-2-yl)oxy)methyl)phenyl)-6-methylnicotinamide [ka] A solution of 4-(2-fluoro-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)phenyl)-6-methylnicotinic acid (250 mg, 0.72 mmol) in ACN (5 mL) was added to 5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-amine (223 mg, 0.72 mmol, intermediate C), NMI (177 mg, 2.16 mmol) and TCFH (302 mg, 1.08 mmol) was added. This mixture was stirred at room temperature for 2 hours. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane to give N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazole-2 -yl)-4-(2-fluoro-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)phenyl)-6-methylnicotinamide (170 mg, 38%) was obtained as a yellow solid. . (C 27 H 2 ClFN 5 O 4 S)(M+1) + MS(ESI) calculated value for 570.1; measured value 570.0.
[0361] Step-5: N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-fluoro-5-(hydroxymethyl)phenyl )-6-Methylnicotinamide [ka] CH 2 Cl 2 (6 mL), N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-fluoro-5-(((tetrahydro To a mixture of -2H-pyran-2-yl)oxy)methyl)phenyl)-6-methylnicotinamide (170 mg, 0.29 mmol) was added TFA (2 mL). The resulting mixture was stirred at room temperature for 3 hours, then concentrated in vacuo. The residue was purified under the following conditions: (Column: XBridge Prep OBD C18 column, 30×150mm 5um; Mobile phase A: Water (10mmol / L NH 4 HCO 3 ), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 23B to 36B in 8 min; 254 / 220 nm) and purified by prep-HPLC using N-(5-((5-chloropyridine-2 -yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-fluoro-5-(hydroxymethyl)phenyl)-6-methylnicotinamide (48 mg, 33%) as a white solid. Obtained. (C 22 H 17 FClN 5 O 3 S)(M+1) + MS(ESI) calculated value for 486.1; measured value 486.1. 1 H NMR (400 MHz, methanol-d 4 ) δ 8.77 (s, 1H), 8.59 - 8.58 (s, 1H), 7.94 - 7.91 (m, 1H), 7.62 - 7.60 (m, 1H), 7.48 - 7.45 (m, 3H), 7.13 - 7.10 (m , 1H), 5.57 (s, 2H), 4.89 - 4.61 (m, 2H), 2.68 (s, 3H).
[0362] Example 24 4-(2-fluoro-6-methoxyphenyl)-6-methyl-N-(5-((5-(methylsulfonyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl )Nicotinamide [ka]
[0363] Step-1: (5-(methylsulfonyl)pyridin-2-yl)methanol [ka] A stirred solution of methyl 5-methanesulfonylpyridine-2-carboxylate (500 mg, 2.32 mmol) and NaOMe (1 mg, 0.02 mmol) in MeOH (15 mL) was added with NaBH 4 (175 mg, 4.64 mmol) at room temperature, N 2 It was added little by little under atmosphere. The resulting mixture was heated with N for 3 h at room temperature. 2Stir under atmosphere. The reaction mixture was quenched with water and extracted with ethyl acetate / THF. The combined organic layers were washed with saturated brine and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to give (5-(methylsulfonyl)pyridin-2-yl)methanol (165 mg, 37.9%) as a yellow oil. (C 7 H 9 NO. 3 S)(M+1) + MS(ESI) calculated value for 188.0; measured value 188.1.
[0364] Step-2: S-methyl O-((5-(methylsulfonyl)pyridin-2-yl)methyl)carbodithioate [ka] A solution of (5-(methylsulfonyl)pyridin-2-yl)methanol (200 mg, 1.08 mmol) in THF (3 mL) was added to a solution of NaH (90 mg, 3.75 mmol, 60%) in THF (10 mL). Added at °C. The resulting mixture was stirred at 0°C for 30 minutes. CS to the above mixture 2 (122 mg, 1.60 mmol) was added dropwise at 0°C, and the mixture was stirred at 0°C for 20 minutes. Next, MeI (227 mg, 1.60 mmol) was added dropwise to the above mixture at 0°C. The resulting mixture was stirred at room temperature for 1 hour. The resulting mixture was quenched with water. The aqueous layer was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated in vacuo. The residue was purified by reverse-phase flash column chromatography using 5-70% acetonitrile in water to give S-methyl O-((5-(methylsulfonyl)pyridin-2-yl)methyl)carbodithioate (140 mg, 47.2%). Obtained as a brown solid. (C 9 H 11 NO. 3 S 3 )(M+1) + MS(ESI) calculated value for 277.1; measured value 277.1.
[0365] Step-3: Hydrazinecarbothioate O-((5-(methylsulfonyl)pyridin-2-yl)methyl) [ka] To a mixture of S-methyl O-((5-(methylsulfonyl)pyridin-2-yl)methyl)carbodithioate (120 mg, 0.43 mmol) in MeOH (5 mL) was added hydrazine (14 mg, 0.43 mmol). This mixture was stirred at 0°C for 1 hour. The resulting mixture was concentrated in vacuo and diluted with water. The resulting mixture was extracted with ethyl acetate. The combined organic layers were washed with saturated sodium chloride and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated in vacuo to give hydrazinecarbothioate O-((5-(methylsulfonyl)pyridin-2-yl)methyl) (120 mg, crude product) as a brown solid. (C 8 H 11 N 3 O 3 S 2 )(M+1) + MS(ESI) calculated value for 262.0; measured value 262.0.
[0366] Step-4: Hydrazinecarbothioate O-((5-(methylsulfonyl)pyridin-2-yl)methyl) [ka] BrCN (49 mg, 0.46 mmol) was added. This mixture was stirred at room temperature for 1 hour. The resulting mixture was quenched with water. The aqueous layer was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated in vacuo to give 5-((5-methanesulfonylpyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-amine (40 mg, 33.1%) as a brown solid. (C 9 H 10 N 4 O 3 S 2 )(M+1) + MS(ESI) calculated value for 287.0; measured value 287.0.
[0367] Step-5: 4-(2-fluoro-6-methoxyphenyl)-6-methyl-N-(5-((5-(methylsulfonyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazole -2-yl)nicotinamide [ka] In DMF (2 mL), 5-((5-methanesulfonylpyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-amine (40 mg, 0.14 mmol) and 4-(2-fluoro-6- To a stirred solution of (methoxyphenyl)-6-methylpyridine-3-carboxylic acid (36 mg, 0.14 mmol, Intermediate F) was added TCFH (58 mg, 0.21 mmol) and NMI (45 mg, 0.56 mmol) in N 2 Added under atmosphere. The resulting mixture was stirred at room temperature for 1 hour. The residue was purified under the following conditions: (Column: YMC-Pack Diol-120-NP, 20 * 150mm 5um; Mobile phase A: Water (10mmol / L NH 4 HCO 3 ), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 39B to 52B in 8 min; 220 / 254 nm; RT 1: 4.2 min) and purified by prep-HPLC using -methoxyphenyl)-6-methyl-N-(5-((5-(methylsulfonyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)nicotinamide (20 mg, 27.0% ) was obtained as a white solid. (C 23 H 20 FN 5 O 5 S 2 )(M+1) + MS(ESI) calculated value for 530.0; measured value 530.0. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.95 (s, 1H), 9.09 (d, J = 2.4 Hz, 1H), 8.82 (s, 1H), 8.47 - 8.33 (m, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.47 - 7.38 (m, 1H), 7.34 (s, 1H), 6.99 - 6.86 (m, 2H), 5.69 (s, 2H), 3.60 (s, 3H), 3.30 (s, 3H), 2.58 (s, 3H) ).
[0368] Example 25 4-(2-(difluoromethoxy)-6-fluorophenyl)-N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl) -6-Methylnicotinamide [ka]
[0369] Step-1: Methyl 6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-3-carboxylate [ka] To a stirred solution of NaH (575.0 mg, 14.37 mmol, 60% purity) in THF (20.00 mL) was added methyl 6-(hydroxymethyl)pyridine-3-carboxylate (2.00 g, 11.96 mmol) in THF (10 mL). A solution of was added dropwise at 0°C, and the mixture was stirred at 0 to 5°C for 1 hour. A solution of 5-bromo-1,3,4-thiadiazol-2-amine (2.57 g, 14.27 mmol) in THF (10 mL) was then added to the above mixture. The resulting mixture was stirred at room temperature overnight under nitrogen atmosphere. Saturate the reaction mixture with NH 4 Quenched with aqueous Cl solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by reverse phase flash column chromatography using 5-50% MeCN in water to give 6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-3-carvone. Methyl acid (800 mg, 21.85%) was obtained as a brown solid. (C 10 H 10 N 4 O 3 S)(M+1) + MS(ESI) calculated value for 267.1; measured value 267.0.
[0370] Step-2: 6-(((5-(4-(2-(difluoromethoxy)-6-fluorophenyl)-6-methylpyridin-3-amido)-1,3,4-thiadiazol-2-yl) Methyl oxy)methyl)pyridine-3-carboxylate [ka] 4-(2-(difluoromethoxy)-6-fluorophenyl)-6-methylpyridine-3-carboxylic acid (320.00 mg, 1.07 mmol) and 6-(((5 TCFH (332.28 mg, 1.184 mmol) and NMI (265.18 mg, 3.230 mmol) were added. The resulting mixture was stirred at room temperature for 2 hours under nitrogen atmosphere. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by reverse phase flash column chromatography using 5-95% acetonitrile in water to give 6-(((5-(4-(2-(difluoromethoxy)-6-fluorophenyl)-6-methylpyridine-3 -Amido)-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-3-carboxylate (300 mg, 47.51%) was obtained as a white solid. (C 24 H 18 F 3 N 5 O 5 S)(M+1) + MS(ESI) calculated value for 546.1; measured value 546.0.
[0371] Step-3: 4-(2-(difluoromethoxy)-6-fluorophenyl)-N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazole- 2-yl)-6-methylnicotinamide [ka] 6-(((5-(4-(2-(difluoromethoxy)-6-fluorophenyl)-6-methylpyridine-3-amide)-1,3,4-thiadiazole-2- in THF (8 mL). To a stirred solution of methyl(yl)oxy)methyl)pyridine-3-carboxylate (180.00 mg, 0.330 mmol) was added LiAlH4 (25.05 mg, 0.660 mmol) at 0<0>C. The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified under the following conditions: (Column: XBridge Prep OBD C18 column, 30×150mm 5um; Mobile phase A: Water (10mmol / L NH 4 HCO 3 +0.1%NH 3 .H 2 O), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 10B to 42B in 7 min; 220 nm; 6-fluorophenyl)-N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methylnicotinamide (23 mg, 13.3 %) as a white solid. (C 23 H 18 F 3 N 5 O 4 S)(M+1) + MS(ESI) calculated value for 518.1; measured value 518.3. 1 H NMR (400 MHz, DMSO-d 6 ) δ 13.03 (s, 1H), 9.35 (s, 1H), 8.94 (s, 1H), 7.79 - 7.76 (m, 1H), 7.56 - 7.37 (m, 2H), 7.31 - 7.11 (m, 4H), 5.51 (s, 2H), 5.37 - 5.34 (m, 1H), 4.55 (d, J = 6.4 Hz, 2H), 2.68 (s, 3H).
[0372] Example 26 N-(5-((6-(methoxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide [ka]
[0373] Step-1: (6-(methoxymethyl)pyridin-2-yl)methanol [ka] A solution of 6-(methoxymethyl)pyridine-2-carbaldehyde (450.00 mg, 2.977 mmol) in MeOH (10.00 mL) was added with NaBH 4 (112.6 mg, 2.977 mmol) was added portionwise at 0°C. The resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was then quenched by adding water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give (6-(methoxymethyl)pyridin-2-yl)methanol (338 mg, 70.4%) as a yellow oil. Ta. (C 7 H 8 ClNO)(M+1) + MS(ESI) calculated value of 154.1, measured value of 154.1.
[0374] Step-2: 5-((6-(methoxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-amine [ka] A solution of NaH (75.90 mg, 3.163 mmol, 60%) in THF (10.00 mL) was added with (6-(methoxymethyl)pyridin-2-yl)methanol (323.0 mg, 2.109 mmol) in THF (2 mL). The solution was added at 0°C under nitrogen and stirred at 0°C for 1 hour. 5-Bromo-1,3,4-thiadiazol-2-amine (455.51 mg, 2.531 mmol) was added portionwise to the above solution at 0° C. under nitrogen. The resulting mixture was stirred at room temperature for 4 hours. The reaction mixture was quenched by adding water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-50% ethyl acetate in petroleum ether to give 5-((6-(methoxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazole. -2-amine (110 mg, 21.3%) was obtained as a yellow solid. (C 10 H 12 N 4 O 2 S)(M+1) + MS (ESI) calculated value of 253.1, measured value of 253.1.
[0375] Step-3: N-(5-((6-(methoxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6- methylnicotinamide [ka] A solution of 5-((6-(methoxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-amine (110 mg, 0.44 mmol) in ACN (5 mL) was added to -Methoxyphenyl)-6-methylnicotinic acid (281.00 mg, 0.52 mmol, Intermediate D), NMI (263 mg, 3.21 mmol) and TCFH (449 mg, 1.61 mmol) were added. This mixture was stirred at room temperature for 2 hours. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane using the following conditions: (Column: XBridge Prep OBD C18 column, 30 × 150 mm 5 um; Mobile phase A: water (10 MMOL / L NH 4 HCO 3 +0.1%NH 3 .H 2 O), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 7B to 40B in 8 min; 220 nm) and further purified by prep-HPLC using N-(5-((6-(methoxymethyl) Pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide (61 mg, 29.3%) was obtained as a yellow solid. (C 25 H 23 N 5 O 4 S)(M+1) + MS(ESI) calculated value for 478.2; measured value 478.2. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.77 (s, 1H), 8.70 (s, 1H), 7.89 - 7.88 (m, 1H), 7.46 - 7.30 (m, 5H), 7.06 - 7.55 (m, 1H), 6.99 - 6.97 (m, 1H) ), 5.56 (s, 2H), 4.72 (s, 2H), 3.69 (s, 3H), 3.37 (s, 3H), 2.62 (s, 3H).
[0376] Examples 27, 28, 29 and 30 (R)-N-(5-(2-(5-chloropyridin-2-yl)-2-hydroxyethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl) -6-Methylnicotinamide (Example 27), (S)-N-(5-(2-(5-chloropyridin-2-yl)-2-hydroxyethoxy)-1,3,4-thiadiazole-2 -yl)-4-(2-methoxyphenyl)-6-methylnicotinamide (Example 28), (R)-N-(5-(1-(5-chloropyridin-2-yl)-2-hydroxy ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide (Example 29), (S)-N-(5-(1-(5 -chloropyridin-2-yl)-2-hydroxyethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide (Example 30) [ka]
[0377] Step-1: 5-chloro-2-vinylpyridine [ka] 1,4-dioxane (100.0mL) and H 2 To a stirred mixture of 2,5-dichloropyridine (10.0 g, 51.96 mmol) in O (10 mL) was added K 2 C.O. 3 (21.5g, 155.89mmol), trifluoro(vinyl)-l4-borane potassium salt (13.9g, 103.92mmol) and Pd(dppf)Cl 2 (3.8g, 5.19mmol) was added. The resulting mixture was incubated for 2 h at 80 °C, N 2 Stir under atmosphere. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography using 0-13% ethyl acetate in petroleum ether to give 5-chloro-2-vinylpyridine (2.5 g, 34.3%) as an orange oil. (C 7 H 6 ClN)(M+1) + MS(ESI) calculated value of 140.0, actual value of 140.0.
[0378] Step-2: (R)-1-(5-chloropyridin-2-yl)ethane-1,2-diol [ka] tert-butanol / H 2 AD-mix- β (27.9 g, 35.91 mmol) was added in portions at room temperature under nitrogen atmosphere. The resulting mixture was heated at room temperature for 24 h in N 2 Stir under atmosphere. The reaction mixture was 2 S.O. 3 and stirred at room temperature for 1 hour. The resulting mixture was extracted with isopropanol and ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give (R)-1-(5-chloropyridin-2-yl)ethane-1,2-diol (3100 mg, 98%) was obtained as an off-white solid. (C 7 H 8 ClNO 2 )(M+1) + MS (ESI) calculated value of 174.0, measured value of 174.0.
[0379] Step-3: (R)-2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridin-2-yl)ethan-1-ol and (R)-2-((tert-butyl dimethylsilyl)oxy)-2-(5-chloropyridin-2-yl)ethane-1-ol [ka] Stirred solution of (R)-1-(5-chloropyridin-2-yl)ethane-1,2-diol (2.18 g, 7.57 mmol) and imidazole (2.57 g, 37.79 mmol) in dichloromethane (30.0 mL). To the solution, TBS-Cl (1.14 g, 7.57 mmol) was added portionwise at 0°C. The resulting mixture was stirred at 0°C for 1 hour. The resulting mixture was concentrated in vacuo. The residue was purified by flash column chromatography using 0-15% ethyl acetate in petroleum ether to give (R)-2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridin-2-yl). A mixture of ethan-1-ol and (R)-2-((tert-butyldimethylsilyl)oxy)-2-(5-chloropyridin-2-yl)ethane-1-ol (1.0 g, 45%) Obtained as a yellow-green oil. (C 13 H 22 ClNO 2 Si)(M+1) + MS(ESI) calculated value of 288.1, actual value of 288.0.
[0380] Step-4: (S)-1-(5-chloropyridin-2-yl)ethane-1,2-diol [ka] tert-butanol / H 2 AD-mix- α (30.0 g, 38.46 mmol) was added in portions at room temperature under nitrogen atmosphere. The resulting mixture was heated at room temperature for 24 h in N 2 Stir under atmosphere. The reaction mixture was 2 S.O. 3 and stirred at room temperature for 1 hour. The resulting mixture was extracted with isopropanol and ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography using 0-10% methyl alcohol in dichloromethane to give (S)-1-(5-chloropyridin-2-yl)ethane-1,2-diol (2.8 g, 75%). was obtained as an off-white solid. (C 7 H 8 ClNO 2 )(M+1) + MS (ESI) calculated value of 174.0, measured value of 174.0.
[0381] Step-5: (S)-2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridin-2-yl)ethan-1-ol and (S)-2-((tert-butyl dimethylsilyl)oxy)-2-(5-chloropyridin-2-yl)ethane-1-ol [ka] Stirred solution of (S)-1-(5-chloropyridin-2-yl)ethane-1,2-diol (3.0 g, 17.28 mmol) and imidazole (3.53 g, 52.01 mmol) in dichloromethane (30.0 mL). To the solution, TBS-Cl (2.60 g, 17.28 mmol) was added portionwise at 0°C. The resulting mixture was stirred at 0°C for 1 hour. The resulting mixture was concentrated in vacuo. The residue was purified by flash column chromatography using 0-20% ethyl acetate in petroleum to give (S)-2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridin-2-yl)ethane. A colorless mixture of -1-ol and (S)-2-((tert-butyldimethylsilyl)oxy)-2-(5-chloropyridin-2-yl)ethane-1-ol (1.45 g, 25%) Obtained as an oil. (C 13 H 22 ClNO 2 Si)(M+1) + MS(ESI) calculated value of 288.1, actual value of 288.0.
[0382] Step-6: (R)-5-(2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-amine and (R)-5-(2-((tert-butyldimethylsilyl)oxy)-2-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-amine [ka] In THF (10.0 mL), (R)-2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridin-2-yl)ethan-1-ol and (R)-2-(( To a stirred mixture of tert-butyldimethylsilyl)oxy)-2-(5-chloropyridin-2-yl)ethan-1-ol (800.0 mg, 2.77 mmol) was added NaH (133.3 mg, 5.55 mmol, 60%). It was added portionwise at 0°C and stirred at 0°C for 30 minutes under nitrogen. 5-bromo-1,3,4-thiadiazol-2-amine (550.3 mg, 3.05 mmol) was added to the above mixture at 0°C. The resulting mixture was stirred for an additional 4 hours at 0°C. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography using 0-60% ethyl acetate in petroleum ether to give (R)-5-(2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridine-2 -yl)ethoxy)-1,3,4-thiadiazol-2-amine and (R)-5-(2-((tert-butyldimethylsilyl)oxy)-2-(5-chloropyridin-2-yl) A mixture of (ethoxy)-1,3,4-thiadiazol-2-amines (210 mg, 19%) was obtained as a brown solid. (C 15 H 23 ClN 4 O 2 SSi)(M+1) + MS(ESI) calculated value of 387.1, actual value of 387.0.
[0383] Step-7: (R)-N-(5-(2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazole- 2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide and (R)-N-(5-(2-((tert-butyldimethylsilyl)oxy)-2-(5-chloropyridine) -2-yl)ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide [ka] (R)-5-(2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazole- in MeCN (3.0 mL). 2-Amine and (R)-5-(2-((tert-butyldimethylsilyl)oxy)-2-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-amine (210.0 mg, 0.54 mmol), TCFH (167.4 mg, 0.59 mmol), 4-(2-methoxyphenyl)-6-methylnicotinic acid (145.2 mg, 0.59 mmol, Intermediate D) and NMI (133.6 mg, 1.62 mmol) was added. The resulting mixture was stirred at room temperature for 1.5 hours. The resulting mixture was concentrated in vacuo. The residue was purified by reverse phase flash chromatography using 5-85% acetonitrile in water to give (R)-N-(5-(2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridine- 2-yl)ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide and (R)-N-(5-(2-((tert -butyldimethylsilyl)oxy)-2-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide A mixture of (146 mg, 46%) was obtained as a brown oil. (C 29 H 34 ClN 5 O 4 SSi)(M+1) + MS(ESI) calculated value of 612.2, measured value of 612.0.
[0384] Step-8: (R)-N-(5-(1-(5-chloropyridin-2-yl)-2-hydroxyethoxy)-1,3,4-thiadiazol-2-yl)-4-(2 -methoxyphenyl)-6-methylnicotinamide and (R)-N-(5-(2-(5-chloropyridin-2-yl)-2-hydroxyethoxy)-1,3,4-thiadiazole-2- yl)-4-(2-methoxyphenyl)-6-methylnicotinamide [ka] (R)-N-(5-(2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridin-2-yl) in THF (3.0 mL) and HCl (6N) (3.0 mL). )ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide and (R)-N-(5-(2-((tert-butyldimethyl mixture of silyl)oxy)-2-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide ( 146 mg, 0.23 mmol) was stirred at room temperature for 1 hour. Saturate the residue with NaHCO 3 (aqueous solution) to pH 7. The resulting mixture was extracted with ethyl acetate. The combined organic layers were washed with brine and anhydrous Na 2 S.O. 4 dried with. After filtration, the filtrate was concentrated in vacuo. The crude product was purified under the following conditions: (Column: XBridge Shield RP18 OBD column, 30 * 150mm, 5um; Mobile phase A: Water (10mmol / L NH 4 HCO 3 ), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 20B to 50B in 7 min; 254 nm) and purified by Prep-HPLC using (R)-N-(5-(1 -(5-chloropyridin-2-yl)-2-hydroxyethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide (6.4 mg, purity 93%) and (R)-N-(5-(2-(5-chloropyridin-2-yl)-2-hydroxyethoxy)-1,3,4-thiadiazol-2-yl)- as a white solid. 4-(2-methoxyphenyl)-6-methylnicotinamide (18.0 mg, purity 98%) was obtained.
[0385] (R)-N-(5-(1-(5-chloropyridin-2-yl)-2-hydroxyethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl) -6-Methylnicotinamide:(C 23 H 20 ClN 5 O 4 S)(M+1) + MS (ESI) calculated value of 498.1, measured value of 498.0. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.72 (s, 1H), 8.66 (s, 1H), 8.59 (s, 1H), 7.96 - 7.93 (m, 1H), 7.51 (d, J = 8.4 Hz, 1H), 7.40 - 7.36 (m, 2H), 7.34 - 7.28 (m, 1H), 7.08 - 7.05 (m, 1H), 6.98 (d, J = 8.0 Hz, 1H), 5.88 - 5.85 (m, 1H), 5.30 - 5.27 (m, 1H) , 3.88 - 3.85 (s, 2H), 3.49 (ds, 3H), 2.55 (s, 3H).
[0386] (R)-N-(5-(2-(5-chloropyridin-2-yl)-2-hydroxyethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl) -6-Methylnicotinamide:(C 23 H 20 ClN 5 O 4 S)(M+1) + MS (ESI) calculated value of 498.1, measured value of 498.1. 1 H NMR (400 MHz, CD 3 OD) δ 8.65 (s, 1H), 8.54 (d, J = 2.4 Hz, 1H), 7.91 - 7.88 (m, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.45 - 7.37 (m, 3H) ), 7.12 - 7.08 (m, 1H), 6.98 (d, J = 8.0 Hz, 1H), 5.15 - 5.12 (m, 1H), 4.80 - 4.76 (m, 1H), 4.66 - 4.62 (m, 1H), 3.60 (s, 3H), 2.67 (s, 3H).
[0387] Step-9: (S)-5-(2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-amine and (S)-5-(2-((tert-butyldimethylsilyl)oxy)-2-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-amine [ka] In THF (10.0 mL), (S)-2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridin-2-yl)ethan-1-ol and (S)-2-(( To a stirred mixture of tert-butyldimethylsilyl)oxy)-2-(5-chloropyridin-2-yl)ethan-1-ol (900.0 mg, 3.12 mmol) was added NaH (150.0 mg, 6.25 mmol, 60%). It was added portionwise at 0°C and stirred at 0°C for 30 minutes under nitrogen. 5-bromo-1,3,4-thiadiazol-2-amine (550.3 mg, 3.05 mmol) was added to the above mixture at 0°C. The resulting mixture was stirred for an additional 4 hours at 0°C. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography using 0-60% ethyl acetate in petroleum ether to give (S)-5-(2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridine-2 -yl)ethoxy)-1,3,4-thiadiazol-2-amine and (R)-5-(2-((tert-butyldimethylsilyl)oxy)-2-(5-chloropyridin-2-yl) A mixture of (ethoxy)-1,3,4-thiadiazol-2-amines (230 mg, 28%) was obtained as a brown solid. (C 15 H 23 ClN 4 O 2 SSi)(M+1) + MS(ESI) calculated value of 387.1, actual value of 387.0.
[0388] Step-10: (S)-N-(5-(2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazole- 2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide and (S)-N-(5-(2-((tert-butyldimethylsilyl)oxy)-2-(5-chloropyridine) -2-yl)ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide [ka] (S)-5-(2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazole- in MeCN (3.0 mL). 2-Amine and (S)-5-(2-((tert-butyldimethylsilyl)oxy)-2-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-amine (230.0 mg, 0.59 mmol), TCFH (277.6 mg, 0.98 mmol), 4-(2-methoxyphenyl)-6-methylnicotinic acid (262.5 mg, 1.07 mmol, Intermediate D) and NMI (221.5 mg, 2.69 mmol) was added. The resulting mixture was stirred at room temperature for 3 hours. The resulting mixture was concentrated in vacuo. The residue was purified by reverse phase flash chromatography using 5-85% acetonitrile in water to give (S)-N-(5-(2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridine- (2-yl)ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide and (S)-N-(5-(2-((tert -butyldimethylsilyl)oxy)-2-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide A mixture of (130 mg, 23%) was obtained as a brown oil. (C 29 H 34 ClN 5 O 4 SSi)(M+1) + MS(ESI) calculated value of 612.2, measured value of 612.0.
[0389] Step-11: (S)-N-(5-(1-(5-chloropyridin-2-yl)-2-hydroxyethoxy)-1,3,4-thiadiazol-2-yl)-4-(2 -methoxyphenyl)-6-methylnicotinamide and (S)-N-(5-(2-(5-chloropyridin-2-yl)-2-hydroxyethoxy)-1,3,4-thiadiazole-2- yl)-4-(2-methoxyphenyl)-6-methylnicotinamide [ka] (S)-N-(5-(2-((tert-butyldimethylsilyl)oxy)-1-(5-chloropyridin-2-yl) in THF (3.0 mL) and HCl (6N) (3.0 mL). )ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide and (S)-N-(5-(2-((tert-butyldimethyl) mixture of silyl)oxy)-2-(5-chloropyridin-2-yl)ethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide ( 130 mg, 0.21 mmol) was stirred at room temperature for 1 hour. Saturate the residue with NaHCO 3 (aqueous solution) to pH 7. The resulting mixture was extracted with ethyl acetate. The combined organic layers were washed with brine and anhydrous Na 2 S.O. 4 It was dried with. After filtration, the filtrate was concentrated in vacuo. The crude product was purified under the following conditions: (Column: XBridge Shield RP18 OBD column, 30 * 150mm, 5um; Mobile phase A: Water (10mmol / L NH 4 HCO 3 ), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 20B to 45B in 7 min; 254 nm) and purified by Prep-HPLC using (S)-N-(5-(1 -(5-chloropyridin-2-yl)-2-hydroxyethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl)-6-methylnicotinamide (10.4 mg, purity 93%) and (S)-N-(5-(2-(5-chloropyridin-2-yl)-2-hydroxyethoxy)-1,3,4-thiadiazol-2-yl)- as a white solid. 4-(2-methoxyphenyl)-6-methylnicotinamide (15.8 mg, purity 98%) was obtained.
[0390] (S)-N-(5-(1-(5-chloropyridin-2-yl)-2-hydroxyethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl) -6-Methylnicotinamide:(C 23 H 20 ClN 5 O 4 S)(M+1) + MS (ESI) calculated value of 498.1, measured value of 498.0. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.72 (s, 1H), 8.66 (s, 1H), 8.59 (s, 1H), 7.96 - 7.93 (m, 1H), 7.51 (d, J = 8.4 Hz, 1H), 7.40 - 7.36 (m, 2H), 7.34 - 7.28 (m, 1H), 7.08 - 7.05 (m, 1H), 6.98 (d, J = 8.0 Hz, 1H), 5.88 - 5.85 (m, 1H), 5.30 - 5.27 (m, 1H) , 3.88 - 3.85 (s, 2H), 3.49 (ds, 3H), 2.55 (s, 3H).
[0391] (S)-N-(5-(2-(5-chloropyridin-2-yl)-2-hydroxyethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-methoxyphenyl) -6-Methylnicotinamide:(C 23 H 20 ClN 5 O 4 S)(M+1) + MS (ESI) calculated value of 498.1, measured value of 498.1. 1 H NMR (400 MHz, CD 3 OD) δ 8.64 (d, J = 4.0 Hz, 1H), 8.57 (d, J = 2.0 Hz, 1H), 7.89 - 7.86 (m, 1H), 7.55 (d, J = 8.4 Hz, 1H), 7.44 - 7.36 (m, 3H), 7.12 - 7.08 (m, 1H), 6.97 (d, J = 8.0 Hz, 1H), 5.98 - 5.95 (m, 1H), 4.08 - 4.00 (m, 2H), 3.60 (s, 3H), 2.66 (s, 3H).
[0392] Example 31 N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(4-(hydroxymethyl)-2-methoxyphenyl)-6- methylnicotinamide [ka]
[0393] Step-1: 4-(5-((5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)carbamoyl)-2-methylpyridin-4-yl )-3-Methoxybenzoate methyl [ka] Dioxane (5 mL) and H 24-chloro-N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methylnicotinamide (83 mg, (2-methoxy-4-(methoxycarbonyl)phenyl)boronic acid (130 mg, 0.619 mmol), K 3 P.O. 4 (223mg, 1.052mmol) and Pd(dtbpf)Cl 2 (28mg, 0.043mmol) was added under nitrogen. The resulting solution was stirred at 100° C. for 8 hours under nitrogen. The mixture was concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-50% ethyl acetate in petroleum ether to give 4-(5-((5-((5-chloropyridin-2-yl)methoxy)-1,3 ,4-thiadiazol-2-yl)carbamoyl)-2-methylpyridin-4-yl)-3-methoxybenzoate (70 mg, 84.3%) was obtained as a white solid. (C 24 H 20 ClN 5 O 3 S)(M+1) + MS(ESI) calculated value for 526.1; measured value 526.1.
[0394] Step-2: N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(4-(hydroxymethyl)-2-methoxyphenyl )-6-Methylnicotinamide [ka] 4-(5-((5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)carbamoyl)-2-methylpyridine-4 in THF (5 mL). -yl)-3-methoxybenzoate (70 mg, 0.133 mmol) was added with LiAlH 4 (25 mg, 0.665 mmol) was added little by little at 0 to 5°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was then quenched by adding water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane to give N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazole-2 -yl)-4-(4-(hydroxymethyl)-2-methoxyphenyl)-6-methylnicotinamide (2.8 mg, 4%) was obtained as a white solid. (C 23 H 20 ClN 5 O 4 S)(M+1) + MS(ESI) calculated value for 498.1; measured value 498.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.76 (s, 1H), 8.65 (s, 2H), 8.02 - 7.99 (m, 1H), 7.61 - 7.59 (m, 1H), 7.30 - 7.27 (m, 2H), 7.02 - 7.00 (m, 1H) ), 6.93 (s, 1H), 5.54 (s, 2H), 5.31 - 5.28 (m, 1H), 4.54 - 4.53 (m, 2H), 3.50 (s, 3H), 2.56 (s, 3H).
[0395] Example 32 4-(5-cyano-2-methoxyphenyl)-N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6- Methylpyridine-3-carboxamide [ka]
[0396] Step-1: tert-butyl 4-chloro-6-methylpyridine-3-carboxylate [ka] 4-chloro-6-methylpyridine-3-carboxylic acid (1.0 g, 5.82 mmol) and BoC in N-methylpyrrolidone (4 mL) 2 To a stirred solution of O (2.9 g, 13.28 mmol) was added dimethylaminopyridine (143 mg, 1.17 mmol). The resulting mixture was stirred at 30°C for 16 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography using 0-10% ethyl acetate in petroleum ether to give tert-butyl 4-chloro-6-methylpyridine-3-carboxylate (900 mg, 67.8%) as a yellow oil. . (C 11 H 14 ClNO 2 )(M+1) + MS(ESI) calculated value for 228.1; measured value 228.1.
[0397] Step-2: tert-butyl 4-(5-cyano-2-methoxyphenyl)-6-methylpyridine-3-carboxylate [ka] tert-Butyl 4-chloro-6-methylpyridine-3-carboxylate (800 mg, 3.51 mmol) and 5-cyano-2-methoxyphenylboronic acid (619 mg, 3.49 mmol) in dioxane (6 mL) and water (2 mL). Pd(PPh 3 ) 4 (407mg, 0.35mmol) and K 2 C.O. 3 (1.5g, 10.56mmol) was added. The resulting mixture was stirred at 80° C. for 16 hours under nitrogen atmosphere. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography using 0-30% ethyl acetate in petroleum ether to give tert-butyl 4-(5-cyano-2-methoxyphenyl)-6-methylpyridine-3-carboxylate (550 mg, 43.4 %) as a yellow solid. (C 19 H 20 N 2 O 3 )(M+1) + MS(ESI) calculated value for 325.1; measured value 325.1.
[0398] Step-3: 4-(5-cyano-2-methoxyphenyl)-6-methylnicotinic acid [ka] To a stirred solution of tert-butyl 4-(5-cyano-2-methoxyphenyl)-6-methylpyridine-3-carboxylate (250 mg, 0.77 mmol) in dichloromethane (4 mL) was added trifluoroacetaldehyde (2 mL). Ta. The resulting mixture was stirred at room temperature for 16 hours. The residue was purified by reverse phase flash chromatography using 5-50% acetonitrile in water to give 4-(5-cyano-2-methoxyphenyl)-6-methylpyridine-3-carboxylic acid (189 mg, 91.4%) as a white solid. obtained as. (C 15 H 12 N 2 O 3 )(M+1) + MS(ESI) calculated value for 269.1; measured value 269.1.
[0399] Step-4: Methyl 6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)nicotinate [ka] Methyl 6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine-3-carboxylate (500 mg, 1.87 mmol, Example 5, Step 1) in tetrahydrofuran (3 mL) ) into a stirred solution of LiAlH 4 (142 mg, 3.75 mmol) was added little by little at 0°C under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 2 hours under nitrogen atmosphere. The reaction mixture was quenched with water and the residue was purified by reverse phase flash chromatography using 5-35% acetonitrile in water to give 6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy) Methyl)nicotinate (150 mg, 33.5%) was obtained as a green oil. C 9 H 10 N 4 O 2 S)(M+1) + MS(ESI) calculated value for (, 239.1; measured value 239.1.
[0400] Step-5: 4-(5-cyano-2-methoxyphenyl)-N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl )-6-methylpyridine-3-carboxamide [ka] (6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridin-3-yl)methanol (50 mg, 0.21 mmol) in DMF (2 mL) and MeCN (2 mL). and 4-(5-cyano-2-methoxyphenyl)-6-methylpyridine-3-carboxylic acid (56 mg, 0.21 mmol) in a stirred solution of TCFH (88 mg, 0.31 mmol) and N-methylimidazole (68 mg, 0.83 mmol) was added. The resulting mixture was stirred at room temperature for 2 hours and then concentrated in vacuo. The residue was purified under the following conditions: (Column: XBridge Prep OBD C18 column, 30×150mm 5um; Mobile phase A: Water (10MMOL / L NH 4 HCO 3 +0.1%NH 3 .H 2 4-(5-cyano-2-methoxyphenyl)-N -(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methylpyridine-3-carboxamide (11.7 mg, 11.4%) Obtained as a white solid. (C 24 H 20 N 6 O 4 S)(M+1) + , MS(ESI) calculated value for 489.1; measured value 489.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.83 (s, 1H), 8.75 (s, 1H), 8.53 (d, J = 2.0 Hz, 1H), 7.91 - 7.85 (m, 1H), 7.85 (d, J = 2.0 Hz, 1H), 7.79 - 7.77 (m, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.39 (s, 1H), 7.18 (d, J = 8.8 Hz, 1H), 5.52 (s, 2H), 5.37 (s, 1H), 4.55 (d, J = 5.2 Hz, 2H), 3.39 (s, 3H), 2.58 (s, 3H).
[0401] Example 33 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-(2-hydroxypropan-2-yl)pyridin-2-yl)methoxy)-1,3,4-thiadiazole-2 -yl)-6-methylnicotinamide [ka]
[0402] Step-1: 2-(6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridin-3-yl)propan-2-ol [ka] 1-(6-(((5-Amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridin-3-yl)ethenone (1.5 g, 5.993 mmol, Example 22 To the solution of step 3), MeMgBr (24 mL, 23.973 mmol, 1M in THF) was added dropwise at 0 °C. The resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched by adding methanol and then concentrated in vacuo. The residue was purified by flash column chromatography using 0-10% methanol in dichloromethane to give 2-(6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridine- 3-yl)propan-2-ol (400 mg, 13.3%) was obtained as a colorless oil. (C 11 H 14 N 4 O 2 S)(M+1) + MS(ESI) calculated value for 267.0; measured value 267.0.
[0403] Step-2: 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-(2-hydroxypropan-2-yl)pyridin-2-yl)methoxy)-1,3,4 -thiadiazol-2-yl)-6-methylnicotinamide [ka] 2-(6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)pyridin-3-yl)propan-2-ol in DMF (5 mL) and MeCN (5 mL). (856.3 mg, 3.215 mmol) and 4-(2-fluoro-6-methoxyphenyl)-6-methylpyridine-3-carboxylic acid (700.0 mg, 2.679 mmol, intermediate F) was added with 8.038 mmol) and TCFH (826.9 mg, 2.947 mmol) were added. The resulting mixture was stirred at room temperature for 2 hours and then concentrated in vacuo. The residue was purified by reverse phase flash chromatography using 10-50% acetonitrile in water to give 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-(2-hydroxypropan-2-yl) ) Pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methylnicotinamide (500 mg, 36.6%) was obtained as a white solid. (C 25 H 24 FN 5 O 4 S)(M+1) + MS(ESI) calculated value for 510.2; measured value 510.2. 1 H NMR (400 MHz, DMSO-d 6 )δ12.89 (s, 1H), 8.81 (s, 1H), 8.69 (s, 1H), 7.90 - 7.88 (m, 1H), 7.48 - 7.32 (m, 3H), 6.94 - 6.88 (m, 2H) , 5.50 (s, 2H), 5.24 (s, 1H), 3.59 (s, 3H), 2.57 (s, 3H), 1.46 (s, 6H).
[0404] Example 34 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-(methoxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6- methylnicotinamide [ka]
[0405] Step-1: 6-(((5-(4-(2-fluoro-6-methoxyphenyl)-6-methylnicotinamide)-1,3,4-thiadiazol-2-yl)oxy)methyl)nicotinic acid methyl [ka] A mixture of methyl 6-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)nicotinate (2.9 g, 0.011 mol) in ACN (50 mL) was added with NMI (1.8 g, 0.022 mol), 4-(2-fluoro-6-methoxyphenyl)-6-methylnicotinic acid (1.9 g, 0.007 mol, intermediate F) and TCFH (2.5 g, 0.009 mol). This mixture was stirred at room temperature for 2 hours. The mixture was concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane to give 6-(((5-(4-(2-fluoro-6-methoxyphenyl)-6-methylnicotinamide)- Methyl 1,3,4-thiadiazol-2-yl)oxy)methyl)nicotinate (2.0 g, 69%) was obtained as a white solid. (C 24 H 20 FN 5 O 5 S)(M+1) + MS(ESI) calculated value for 510.1; measured value 510.1.
[0406] Step-2: 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl )-6-Methylnicotinamide [ka] 6-(((5-(4-(2-fluoro-6-methoxyphenyl)-6-methylnicotinamide)-1,3,4-thiadiazol-2-yl)oxy)methyl) in THF (50 mL). LiAlH in a solution of nicotinate (2.0g, 0.004mol) 4 (300.0 mg, 7.895 mmol) was added little by little at 0 to 5°C, and the mixture was stirred at 5°C for 30 minutes. The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was then quenched by adding water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane to give 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-(hydroxymethyl)pyridine- 2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-6-methylnicotinamide (300.0 mg, 15%) was obtained as a white solid. (C 23 H 20 FN 5 O 4 S)(M+1) + MS(ESI) calculated value for 482.0; measured value 482.2.
[0407] Step-3: Methanesulfonic acid (6-(((5-(4-(2-fluoro-6-methoxyphenyl)-6-methylnicotinamide)-1,3,4-thiadiazol-2-yl)oxy) methyl)pyridin-3-yl)methyl [ka] 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazole-2 in DCM (30 mL). -yl)-6-methylnicotinamide (250 mg, 0.519 mmol) and TEA (158 mg, 1.564 mmol) was added MsCl (88.7 mg, 0.778 mmol) at 0°C. The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was then quenched by adding water and extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated in vacuo to give methanesulfonic acid (6-(((5-(4-(2-fluoro-6-methoxyphenyl)-6-methylnicotinamide)-1,3,4-thiadiazol-2-yl). Oxy)methyl)pyridin-3-yl)methyl (120 mg, crude product) was obtained as a white solid. (C 24 H 22 FN 5 O 6 S 2 )(M+1) + MS(ESI) calculated value for 560.1; measured value 560.0.
[0408] Step-4: 4-(2-fluoro-6-methoxyphenyl)-N-(5-((5-(methoxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl )-6-Methylnicotinamide [ka] CH 3 Methanesulfonic acid (6-(((5-(4-(2-fluoro-6-methoxyphenyl)-6-methylnicotinamide)-1,3,4-thiadiazol-2-yl) in OH (5 mL). A mixture of oxy)methyl)pyridin-3-yl)methyl (80 mg, 0.143 mmol) was stirred at 50° C. for 3 hours. The mixture was concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-10% methanol in dichloromethane using the following conditions: (Column: Sunfire prep C18 column, 30 * by prep-HPLC using 150 um, 5 um; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 25B to 55B in 8 min; 220 nm; RT1: 7.23 min) Further purification resulted in N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-4-(3,5-dimethyl-1H-pyrazole-4 -yl)-6 methylnicotinamide (33.1 mg, 41.3%) was obtained as a white solid. (C 24 H 22 FN 5 O 4 S)(M+1) + MS(ESI) calculated value for 495.1; measured value 495.2. 1 H NMR (400 MHz, methanol-d 4 ) δ 8.94 (s, 1H), 8.67 - 8.63 (m, 1H), 8.09 - 8.07 (m, 1H), 7.79 - 7.71 (m, 2H), 7.50 - 7.44 (m, 1H), 6.93 - 6.89 (m , 2H), 5.66 (s, 2H), 4.89 (s, 2H), 3.86 (s, 3H), 3.46 (s, 3H). 2.76 (s, 3H).
[0409] Example 35 N-(5-(2H,3H-(1,4)dioxino(2,3-b)pyridin-6-ylmethoxy)-1,3,4-thiadiazol-2-yl)-4-(2-fluoro- 6-Methoxyphenyl)-6-methylpyridine-3-carboxamide [ka]
[0410] Step-1: 5-(2H,3H-(1,4)dioxino(2,3-b)pyridin-6-ylmethoxy)-1,3,4-thiadiazol-2-amine [ka] A solution of NaH (215.3 mg, 8.973 mmol, 60% purity) in THF (5 mL) was added with 2H,3H-(1,4)dioxino(2,3-b)pyridin-6-yl in THF (3 mL). A solution of methanol (500.0 mg, 2.991 mmol) was added dropwise at 0 to 5°C, and the mixture was stirred at 0 to 5°C for 30 minutes under a nitrogen atmosphere. To the above mixture at 0° C. was added a solution of 5-bromo-1,3,4-thiadiazol-2-amine (646.1 mg, 3.589 mmol) in THF (2 mL). The resulting mixture was stirred at room temperature for 16 hours under nitrogen atmosphere. The resulting mixture was quenched with water and the aqueous phase was extracted with ethyl acetate. The combined organic solutions were dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography using 0-20% ethyl acetate in petroleum ether to give 5-(2H,3H-(1,4)dioxino(2,3-b)pyridin-6-ylmethoxy)-1, 3,4-Thiadiazol-2-amine (187 mg, 23.48%) was obtained as a pink solid. (C10H10N4O3S)(M+1) + MS(ESI) calculated value of 267.0, actual value of 267.0.
[0411] Step-2: N-(5-(2H,3H-(1,4)dioxino(2,3-b)pyridin-6-ylmethoxy)-1,3,4-thiadiazol-2-yl)-4-( 2-Fluoro-6-methoxyphenyl)-6-methylpyridine-3-carboxamide [ka] 5-(2H,3H-(1,4)dioxino(2,3-b)pyridin-6-ylmethoxy)-1,3,4-thiadiazole-2- in MeCN (0.5 mL) and DMF (0.5 mL). NMI (13.5 mg, 0.165 mmol) and TCFH (17.0 mg, 0.090 mmol) were added. The resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified under the following conditions: (Column: XBridge Prep OBD C18 column, 30 47B; 254 / 220 nm; RT1: 7.53 min) and purified by prep-HPLC using N-(5-(2H,3H-(1,4)dioxino(2,3-b)pyridin-6-ylmethoxy) -1,3,4-thiadiazol-2-yl)-4-(2-fluoro-6-methoxyphenyl)-6-methylpyridine-3-carboxamide (27.1 mg, 71%) was obtained as a white solid. (C 24 H 20 FN 5 O 5 S)(M+1) + MS(ESI) calculated value of 510.1, actual value of 510.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.88 (s, 1H), 8.81 (s, 1H), 7.46 - 7.36 (m, 1H), 7.36 - 7.29 (m, 2H), 7.11 (d, J = 8.0 Hz, 1H), 6.97 - 6.86 ( m, 2H), 5.33 (s, 2H), 4.45 - 4.39 (m, 2H), 4.30 - 4.24 (m, 2H), 3.59 (s, 3H), 2.57 (s, 3H).
[0412] Example 36 N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5'-methoxy-2',6-dimethyl-(4,4'- Bipyridine)-3-carboxamide [ka]
[0413] Step-1: Benzyl 4-chloro-6-methylnicotinate [ka] 4-chloro-6-methylpyridine-3-carboxylic acid (10.00g, 58.3mmol) and Cs in DMF (100mL) 2 C.O. 3(37.98g, 116.6mmol) was added benzyl bromide (14.95g, 87.45mmol). The resulting mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-30% ethyl acetate in petroleum ether to give benzyl 4-chloro-6-methylnicotinate (12.94 g, 84.8%) as a yellow oil. (C 14 H 12 ClNO 2 )(M+1) + MS(ESI) calculated value of 262.0, actual value of 262.1.
[0414] Step-2: Benzyl 2’-chloro-5’-methoxy-6-methyl-(4,4’-bipyridine)-3-carboxylate [ka] 1,4-dioxane (50mL) and H 2 of methylbenzyl 4-chloro-6-methylpyridin-3-carboxylate (6.00 g, 22.926 mmol) and 2-chloro-5-methoxypyridin-4-ylboronic acid (4.30 g, 22.926 mmol) in O (5 mL). In the degassed mixture, K 2 C.O. 3 (9.51g, 0.069mmol) and Pd(DtBPF)Cl 2 (1.49g, 2.29mmol) was added. The resulting mixture was stirred at 80° C. for 2 hours under nitrogen atmosphere. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-50% ethyl acetate in petroleum ether to give 2'-chloro-5'-methoxy-6-methyl-(4,4'-bipyridine)-3-carvone. Benzyl acid (4g, 47.3%) was obtained as a yellow oil. (C 20 H 17 ClN 2 O 3 )(M+1) + MS (ESI) calculated value of 369.1, actual value of 369.0.
[0415] Step-3: Benzyl 5’-methoxy-2’,6-dimethyl-(4,4’-bipyridine)-3-carboxylate [ka] Benzyl 2-chloro-5-methoxy-6-methyl-(4,4-bipyridine)-3-carboxylate (4.00 g, 10.845 mmol) and K in DME (30 mL). 2 C.O. 3 (4.50g, 33.0mmol) of Pd(dppf)Cl 2 (0.79 g, 1.0 mmol) and trimethyl-1,3,5,2,4,6-trioxatriborinane (1.50 g, 12.0 mmol) were added. The resulting mixture was stirred at 120° C. for 2 hours under nitrogen atmosphere. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by reverse phase flash chromatography using 5-70% acetonitrile in water to give benzyl 5'-methoxy-2',6-dimethyl-(4,4'-bipyridine)-3-carboxylate (2.8 g, 74.1 %) as a yellow oil. (C 21 H 20 N 2 O 3 )(M+1) + MS (ESI) calculated value of 349.1, actual value of 349.0.
[0416] Step-4: 5’-methoxy-2’,6-dimethyl-(4,4’-bipyridine)-3-carboxylic acid [ka] Pd / C (2.80 g, 10% ) was added. The resulting mixture was stirred at room temperature for 1 hour under a hydrogen atmosphere. The resulting mixture was filtered. The filtrate was concentrated in vacuo to give 5'-methoxy-2',6-dimethyl-(4,4'-bipyridine)-3-carboxylic acid (2.5 g, crude product) as a yellow solid, which was subjected to further purification. It was used directly in the next step. (C 14 H 14 N 2 O 3 )(M+1) + MS (ESI) calculated value of 259.1, actual value of 259.0.
[0417] Step-5: N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)-5'-methoxy-2',6-dimethyl-(4 ,4'-bipyridine)-3-carboxamide [ka] 5-methoxy-2,6-dimethyl-(4,4-bipyridine)-3-carboxylic acid (800.00 mg, 3.097 mmol) and 5-((5-chloro A solution of NMI (1271.56 mg, 15.485 mmol) and TCFH (955.99 mg, 3.407 mmol) was added. The resulting mixture was stirred at room temperature for 2 hours. Solvent was removed under reduced pressure. The residue was purified by reverse phase flash chromatography using 5-50% acetonitrile in water to give N-(5-((5-chloropyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl) -5-Methoxy-2,6-dimethyl-(4,4-bipyridine)-3-carboxamide (1.0845g, 72.5%) was obtained as a white solid. (C 22 H 19 ClN 6 O 3 S)(M+1) + MS(ESI) calculated value of 483.1, measured value of 483.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.93 (s, 1H), 8.75 (s, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.19 (s, 1H), 8.08 - 7.96 (m, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.37 (s, 1H), 7.26 (s, 1H), 5.55 (s, 2H), 3.58 (s, 3H), 2.58 (s, 3H), 2.47 (s, 3H).
[0418] Example 37 5-(2-fluoro-6-methoxyphenyl)-N-(5-((5-(hydroxymethyl)pyridin-2-yl)methoxy)-1,3,4-thiadiazol-2-yl)pyrimidine-4 -Carboxamide [ka]
[0419] Step-1: Methyl 5-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxylate [ka] To a degassed solution of 5-bromopyrimidine-4-carboxylic acid (1 g, 4.926 mmol) in dioxane (10 mL) and H2O (2 mL) was added 2-fluoro-6-methoxyphenylboronic acid (1004.66 mg, 5.911 mmol); K 2 C.O. 3 (2042.50mg, 14.778mmol) and Pd(dppf)Cl 2 (360.45mg, 0.493mmol) was added under nitrogen. The resulting mixture was stirred at 80° C. for 5 hours under nitrogen. The reaction mixture was concentrated in vacuo. The residue was purified by flash chromatography on silica gel using 0-50% ethyl acetate in petroleum ether to give ethyl 4-chloro-5-fluoro-6-methylnicotinate (1082 mg, 88.5%) as a yellow solid. . (C 13 H 11 FN 2 O 3 )(M+1) + MS(ESI) calculated value of 263.1, actual value of 263.1.
[0420] Step-2: 5-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxylic acid [ka] MeOH (20mL) and H 2To a solution of methyl 5-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxylate (1082 mg, 4.13 mmol) in O (10 mL) was added NaOH (331 mg, 8.26 mmol). This mixture was stirred at 70°C for 2 hours. The reaction solution was acidified to pH 5-6 with HCl (1N). The aqueous solution was extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated in vacuo to give 5-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxylic acid (826 mg, 80.5%) as a yellow solid. (C 12 H 9 FN 2 O 3 )(M+1) + MS(ESI) calculated value of 249.1, actual value of 249.0.
[0421] Step-3: Methyl 6-(((5-(5-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide)-1,3,4-thiadiazol-2-yl)oxy)methyl)nicotinate [ka] A solution...
Claims
1. Formula (I): [Case 1] (In the formula, X 1 is CH 2 and C substituted with 0 to 1 -OH 2-4 alkylene; Ring A is selected from the group consisting of phenyl and 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from N, O and S as ring vertices; The subscripts m and n are each independently 0 or 1; R 1 and R 2 each independently, if present, is C 1-4 Alkyl, C 1-4 Alkoxy, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Hydroxyalkyl, -X a -O-C 1-4 is selected from the group consisting of alkyl, —C(O)OH and cyano, a independently represents a bond and C 1-4 alkylene; Ar 1 is selected from the group consisting of phenyl, 5-6 membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O and S as ring vertices, 5-6 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, 6-10 membered bicyclic heterocyclyl having 1 to 4 heteroatoms independently selected from N, O and S as ring vertices, 6-10 membered bridged heterocyclyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, and 6-12 membered spiroheterocyclyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, 1 is 0 to 3 R 3 is substituted with; Each R 3 is independently 1-4Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, -X 2 -OH, -X 2 -O-C 1-4 Alkyl, —C(O)—C 1-4 Alkyl and -X 2 -cyano; or two R on adjacent ring vertices are selected from the group consisting of 3 Combined to form C 3-6 Form a cycloalkyl or two R on the same ring vertex 3 are linked to form an oxo, where each X 2 independently represents a bond and C 1-4 alkylene; Z is: (i) 4-6 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, wherein the S ring vertex is optionally S(O) or S(O) 2 4-6 membered heterocycloalkyl, which is oxidized to (ii) C 5-8 Bridged cycloalkyl; (iii) C 6-12 Spirocyclyl; (iv) adjacent ring vertices are replaced by moieties which, when joined together, form a 5-6 membered heteroaryl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, thereby forming a fused ring system; 5-7 Cycloalkyl; (v) 5-7 membered heterocycloalkyl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, where adjacent ring vertices are replaced by moieties which bond to form 5-6 membered heteroaryl having 0-2 additional heteroatoms independently selected from N, O and S as ring vertices, thereby forming a fused ring system; (vi) a 5-6 membered heteroaryl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, where adjacent ring vertices are replaced by two moieties which bond together to form a 5-6 membered saturated or partially unsaturated ring containing 0-2 additional heteroatoms independently selected from the group consisting of N, O and S as ring vertices, thereby forming a fused ring system; (vii) C having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices 5-7 Bridged heterocyclyl; (viii) a 6- to 12-membered spiroheterocyclyl having 1 to 3 heteroatoms independently selected from N, O, and S as ring vertices; and (ix) a 4- to 10-membered bicyclic heterocyclyl having 1 to 4 heteroatoms independently selected from N, O and S as ring vertices; is selected from the group consisting of Each Z is 0 to 3 R 4 Substituted by substituents, each of which is independently selected from the group consisting of 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, -X 3 -OH, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, -X 3 -Cyano, -X 3 -O-C 1-4 Alkyl, -X 3 -C(O)OH, -S(O)(NH)-C 1-4 Alkyl, -S(O) 2 -C 1-4 Alkyl, —C(O)—C 1-4 alkyl and -X containing 4 to 6 ring members and 1 to 3 heteroatoms independently selected from N, O and S as ring vertices; 4 -heterocycloalkyl; or two R 4 the substituents are linked to form an oxo moiety, wherein each cycloalkyl is independently C 1-4Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Alkoxy, -X 3 -O-C 1-4 Alkyl, -X 3 -C(O)OH and -X 3 -substituted with 0 to 3 substituents independently selected from the group consisting of -OH; Each X 3 independently represents a bond and C 1-4 alkylene; Each X 4 are independently a bond, —O— and C 1-4 alkylene). or a pharma- ceutically acceptable salt thereof.
2. Formula (I): [Case 2] (In the formula, X 1 is CH 2 and C substituted with 0 to 1 -OH 2-4 alkylene; Ring A is selected from the group consisting of phenyl and 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from N, O and S as ring vertices; The subscripts m and n are each independently 0 or 1; R 1 and R 2 each independently, if present, is C 1-4 Alkyl, C 1-4 Alkoxy, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 selected from the group consisting of hydroxyalkyl, —C(O)OH and cyano; Ar 1is selected from the group consisting of phenyl, 5-6 membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O and S as ring vertices, 5-6 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, 6-10 membered bicyclic heterocyclyl having 1 to 4 heteroatoms independently selected from N, O and S as ring vertices, 6-10 membered bridged heterocyclyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, and 6-12 membered spiroheterocyclyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, 1 is 0 to 3 R 3 is substituted with; Each R 3 is independently 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, -X 2 -OH, -X 2 -O-C 1-4 Alkyl, —C(O)—C 1-4 Alkyl and -X 2 -cyano; or two R on adjacent ring vertices are selected from the group consisting of 3 Combined to form C 3-6 Form a cycloalkyl or two R on the same ring vertex 3 are linked to form an oxo, where each X 2 independently represents a bond and C 1-4 alkylene; Z is: (i) 4-6 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, wherein the S ring vertex is optionally S(O) or S(O) 2 4-6 membered heterocycloalkyl, which is oxidized to (ii) C 5-8 Bridged cycloalkyl; (iii) C 6-12 Spirocyclyl; (iv) adjacent ring vertices are replaced by moieties which, when joined together, form a 5-6 membered heteroaryl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, thereby forming a fused ring system; 5-7 Cycloalkyl; (v) 5-7 membered heterocycloalkyl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, where adjacent ring vertices are replaced by moieties which bond to form 5-6 membered heteroaryl having 0-2 additional heteroatoms independently selected from N, O and S as ring vertices, thereby forming a fused ring system; (vi) a 5-6 membered heteroaryl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, where adjacent ring vertices are replaced by two moieties which bond together to form a 5-6 membered saturated or partially unsaturated ring containing 0-2 additional heteroatoms independently selected from the group consisting of N, O and S as ring vertices, thereby forming a fused ring system; (vii) C having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices 5-7 Bridged heterocyclyl; and (viii) a 6- to 12-membered spiroheterocyclyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices; is selected from the group consisting of Each Z is 0 to 3 R 4 Substituted by substituents, each of which is independently selected from the group consisting of 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, -X 3 -OH, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, -X 3 -Cyano, -X 3 -O-C 1-4 Alkyl, -X 3-C(O)OH, -S(O)(NH)-C 1-4 Alkyl, -S(O) 2 -C 1-4 Alkyl, —C(O)—C 1-4 alkyl and -X containing 4 to 6 ring members and 1 to 3 heteroatoms independently selected from N, O and S as ring vertices; 4 -heterocycloalkyl, wherein each cycloalkyl is independently C 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Alkoxy, -X 3 -O-C 1-4 Alkyl, -X 3 -C(O)OH and -X 3 -substituted with 0 to 3 substituents independently selected from the group consisting of -OH; Each X 3 independently represents a bond and C 1-4 alkylene; Each X 4 are independently a bond, —O— and C 1-4 alkylene). or a pharma- ceutically acceptable salt thereof.
3. Formula (I): [C3] (In the formula, X 1 is CH 2 and C substituted with 0 to 1 -OH 2-4 alkylene; Ring A is selected from the group consisting of phenyl and 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from N, O and S as ring vertices; The subscripts m and n are each independently 0 or 1; R 1 and R 2 each independently, if present, is C 1-4 Alkyl, C 1-4 Alkoxy, halo, C 1-4Haloalkyl, C 1-4 Haloalkoxy, C 1-4 selected from the group consisting of hydroxyalkyl, —C(O)OH and cyano; Ar 1 is selected from the group consisting of phenyl, 5-6 membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O and S as ring vertices, 5-6 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, 6-10 membered bicyclic heterocyclyl having 1 to 4 heteroatoms independently selected from N, O and S as ring vertices, 6-10 membered bridged heterocyclyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, and 6-12 membered spiroheterocyclyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, 1 is 0 to 3 R 3 is substituted with; Each R 3 is independently 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, -X 2 -OH, -X 2 -O-C 1-4 Alkyl, —C(O)—C 1-4 Alkyl and -X 2 -cyano; or two R on adjacent ring vertices are selected from the group consisting of 3 Combined to form C 3-6 Form a cycloalkyl or two R on the same ring vertex 3 are linked to form an oxo, where each X 2 independently represents a bond and C 1-4 alkylene; Z is: (i) 5-6 membered heterocycloalkyl; (ii) C 5-8 Bridged cycloalkyl; (iii) C 6-12 Spirocyclyl; (iv) adjacent ring vertices are replaced by moieties which, when joined together, form a 5-6 membered heteroaryl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, thereby forming a fused ring system; 5-7 Cycloalkyl; (v) 5-7 membered heterocycloalkyl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, where adjacent ring vertices are replaced by moieties which bond to form 5-6 membered heteroaryl having 0-2 additional heteroatoms independently selected from N, O and S as ring vertices, thereby forming a fused ring system; (vi) a 5-6 membered heteroaryl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, where adjacent ring vertices are replaced by two moieties which bond together to form a 5-6 membered saturated or partially unsaturated ring containing 0-2 additional heteroatoms independently selected from the group consisting of N, O and S as ring vertices, thereby forming a fused ring system; and (vii) C having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices 5-7 Bridged Heterocyclyl is selected from the group consisting of Each Z is 0 to 3 R 4 Substituted by substituents, each of which is independently selected from the group consisting of 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, -X 3 -OH, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, -X 3 -Cyano, -X 3 -O-C 1-4 Alkyl, -X 3 -C(O)OH, -S(O)(NH)-C 1-4 Alkyl, -S(O) 2 -C 1-4 Alkyl, —C(O)—C 1-4 alkyl and -X containing 4 to 6 ring members and 1 to 3 heteroatoms independently selected from N, O and S as ring vertices; 4 -heterocycloalkyl, wherein each cycloalkyl is independently C 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Alkoxy, -X 3 -O-C 1-4 Alkyl, -X 3 -C(O)OH and -X 3 -substituted with 0 to 3 substituents independently selected from the group consisting of -OH; Each X 3 independently represents a bond and C 1-4 alkylene; Each X 4 are independently a bond, —O— and C 1-4 alkylene). or a pharma- ceutically acceptable salt thereof.
4. Formula (Ia): [C4] 4. The compound according to any one of claims 1 to 3, having the formula: or a pharma- ceutically acceptable salt thereof.
5. Z is 0 to 3 R 4 5. The compound of claim 1, which is a 4-membered heterocycloalkyl substituted with: or a pharma- ceutically acceptable salt thereof.
6. Z is 0 to 3 R 4 5. The compound of claim 1, which is a 5-membered heterocycloalkyl substituted with:
7. Z is 0 to 3 R 4 5. The compound of claim 1, which is a 6-membered heterocycloalkyl substituted with: or a pharma- ceutically acceptable salt thereof.
8. Z is 0 to 3 R 4 C substituted with 5-8 The compound of any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, which is a bridged cycloalkyl.
9. Z is 0 to 3 R 4 C substituted with 6-12 5. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, which is a spirocyclyl.
10. Z is C 5-7 Cycloalkyl in which adjacent ring vertices are replaced by two moieties which combine to form a 5-6 membered heteroaryl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, thereby forming a fused ring system; 5-7 cycloalkyl, and the fused system has 0 to 3 R 4 5. The compound of claim 1, further substituted with:
11. Z is a 5-7 membered heterocycloalkyl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, where adjacent ring vertices are replaced by two moieties which, when joined together, form a 5-6 membered heteroaryl having 0-2 additional heteroatoms independently selected from N, O and S as ring vertices, thereby forming a fused ring system, said fused system being substituted with 0-3 R 4 5. The compound of claim 1, further substituted with:
12. Z is a 5-6 membered heteroaryl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, where adjacent ring vertices are replaced by two moieties which bond together to form a 5-6 membered ring containing 0-2 additional heteroatoms independently selected from the group consisting of N, O and S as ring vertices, thereby forming a fused ring system, said fused system being substituted by 0-3 R 4 5. The compound of claim 1, further substituted with:
13. Z is 0 to 3 R 4 C substituted with 5-7 The compound of any one of claims 1 to 4, which is a bridged heterocyclyl, or a pharma- ceutically acceptable salt thereof.
14. The compound according to any one of claims 1 to 4, wherein Z is a 6- to 12-membered spiroheterocyclyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, or a pharma- ceutically acceptable salt thereof.
15. The compound according to any one of claims 1 to 4, wherein Z is a 4-10 membered bicyclic heterocyclyl having 1 to 4 heteroatoms independently selected from N, O and S as ring vertices, or a pharma- ceutically acceptable salt thereof.
16. Formula (II): [C5] (In the formula, X 1 is CH 2 and C substituted with 0 to 1 -OH 2-4 alkylene; Ring A is selected from the group consisting of phenyl and 5-10 membered heteroaryl having 1-3 heteroatoms independently selected from N, O and S as ring vertices; The subscripts m and n are each independently 0 or 1; Each R 1 and R 2 each independently, if present, is C 1-4 Alkyl, C 1-4 Alkoxy, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 selected from hydroxyalkyl, —C(O)OH and cyano; Ar 1 is selected from the group consisting of phenyl, 5-6 membered heteroaryl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, 5-6 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, 6-10 membered bicyclic heterocyclyl having 1 to 4 heteroatoms independently selected from N, O and S as ring vertices, 6-10 membered bridged heterocyclyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, and 6-12 membered spiroheterocyclyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, 1 is 0 to 3 R 3 is substituted with; Each R 3 is independently 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, -X 2 -OH, -X 2 -O-C 1-4 Alkyl, —C(O)—C 1-4 Alkyl and -X 2 -cyano; or two R on adjacent ring vertices are selected from the group consisting of 3 Combined to form C 3-6 Form a cycloalkyl or two R on the same ring vertex 3 are linked to form an oxo, where each X 2 independently represents a bond and C 1-4 alkylene; Ar 2 is a 5- to 10-membered heteroaryl having 1 to 3 heteroatoms independently selected from phenyl, N, O and S as ring vertices, and C 3-6 cycloalkyl; Each Ar 2 is -X 3 -OH, -X 3 -O-C 1-4 Alkyl, C 3-6 Cycloalkyl, -X 5 -C(O)OH, -C 2-4 Alkylene-cyano, -S(O)(NH)-C 1-4 Alkyl, -S(O) 2 -C 1-4 alkyl and -X containing 4 to 6 ring members and 1 to 3 heteroatoms independently selected from N, O and S as ring vertices; 4 -R selected from the group consisting of heterocycloalkyl 4a is substituted with a substituent, Each cycloalkyl is independently -X 3 -O-C 1-4 Alkyl, -X 5 -C(O)OH and -X 3 substituted with 1 to 2 substituents independently selected from -OH; Each Ar 2 is 0 to 2 R 4 is further substituted with substituents, each of which is independently selected from the group consisting of 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, -X 5 -OH, C 3-6 Cycloalkyl, -X 5 -cyano and C 3-6 cycloalkyloxy; Each X 3 is independently 1-4 is alkylene; Each X 4 is -O- and C 1-4 alkylene; Each X 5 independently represents a bond and C 1-4 alkylene). or a pharma- ceutically acceptable salt thereof.
17. R 4a But, -X 3 17. The compound of claim 16, or a pharma- ceutically acceptable salt thereof, wherein: R is -OH.
18. R 4a But, -X 3 -O-C 1-4 17. The compound of claim 16, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;
19. R 4a is substituted with 1 to 2 substituents independently selected from the group consisting of -C(O)OH and hydroxymethyl; 3-6 17. The compound of claim 16, or a pharma- ceutically acceptable salt thereof, which is cycloalkyl.
20. R 4a But, -X 5 17. The compound of claim 16, which is -C(O)OH, or a pharma- ceutically acceptable salt thereof.
21. R 4a But, -C 2-4 17. The compound of claim 16, which is alkylene-cyano, or a pharma- ceutically acceptable salt thereof.
22. R 4a is -S(O)(NH)-C 1-4 17. The compound of claim 16, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;
23. R 4a But -S(O) 2 -C 1-4 17. The compound of claim 16, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;
24. R 4a contains 4 to 6 ring members and 1 to 3 heteroatoms independently selected from N, O and S as ring vertices; 4 -heterocycloalkyl, or a pharma- ceutically acceptable salt thereof.
25. Formula (III): [C6] (In the formula, X 0 is a C substituted with —OH 2-4is alkylene; Ring A is selected from the group consisting of phenyl and 5-10 membered heteroaryl having 1-3 heteroatoms independently selected from N, O and S as ring vertices; The subscripts m and n are each independently 0 or 1; Each R 1 and R 2 each independently, if present, is C 1-4 Alkyl, C 1-4 Alkoxy, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 selected from hydroxyalkyl, —C(O)OH and cyano; Ar 1 is selected from the group consisting of phenyl and 5-6 membered heteroaryl having 1-3 heteroatoms independently selected from N, O and S as ring vertices, where Ar 1 is 0 to 3 R 3 is substituted with; Each R 3 is independently 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, -X 2 -OH, -X 2 -O-C 1-4 Alkyl, —C(O)—C 1-4 Alkyl and -X 2 -cyano; or two R on adjacent ring vertices are selected from the group consisting of 3 Combined to form C 5-6 Form a cycloalkyl, where each X 2 independently represents a bond and C 1-4 alkylene; Ar 2 is a 5- to 10-membered heteroaryl having 1 to 3 heteroatoms independently selected from phenyl, N, O and S as ring vertices, and C 3-6 cycloalkyl; Each Ar 2 is 0 to 3 R 4 and each R 4 is independently 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, -X 3 -OH, -X 3 -O-C 1-4 Alkyl, -X 5 -C(O)OH, -C 2-4 Alkylene-cyano, -S(O)(NH)-C 1-4 Alkyl, -S(O) 2 -C 1-4 alkyl and -X containing 4 to 6 ring members and 1 to 3 heteroatoms independently selected from N, O and S as ring vertices; 4 -heterocycloalkyl, each cycloalkyl being independently selected from the group consisting of -X 3 -O-C 1-4 Alkyl, -X 5 -C(O)OH and -X 3 substituted with 1 to 2 substituents independently selected from -OH; Each X 3 is independently 1-4 is alkylene; Each X 4 are independently -O- and C 1-4 alkylene; Each X 5 independently represents a bond and C 1-4 alkylene). or a pharma- ceutically acceptable salt thereof.
26. Formula (IV): [C7] (In the formula, X 1 is CH 2 and C substituted with 0 to 1 -OH 2-4 alkylene; Ring A is selected from the group consisting of phenyl and 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from N, O and S as ring vertices; The subscripts m and n are each independently 0 or 1; R 1 and R 2 each independently, if present, is C 1-4 Alkyl, C 1-4 Alkoxy, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 Hydroxyalkyl, -X a -O-C 3-6 cycloalkyl, —C(O)OH and cyano, a independently represents a bond and C 1-4 alkylene; Ar 1 is selected from the group consisting of phenyl, 5-6 membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O and S as ring vertices, 5-6 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, 6-10 membered bicyclic heterocyclyl having 1 to 4 heteroatoms independently selected from N, O and S as ring vertices, 6-10 membered bridged heterocyclyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, and 6-12 membered spiroheterocyclyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, 1 is 0 to 3 R 3 is substituted with; Each R 3 is independently 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, -X 2 -OH, -X 2 -O-C 1-4 Alkyl, —C(O)—C 1-4Alkyl and -X 2 -cyano; or two R on adjacent ring vertices are selected from the group consisting of 3 Combined to form C 3-6 Form a cycloalkyl or two R on the same ring vertex 3 are linked to form an oxo, where each X 2 is a bond and C 1-4 alkylene; Z 1 is 1 to 3 R 5 C substituted with a substituent 3-6 is cycloalkyl, Each R 5 are independently -OH, cyano, C 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy) or a pharma- ceutically acceptable salt thereof.
27. Formula (IV): [C8] (In the formula, X 1 is CH 2 and C substituted with 0 to 1 -OH 2-4 alkylene; Ring A is selected from the group consisting of phenyl and 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from N, O and S as ring vertices; The subscripts m and n are each independently 0 or 1; R 1 and R 2 each independently, if present, is C 1-4 Alkyl, C 1-4 Alkoxy, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 1-4 selected from the group consisting of hydroxyalkyl, —C(O)OH and cyano; Ar 1is selected from the group consisting of phenyl, 5-6 membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O and S as ring vertices, 5-6 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, 6-10 membered bicyclic heterocyclyl having 1 to 4 heteroatoms independently selected from N, O and S as ring vertices, 6-10 membered bridged heterocyclyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, and 6-12 membered spiroheterocyclyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, 1 is 0 to 3 R 3 is substituted with; Each R 3 is independently 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkyloxy, -X 2 -OH, -X 2 -O-C 1-4 Alkyl, —C(O)—C 1-4 Alkyl and -X 2 -cyano; or two R on adjacent ring vertices are selected from the group consisting of 3 Combined to form C 3-6 Form a cycloalkyl or two R on the same ring vertex 3 are linked to form an oxo, where each X 2 is a bond and C 1-4 alkylene; Z 1 is 1 to 3 R 5 C substituted with a substituent 3-6 is cycloalkyl, Each R 5 are independently -OH, cyano, C 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy) or a pharma- ceutically acceptable salt thereof.
28. X 1 Or X 0 is substituted with -OH 2 28. The compound of any one of claims 1 to 27, or a pharma- ceutically acceptable salt thereof, which is alkylene.
29. Formula (IVa): [C9] 28. The compound of claim 27 having the formula: or a pharma- ceutically acceptable salt thereof.
30. Z 1 But one R 5 30. The compound of any one of claims 26 to 29, which is cyclobutyl substituted with: or a pharma- ceutically acceptable salt thereof.
31. Z 1 But one R 5 30. The compound of any one of claims 26 to 29, which is cyclopentyl substituted with: or a pharma- ceutically acceptable salt thereof.
32. Z 1 But one R 5 30. The compound of any one of claims 26 to 29, which is cyclohexyl substituted with:
33. Each R 5 The compound of any one of claims 26 to 32, or a pharma- ceutically acceptable salt thereof, wherein is halo.
34. Each R 5 But, C 1-4 33. The compound of any one of claims 26 to 32, or a pharma- ceutically acceptable salt thereof, which is alkoxy.
35. Each R 5 The compound of any one of claims 26 to 32, or a pharma- ceutically acceptable salt thereof, wherein: is -OH.
36. Ring A is phenyl, pyridinyl, pyridazinyl, imidazolyl, pyrazolyl, triazolyl, imidazo[1,2-a]pyridinyl, [1,2,3]triazolo[1,5-a]pyridinyl, imidazo[1,5-a]pyridinyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl, 1,6-naphthyridinyl or 1,7-naphthyridinyl.
36. The compound of any one of claims 1 to 35, which is: or a pharma- ceutically acceptable salt thereof.
37. 36. The compound of any one of claims 1 to 35, or a pharma- ceutically acceptable salt thereof, wherein Ring A is phenyl.
38. 36. The compound of any one of claims 1 to 35, or a pharma- ceutically acceptable salt thereof, wherein Ring A is a 5- to 6-membered heteroaryl ring.
39. 36. The compound of any one of claims 1 to 35, or a pharma- ceutically acceptable salt thereof, wherein Ring A is pyridyl.
40. Ring A is [C10] 36. The compound of any one of claims 1 to 35, which is: or a pharma- ceutically acceptable salt thereof.
41. Ring A is [C11] 36. The compound of any one of claims 1 to 35, which is: or a pharma- ceutically acceptable salt thereof.
42. 36. The compound of any one of claims 1 to 35, or a pharma- ceutically acceptable salt thereof, wherein Ring A is not a pyrimidine.
43. Ar 1is selected from the group consisting of phenyl, 5- to 6-membered heteroaryl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices, and 5- to 6-membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from N, O and S as ring vertices; 1 But 0 to 3 R 3 43. The compound of any one of claims 1 to 42, or a pharma- ceutically acceptable salt thereof, substituted with:
44. Ar 1 But 0 to 3 R 3 43. The compound of any one of claims 1 to 42, which is heteroaryl substituted with: or a pharma- ceutically acceptable salt thereof.
45. Ar 1 But 0 to 3 R 3 45. The compound of claim 44, which is pyridinyl, pyrimidinyl, pyrazolyl, pyrrolyl, imidazolyl or triazolyl substituted with, or a pharma- ceutically acceptable salt thereof.
46. Ar 1 But 0 to 3 R 3 43. The compound of any one of claims 1 to 42, which is pyridyl substituted with: or a pharma- ceutically acceptable salt thereof.
47. Ar 1 but, [C12] 43. The compound of any one of claims 1 to 42, which is: or a pharma- ceutically acceptable salt thereof.
48. Ar 1 but, [C13] 43. The compound of any one of claims 1 to 42, which is: or a pharma- ceutically acceptable salt thereof.
49. Ar 1 But 0 to 3 R 343. The compound of any one of claims 1 to 42, which is phenyl substituted with: or a pharma- ceutically acceptable salt thereof.
50. Ar 1 but, [C14] 50. The compound of claim 49, which is: or a pharma- ceutically acceptable salt thereof.
51. Ar 1 But 0 to 3 R 3 43. The compound of any one of claims 1 to 42, which is morpholin-4-yl substituted with: or a pharma- ceutically acceptable salt thereof.
52. R 1 and R 2 each independently, if present, 1-4 Alkyl, C 1-4 Alkoxy, halo and C 1-4 52. The compound of any one of claims 1 to 51, or a pharma- ceutically acceptable salt thereof, selected from the group consisting of haloalkyl.
53. R 1 and R 2 each independently, if present, 1-4 52. The compound of any one of claims 1 to 51, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;
54. Each R 3 But independently, C 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, and C 3-6 Cycloalkyl, -X 2 -OH and -X 2 -cyano, or a pharma- ceutically acceptable salt thereof.
55. Each R 3 But independently, C 1-4 Alkyl, halo, C 1-4Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 3-6 54. The compound of any one of claims 1 to 53, or a pharma- ceutically acceptable salt thereof, selected from cycloalkyl and cyano.
56. Each R 3 54. The compound of any one of claims 1 to 53, or a pharma- ceutically acceptable salt thereof, wherein is independently selected from methoxy, methyl, ethyl, fluoro, chloro, difluoromethoxy, cyano, and cyclopropyl.
57. Each R 3 54. The compound of any one of claims 1 to 53, or a pharma- ceutically acceptable salt thereof, wherein is independently selected from methyl, fluoro, chloro and cyclopropyl.
58. Each R 3 54. The compound of any one of claims 1 to 53, or a pharma- ceutically acceptable salt thereof, wherein is independently selected from difluoromethoxy, fluoro, chloro and cyano.
59. Each R 3 54. The compound of any one of claims 1 to 53, or a pharma- ceutically acceptable salt thereof, wherein is independently selected from methoxy, fluoro and chloro.
60. Z or Ar 2 But 0 to 2 R 4 Each R 4 But independently, C 1-4 Alkyl, halo, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 60. The compound of any one of claims 1-25 or 35-59, or a pharma- ceutically acceptable salt thereof, selected from the group consisting of haloalkoxy, -OH and cyano.
61. Z or Ar 2 0 to 1 R 4 Each R 4 But independently, C 1-4 Alkyl, halo, C 1-4 60. The compound of any one of claims 1-25 or 35-59, or a pharma- ceutically acceptable salt thereof, selected from the group consisting of haloalkyl and -OH.
62. Z or Ar 2 But there are 0 R 4 60. The compound according to any one of claims 1 to 25 or 35 to 59, or a pharma- ceutically acceptable salt thereof, which is substituted with a substituent.
63. 63. The compound of any one of claims 1 to 62, or a pharma- ceutically acceptable salt thereof, wherein the subscripts m and n are both 0.
64. The following: The compound of choice, or a pharma- ceutically acceptable salt thereof.
65. The following: or a pharma- ceutically acceptable salt thereof.
66. 66. A pharmaceutical composition comprising a compound according to any one of claims 1 to 65, or a pharma- ceutically acceptable salt thereof.
67. The pharmaceutical composition of claim 66, comprising at least one pharma- ceutically acceptable excipient.
68. A pharmaceutical composition described in claim 66 or 67 for treating a disease characterized by overexpression of Polθ.
69. The pharmaceutical composition described in claim 68, wherein the disease is cancer.
70. 68. The pharmaceutical composition of claim 66 or 67 for treating a homologous recombination (HR) deficient cancer in a patient.
71. 71. The pharmaceutical composition of claim 70, wherein the patient is identified as being in need of such treatment.
72. 68. The pharmaceutical composition of claim 66 or 67 for treating cancer.
73. The pharmaceutical composition described in claim 72, wherein the cancer is characterized by reduced or absent BRCA gene expression, absence of the BRAC gene, or reduced function of the BRCA protein.
74. 74. The pharmaceutical composition of any one of claims 69 to 73, wherein the cancer is lymphoma, rhabdomyoma, multiple myeloma, uterine cancer, gastric cancer, peripheral nervous system cancer, rhabdomyosarcoma, bone cancer, colorectal cancer, mesothelioma, breast cancer, ovarian cancer, lung cancer, fibroblast cancer, central nervous system cancer, urinary tract cancer, upper gastrointestinal cancer, leukemia, kidney cancer, skin cancer, esophageal cancer or pancreatic cancer.
